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Abstract 
 
  Tuberculosis (TB) has plagued human populations throughout much of known human history and now listed as one of the top ten causes of death worldwide. Mycobacterium 
tuberculosis, the causative agent of TB, is responsible for most deaths by a single infectious agent. A live attenuated mycobacterium known as Bacillus Calmette–Guérin (BCG) derived from Mycobacterium bovis remains the only vaccine available against this disease. BCG fails to provide sufficient protection against pulmonary TB, the major disease manifestation in adolescents and adults. Due to these limitations, novel TB vaccine candidates have been developed and several have reached clinical trials. Multiple vaccination strategies have been implemented to develop improved TB vaccine candidates including protein and viral vector-based vaccines to boost BCG, or recombinant BCG (rBCG) designed to completely replace the current strain. 
CysVac5 is a novel subunit vaccine containing CysD, a major component of the M. 
tuberculosis sulphate activation pathway which is highly expressed during the chronic stage of M. tuberculosis infection, fused with two major immunodominant-secreted mycobacterial antigens: Ag85B and MPT83. Vaccination of C57BL/6 mice with CysVac5 subunit protein formulated in the monophosphoryl lipid A (MPLA) and dimethyldioctadecylammonium (DDA) adjuvant combination resulted in the potent generation of polyfunctional CD4+ T cells secreting multiple cytokines including IFNγ, IL2, TNF and IL17 both pre- and post-aerosol M. tuberculosis H37Rv challenge. CysVac5/MPLA-DDA vaccination conferred significant protection against infection in mouse lungs, which was greater than that afforded by BCG at extended timepoints post-challenge. Generation of protective immunity was also observed in BALB/c, indicating the vaccine displayed efficacy across multiple genetic backgrounds.  Furthermore, the use of plant-derived polysaccharide Advax adjuvant supplemented with toll-like receptor 9 (TLR9) agonist CpG oligodeoxynucleotidesin CysVac5 vaccination of C57BL/6 mice showed increased proportions in Th1 and Th17 responses and displayed comparable protection to BCG in the lungs and spleen of M. 
tuberculosis-infected mice. 
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Despite its variable efficacy BCG offers a number of unique and beneficial features which make this vaccine suitable as a vaccine vehicle, particularly the ability to express recombinant molecules within the vaccine. BCG∷SecDFG strain was constructed by overexpressing the M. tuberculosis SecDFG proteins in order to improve the efficiency of Sec-dependent export system and thus enhance secretion of immunogenic proteins into the extracellular environment. BCG∷SecDFG displayed better in vitro survival within macrophages and greater persistence in murine organs. In addition, BCG∷SecDFG generated enhanced stimulation of IFNγ secreting T cell in response to secreted mycobacterial antigens compared to BCG, in particular members of the Ag85 complex. The vaccine also elicited strong priming of antigen specific CD4+ T cells and generation of polyfunctional CD4+ T cells producing Th1-type cytokines, however did not improve protective efficacy against aerosol M. tuberculosis infection compared to parental BCG. 
Another approach to design novel rBCG strains implemented in this study was to increase the interaction between the vaccine and dendritic cells (DCs), as these immune cells are known to induce strong immune response by activating naïve T cells for response to foreign pathogens. BCG∷DEC205 was engineered to express a secreted or membrane-bound form of a single-chain variable antibody fragment (scFv) on the surface of BCG specific for the DC receptor DEC205. BCG∷DEC205 displayed enhanced binding in vitro to DEC205-expressing cell lines. Pulmonary vaccination of C57BL/6 mice with BCG∷DEC205 resulted in greater frequencies of Th1 and Th17-type responses and increased proportions of both effector (CD44hiCD62Llo) and central memory (CD44hiCD62Lhi) CD4+ T cells compared to non-immunised mice, with some CD4+ T cell subsets (e.g. CD4+IFNγ+TNF+) significantly elevated compared to parental BCG.  Intranasal BCG∷DEC205 vaccination displayed reduction in pulmonary bacterial numbers, comparable to that achieved by parental BCG, suggesting the heightened immunity displayed did not translate to improved protective efficacy. 
This study emphasises that the incorporation of chronic stage-specific antigens in subunit vaccine contributes to long-term protection against M. tuberculosis infection. Further, novel strategies to design rBCG strains by improving the interaction between the vaccine bacilli and professional antigen presenting cells, as well as increasing the secretion of immunogenic antigens can improve impacts-specific immunogenicity 
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with some impact on protective efficacy against M. tuberculosis. The vaccine candidates assessed in this study warrant further preclinical evaluation to improve their protective effect and develop vaccines for efficacy trials in humans. 
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1.1. Tuberculosis: The global burden Tuberculosis (TB) has plagued human populations throughout much of known human history and now listed as one of the top ten causes of death worldwide. Mycobacterium 
tuberculosis, the causative agent of TB, is responsible for most deaths by a single infectious agent. M. tuberculosis has the capability to infect a healthy host and persist as an indefinite latent infection without overt signs of the disease. Of the estimated 2 billion individuals being latently infected by this disease (WHO, 2017), approximately 90% individuals can control the infection via the host immune response but not to eliminate the pathogen, providing a large reservoir of infection. In 2016, there were over 10.4 million new TB cases being reported and about 1.7 million deaths from this disease, with 10% of who were children (WHO, 2017). TB infection is associated with poverty and most cases occur predominantly in developing countries including India, Indonesia, China, Philippines, Pakistan, Nigeria and South Africa (Barter et al., 2012, WHO, 2017). In addition, TB incidence is particularly high is sub-Saharan African countries due to HIV co-infection with 350,000 deaths from TB in HIV infected individuals in 2016 (Mabunda et al., 2014, WHO, 2017). Hence TB remains a major global infection disease with great challenges involved in TB prevention and treatment. 
In the majority of cases, drug susceptible TB can be effectively treated with a six month course of multiple front-line antibiotics, namely isoniazid, rifampicin, pyrazinamide and ethambutol (Kaufmann, 2011). However, the availability of this treatment in developing countries differs and this impacts on control of the disease (Russell et al., 2010). This is one factor that has contributed to the development of multi-drug-resistant (MDR) strains of M. tuberculosis, defined as resistant to at least the two first line TB drugs rifampicin and isoniazid. Treatment for MDR-TB requires long and expensive antibiotic treatments which frequently cause toxic side-effects. In 2016, there were 490,000 new cases of MDR-TB (WHO, 2017). The strains that are resistant to most of the first line drugs and several of the second line drugs (such as fluoroquinolone and at least one injectable second-line agent) are defined as extensively-drug-resistant (XDR) strains. The rapid spread of XDR-TB is currently being observed and unfortunately in countries including India and Iran, extremely or totally drug resistant strain (XXDR/TDR) strains have been reported to be resistant to all available TB drugs (Zar and Udwadia, 2013).  
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Successful TB treatment relies on accurate diagnosis, consistent access to good health care and affordable medication. Of the 10.4 million new TB cases in 2016, only 6.3 million had access to health care with a treatment success rate of 82%. Additionally, only 1 in 5 patients with MDR-TB received appropriate treatment with a success rate below 50%; this fell to 29% for XDR-TB (WHO, 2017). Without doubt, it is imperative to develop improved diagnostics and novel treatment regimens, but this is a major challenge. Hence, as for many major infectious diseases worldwide, affordable mass vaccination is also an important tool for prevention of TB. 
Mycobacterium bovis Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for TB, developed over a 13-year period between 1906 and 1919 at Institute Pasteur de Lille by French physician and bacteriologist Albert Calmette and his colleague Camille Guérin, a veterinarian. The vaccine was first given to children in 1921 and has been widely used since (Kaufmann et al., 2010). While it is effective in preventing severe childhood forms of TB, BCG does not satisfactorily prevent the development adult pulmonary TB disease. Several clinical trials have demonstrated that the ability of BCG in inducing protection against adolescent and adult pulmonary TB is highly variable, ranging from 0 – 80% (Andersen and Doherty, 2005). In addition, as a live mycobacteria, BCG is contraindicated for use in immunocompromised individuals (WHO, 2018). The 2015 WHO End-TB Strategy identifies scientific research in the development of more effective and easily administrable vaccines as an optimum tool to control TB and bring an end to the global epidemic (WHO, 2015). 
1.2. Mycobacterium tuberculosis 
1.2.1. Microbiology of the genus Mycobacterium The genus Mycobacterium belongs to the family Mycobacteriaceae within the order Actinomycetales. There are more than 150 naturally occurring species of mycobacteria that can be broadly grouped into fast-growing and slow-growing species or the complexity of the species based on physiological, phenotypic and phylogenetic differences (King et al., 2017). The majority of the mycobacteria are generally non-pathogenic saprophytic environmental organisms that can be isolated from diverse environments including water, soil, biofilms, etc. (Sidders and Stoker, 2007, King et al., 2017). However, the importance of the genus Mycobacterium lies in the pathogenic ability of some members than can cause diseases in humans, such as M. tuberculosis, M. 
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leprae and M. ulcerans. These pathogenic species of mycobacteria exist as slow-growing, aerobic, gram-positive pleomorphic rods, about 1 to 4 μm in length and 0.3 
to 0.6 μm in width (Sakamoto, 2012). The thick mycolyl arabinogalactan-peptidoglycan (mAGP) complex and several other components such as phenolic glycolipid, phosphatidylinositol mannosides (PIM) and lipoarabinomannan, that build the cell wall of these species of mycobacteria possess immunomodulatory activity that can reduce their permeability to antibacterial agents (Brennan, 2003, Maartens and Wilkinson, 2007). This complex bacterial cell-wall characteristic categories mycobacteria as acid-fast organisms that can be detected by Ziehl-Neelsen staining (Chen et al., 2012). 
M. tuberculosis is the aetiological agent of TB and is the most intensively studied of all the species of mycobacteria. The bacilli are acid-fast and when grown on solid media the colonies appear rough and wrinkled with an off-white colour and are usually visible after three weeks of growth (Sidders and Stoker, 2007). The cell wall of M. 
tuberculosis comprises more than 30-40% of the bacterial dry mass, and its unique and complex structure provides protection from the extracellular environment and contributes the low permeability of the bacteria causing entry inhibition for many antibiotics (Alderwick et al., 2007). This mycolic acid-rich cell wall complex consists of three different layers; the innermost peptidoglycan layer, followed by an intermediate covalently bound peptidoglycan and arabinogalactan layer, and mycolic acids which form the insoluble skeleton of the cell wall. The mycolic acids extend out towards the outer matrix of the mycobacterial cell wall, together with a polysaccharide-rich layer, this structure is responsible for the acid-fast property of the bacteria. In addition to these cell wall components, the outer layers also contain biologically active loosely bound lipids that can form a capsule-like structure enveloping the bacteria from the extracellular environment (Guenin‐Macé et al., 2009). 
Membrane associated proteins and cell wall phospholipids of M. tuberculosis are very important virulence factors for this pathogen (Maartens and Wilkinson, 2007). They allow the bacteria to tolerate host acidic dehydrating conditions and allow them to play immunomodulatory roles. Cell wall associated phosphatidylinositol mannosides (PIM) stimulate the fusion of early endosomes with infected phagosomes, providing the bacteria the essential nutrients (Guenin‐Macé et al., 2009). PIMs also form the lipid 
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base of the glycolipid lipoarabinomannan (LAM), an immunogenic component as well as a virulence factor that modify the morphology of the host lipid membrane domain morphology to inhibit phago-lysosomal fusion (Strohmeier and Fenton, 1999, Hayakawa et al., 2007) which prevents phagosome acidification and maturation (Robinson et al., 2007). Another cell wall associated component, the glycosylated phosphatidylinositol or mannosylated LAM (manLAM) has also been reported to inhibit the maturation of phagosomes due to its ability to block the increase of cytosolic Ca2+ levels in macrophages (Kang et al., 2005). 
1.2.2. Pathogenesis of M. tuberculosis The progression of M. tuberculosis infection can be described as an interplay between the pathogen and the host immune system. Each of the clinical signs and symptoms are viewed as severe inflammatory responses of the immune system in controlling and clearing the invading pathogens. M. tuberculosis is primarily transmitted via inhalation of aerosol droplets expelled by infected individuals (Gabriel and Mercado, 2011). The infectious dose is very low, 1-200 bacilli are sufficient to establish infection, and each aerosol droplet contains approximately 1-400 bacilli, making contact without infection nearly impossible (Gustin et al., 2013). Upon inhalation, the bacilli reach the alveoli in the distal airways of the lung where they are engulfed by alveolar macrophages (Saunders and Cooper, 2000). The aerobic nature of M. tuberculosis allows the bacteria to thrive in the very oxygen-abundant tissues of the lungs (Smith, 2003). M. 
tuberculosis has also coevolved with the human host to escape and exploit host macrophages and other immune cells to allow the bacteria to persist and replicate indefinitely following phagocytosis (Cambier et al., 2014). 
At the initial stage of infection, the replication of M. tuberculosis is either controlled by the infected host macrophages or allowed to continue until the replication is no longer able to be contained, resulting in necrotic death of the macrophages (Lerner et al., 2017). The fate of the bacterial pathogen during this early stage has critical impact on the outcome of the disease. The rupture of necrotic macrophages may result in further spread of the bacteria, both locally and haematogenously causing the dissemination of the pathogen (McClean and Tobin, 2016). Dissemination of M. tuberculosis to the draining lymph nodes in the lymphatic system causes the onset of the critical acquired cell-mediated immune responses (Cooper, 2009). 
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Figure 1.1. M. tuberculosis transmission and pathogenesis (Nunes-Alves et al., 
2014). Infection is initiated by inhalation of aerosol droplets containing bacteria. The initial stages of infection are characterised by innate immune responses involving the recruitment of inflammatory cells to the lung, followed by bacterial dissemination to the draining lymph node. DC presentation of bacterial antigens leads to T cell priming and expansion. The majority of infected individuals remain in a latent state of infection, in which no clinical symptoms are presents. A small percentage develop active disease which lead to the release of bacteria from granulomas. When individuals with active TB cough, infectious droplets that propagate the infection are generated.   
 
7 Chapter 1. General Introduction 
In individuals with immunocompetence, the replicating bacilli are contained at the site infection within the infected macrophages, which secret soluble factors that recruit immune cells to form granulomas (Pieters, 2008). However, in the majority of cases, latent TB occurs and may develop into active form as a consequence of a weak immune system. Indicative symptoms of active TB include chest pain, a productive cough with blood or sputum, fever, severe fatigue, weight loss and night sweats. As active TB disease progress, granulomas become caseous and liquefy as the bacteria start to replicate and begin dissemination to other organs, such as the brain and bones, leading 
to a deterioration of the patient’s condition (Parida and Kaufmann, 2010). 
1.3. Protein export systems of M. tuberculosis Protein export is essential for all bacteria and many pathogens strictly depend on specialised protein export systems for their virulence (Feltcher et al., 2010). Mycobacteria possess two essentials pathways to perform the bulk of protein export: the conserved general secretion (Sec) and twin-arginine translocation (Tat) pathways. Pathogenic M. tuberculosis has additional specialised protein export systems: the accessory SecA2 system (Sullivan et al., 2012) and the type VII secretion system (T7SS) that encodes five different types of specialised early secretory systems (ESX-1 to ESX-5) (Bottai et al., 2014). Sec export pathway is a post-translational process system which is present in all bacteria and is a primary route for exporting proteins to the cytoplasmic membrane and beyond. Many bacterial proteins with roles in bacterial virulence are exported by the Sec system (Ligon et al., 2012). Several M. tuberculosis proteins proven to function in virulence contain Sec-signal peptides, such as LspA (McCann et al., 2009), LpqH (19 kDa protein) (Henao-Tamayo et al., 2007), LppX (Sulzenbacher et al., 2006), and LprG (Bigi et al., 2004). 
The central component of the Sec pathway is a heterotrimeric protein complex composed of SecY, SecE and SecG, forming a channel in the cytoplasmic membrane through which cytoplasmic-synthesised proteins are transported to the extracellular environment (Feltcher et al., 2010). Another important and multifunctional component of this export system is SecA (with two homologs: SecA1 and SecA2), an ATPase that utilises energy from multiple rounds of ATP binding and hydrolysis to drive preproteins through SecYEG channel (van der Wolk et al., 1997). It has been reported that there is no homolog of SecA1 in other eukaryotic cells (Ligon et al., 2012).  
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Figure 1.2. An illustration of protein export systems in M. tuberculosis (Ligon et 
al., 2012). (A) Preproteins with N-terminal signal peptides are recognized by SecA1, which interacts with SecYEG heterotrimeric channel to form translocase. (B) SecA2 recognises a small subset of proteins and uses its ATPase activity to assist the export mechanism. (C) Tat-dependent preproteins contain N-terminal signal peptide with a twin-arginine (RR) motif and fold in the cytoplasm prior to export. (D) ESX-1 exported CFP10 and EspC proteins possess a targeting element at their C-terminus that directs them to interact with cytosolic AAA ATPases EccCb1 and EccA1 respectively.   
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Most of mycobacteria only possess the canonical SecA system which is SecA1. It is rare for this genus to have a secondary component SecA2 (Rigel and Braunstein, 2008). The accessory part of SecA, SecA2, is nonessential in most bacteria with the exception of 
Corynebacterium glutamicum (Feltcher et al., 2010). However, in M. tuberculosis SecA2 is necessary for the full virulence of the bacteria suggesting that some of the proteins exported through this pathway are important for pathogenesis (Braunstein et al., 2003, Kurtz et al., 2006). The M. tuberculosis secA2 mutant is attenuated for growth and survival in both macrophages (Kurtz et al., 2006) and the mouse model of TB infection (Braunstein et al., 2003) indicating that this export system is critical for M. tuberculosis virulence. SecA2-dependent proteins, such as SodA and KatG, protect M. tuberculosis from the oxidative burst of macrophages (Ligon et al., 2012). SecA2 appears to inhibit the innate immune responses against M. tuberculosis infection (Feltcher et al., 2010). This is supported by the fact that M. tuberculosis secA2 mutant-infected macrophages generate higher levels of proinflammatory cytokines and exhibit more apoptosis than wild-type macrophages (Hinchey et al., 2007). The secA2 mutant of M. tuberculosis also elicits better protective immunity against M. tuberculosis challenge in mice and guinea pigs when compared to that generated by BCG vaccination (Hinchey et al., 2007). 
Similar to Sec export, the Tat system transports proteins across the cytoplasmic membrane in a post-translational manner (Ligon et al., 2012). This pathway is present and linked to virulence in a number of bacterial pathogens (De Buck et al., 2008). In M. 
tuberculosis, Tat export is essential for bacterial growth, as shown in a study that the deletion of tatA, tatB or tatC is not possible unless exogenous copies of the tat genes are provided (Saint-Joanis et al., 2006). The phospholipase C proteins, such as PlcA and PlcB, are shown to have Tat signal peptides and these proteins are important for the full virulence of M. tuberculosis  in mice (Raynaud et al., 2002). This indicates that Tat export system contributes to M. tuberculosis pathogenesis. Another protein identified as Tat-dependence is a virulence factor Rv2525c (McDonough et al., 2005). The 
rv2525c mutant of M. tuberculosis was proven to have higher virulence in both macrophages and mice (Saint-Joanis et al., 2006). 
M. tuberculosis possesses five specialised ESX export pathways (ESX-1 to ESX-5). These ESX systems are named after their first known secreted substrate, the 6 kDa early secreted antigenic target (ESAT-6) of M. tuberculosis (Feltcher et al., 2010, Abdallah et 
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al., 2007). The first ESX system identified was ESX-1 and it is now the well characterised system of ESX secretion machineries. ESX-1 locus centre (spanning genes rv3864 - rv3883c) contains esxA and esxB genes, which encode ESAT-6 (EsxA) and culture filtrate protein 10 kDa (CFP10/EsxB) (Feltcher et al., 2010). Both ESAT-6 and CFP10 are interestingly not produced by the attenuated M. bovis BCG vaccine strain due to the lack or region of difference 1 (RD1) that is present in M. tuberculosis and M. bovis (Feltcher et al., 2010, Pym et al., 2002). ESX-1 promotes growth of M. 
tuberculosis in macrophages (Ohol et al., 2010, Stanley et al., 2003) and is connected in various different processes in M. tuberculosis with potential importance to pathogenesis (Ligon et al., 2012). During macrophage infection, ESX-1 is responsible for blockage phagosome maturation (Xu et al., 2007), limit cytokine production from the host cells (Stanley et al., 2003), and promote apoptosis of infected cells (Derrick and Morris, 2007). It has also been reported that ESX-1 systems assists the bacteria to escape phagolysosomes (van der Wel et al., 2007) and assist host cell lysis to facilitate dissemination (Guinn et al., 2004). 
1.4. Host immune responses to M. tuberculosis infection The capacity for the host to generate effective immune mechanism to control M. 
tuberculosis infection is critical in determining the disease progression (Kaufmann et al., 2010). Following inhalation of M. tuberculosis, the infection is established in the distal alveolar compartment and cell mediated immunity (CMI) develops due to the exponential growth of the bacteria in this compartment (North and Jung, 2004). Mycobacteria then interact with the alveolar epithelium and infect the surrounding alveolar macrophages contributing to the initial inflammatory response. A considerable amount of research has been conducted towards better understanding the role of both innate and adaptive immunity against M. tuberculosis infection. 
1.4.1. Innate immune responses 
M. tuberculosis is primarily acquired via inhalation of infectious aerosol droplets. The induction of innate immunity at the pulmonary mucosa is critical to the development of proper adaptive immune responses against the infection (Martino, 2008). A number of different pattern recognition receptors (PRRs) are able to detect the bacteria on a variety of cells, including macrophages, dendritic cells (DCs), neutrophils, natural killer 
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(NK) cells, B-lymphocytes and several other epithelial and endothelial cells (Martino, 2008).  
1.4.1.1. Macrophages As the main cellular reservoir of the bacilli, macrophages play a crucial role in M. 
tuberculosis infection. Macrophages are considered as the major cell habitat for the growth and survival of M. tuberculosis (Guirado et al., 2013). However, these cells are also responsible for the activation of both innate and acquired protective immune responses which are crucial to control and eliminate the infection (Guirado et al., 2013). Macrophages coordinate the formation of granulomas and function as the final effectors responsible for bacterial killing (Saunders and Cooper, 2000). Along with DCs, alveolar macrophages (AMs) and lung interstitial macrophages are the three main antigen-presenting cells (APCs) M. tuberculosis first encounters upon inhalation (Cooper, 2009). AMs are the first immune cells to interact with M. tuberculosis which phagocytose and internalise the bacteria within phagosome compartments. AMs recognise the bacterial cells using several different receptors i.e. complement receptors, mannose receptors, surfactant protein receptors (Ernst, 1998), and toll-like receptors (TLRs) (Quesniaux et al., 2004). In addition, upregulation of chemokines and chemokine receptors of macrophages, such as macrophage inflammatory protein (MIP)-1, monocyte chemotactic protein (MCP)-2, MCP-3, C-C chemokine receptor (CCR)2, and CCR5 allow the recruitment of circulating leukocytes to the inflammation sites and accelerate granuloma formation (Flynn and Chan, 2001, Saunders and Cooper, 2000). 
M. tuberculosis, like many other pathogenic bacteria, has the ability to manipulate their cellular niche for their own advantages (Ernst, 2012). The bacteria hinder the maturation of phagosome by inhibiting the fusion of this compartment with lysosome to form phagolysosomes, a strongly acidic (pH 4.5-5.0) hybrid organelle enriched in hydrolytic enzymes and antimicrobial peptides that promotes killing and degradation of internalised bacteria (Haas, 2007, Kissing et al., 2015).  M. tuberculosis can also limit vacuole acidification (Wong et al., 2011) and avoid destruction by migrating to less hostile cytosol environment (van der Wel et al., 2007). Active bacterial replication within macrophages leads to host cell death by either necrosis or apoptosis (Butler et al., 2012). Although macrophage activation is essential for controlling M. tuberculosis 
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infection, it also leads to the occurrence of substantial damages in the surrounding tissues (Flynn and Chan, 2001). Therefore, designing vaccines against M. tuberculosis with the ability to reduce immunopathology is crucial in order to eliminate the pathogen as well as reduce any unnecessary tissue damages caused by induced immune responses. 
1.4.1.2. Dendritic cells Dendritic cells (DCs) are professional APCs that serve an important role in coordinating immune responses against pathogens. DCs connect innate and adaptive immunity by presenting antigens and activating naïve T cells in secondary lymphoid organs (Henrickson et al., 2008). DCs serve as a reservoir for chronic infection (Schreiber et al., 2010), but unlike macrophages DCs can migrate from granulomas to the draining lymph nodes (Morel et al., 2008, Schreiber et al., 2011). DCs are often 
characterised as ‘resident’/‘blood-derived’ or ‘migratory’/‘tissue-derived’ cells and these terms relate to their haemopoietic origin and surface phenotypes (Guermonprez et al., 2002). DCs express a range of different PRRs to detect and process different pathogen-associated molecular patterns (PAMPs) (Akira et al., 2006). In humans there are two main populations of DCs: CD8+ DCs and CD8- DCs (Liu, 2001).  CD8+ DCs have the ability to cross-prime and produce IL12 to induce Th1 cells and CD8+ cytotoxic T cell activation whereas CD8- DCs favour a Th2 response and do not possess the ability to cross-prime (Den Haan et al., 2000). The phenotype and function of DCs change as they mature. An immature DC primarily endocytoses pathogens and process their antigens. When activated by PRRs, DCs undergo a functional maturation and upregulate co-stimulatory molecules CD80 and CD86 to support T-cell activation (Madan-Lala et al., 2014). 
CD11c is a marker found primarily on DCs, neutrophils, monocytes, and macrophages in humans, whereas in mice CD11c is generally expressed on mature DCs (Shortman and Liu, 2002). The importance of DCs in controlling M. tuberculosis infection was highlighted when CD11c+ DCs were depleted resulting in the delayed development of the CD4+ T cell responses and greater bacterial numbers in the lungs post infection (Tian et al., 2005). DCs have a higher expression of major histocompatibility complex (MHC) class II compared to macrophages that leads to greater antigen presenting ability (Vono et al., 2017). Stimulated DCs produce a range of chemokines including 
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neutrophil chemoattractant CXCL1 (Zhang et al., 2001), MIP-1α (CCL3), MIP-1β (CCL4) which promote inflammation and homeostasis (Maurer and Von Stebut, 2004). Activated DCs also produce MCP-1 (CCL2) which functions to recruit CD4+ and CD8+ T cells to the site of infection and is known as a more potent chemokine compared to MCP-2 and MCP-3 (Deshmane et al., 2009). 
Better understanding of the early interactions between DCs and M. tuberculosis that lead to the induction of T cell priming is critical for the development of enhanced vaccines and immunotherapies against the TB disease. A murine study employing aerosol delivery of M. tuberculosis expressing green fluorescent protein (GFP) to the lungs of mice showed that M. tuberculosis predominantly infects myeloid DCs within the lungs and lymph nodes, and the bacteria are transported to the lung-draining lymph nodes in a CCL19/21-dependent manner (Wolf et al., 2007). In a separate study by the same group, the administration of a TLR4 agonist lipopolysaccharide (LPS) to the lung airway did not accelerate bacterial transport to the lymph nodes (Wolf et al., 2008). Taken together, these studies suggest that M. tuberculosis may specifically target DC migration and antigen presentation to delay early elimination and promote persistent infection. 
1.4.1.3. Neutrophils Neutrophils are rapidly recruited to the site of mycobacterial infection to phagocytose the pathogen (Lowe et al., 2012), although whether this leads to direct killing of the pathogen is yet to be defined (D'Avila et al., 2008). Neutrophils are less well characterised compared to other components of the host response to M. tuberculosis and the available data is rather controversial (Lowe et al., 2012). Neutrophils are short-lived, easily activated, and cannot be cryopreserved making the study in-vitro prone to variability (Bardoel et al., 2014). Furthermore, isolated or depleted granulocytes are rarely characterized with accuracy in studies examining neutrophil-mycobacteria interactions including neutrophil-mediated killing (Lowe et al., 2012). Neutrophils are highly phagocytic and accommodate live cells to the lymph nodes (Abadie et al., 2005) that leads to the maturation of DCs and antigen presentation to T cells (Morel et al., 2008). BCG-infected DCs were found to generate high levels of neutrophil chemoattractants i.e. CXCL1 and CXCL2 (Doz et al., 2013). In addition, when neutrophils came into contact with BCG-infected DCs, IL10 was produced resulted in 
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the blocking of IL17 production by Th17 cells but had no effect on IFNγ secreting Th1 cells (Doz et al., 2013). Furthermore, BCG-infected DCs in humans produce more IL10 when compared to DCs that phagocytose M. tuberculosis infected neutrophils (Morel et al., 2008). This indicates a critical and close relationship of neutrophils in stimulating and coordinating DCs responses to mycobacteria. 
The ability of neutrophils to phagocyte M. tuberculosis has been demonstrated in many studies, both in-vitro and in-vivo (Kisich et al., 2002, Eruslanov et al., 2005, Lombard et al., 2016). In mice challenged with BCG, one-day post infection neutrophils were found to accumulate in the lung tissue and in the airspaces with 1.6% of them contained mycobacteria (Lombard et al., 2016). In isolated human lung tissue infected in-vitro with various mycobacterial strains, approximately 7% of the infected cells were neutrophils (Ganbat et al., 2016). In contrast to phagocytosis, data regarding the ability of neutrophils to kill M. tuberculosis is proven to be inconsistent. Several in-vitro studies reported poor antimycobacterial activity of neutrophils despite the cells stimulating IFNγ, a cytokine known for its ability to activate macrophage antimycobacterial properties (Eruslanov et al., 2005). A poor capacity of neutrophils for M. tuberculosis killing allowed researchers to consider these cells as a “Trojan horse” hiding the bacteria from potentially bactericidal macrophages (Lowe et al., 2012). It is largely assumed that protective activity of neutrophils is more pronounced at the early stage of M. tuberculosis infection, whereas at the advanced stages these cells become detrimental (Lyadova, 2017). It is suggested that TB disease alters neutrophil population, leading to the accumulation of heterogenous subsets of immature and activated dysfunctional cells although the origin of these cells, signals leading to their generation, and their precise role in TB infection are yet to be determined (Lyadova, 2017, Kimmey et al., 2015). 
1.4.2. Adaptive immune responses The adaptive immune response, also known as the acquired immune system, is characterised by the involvement of the ‘classical’ lymphocyte subsets i.e. CD4+ T cells, CD8+ T cells, B cells and several other non-conventional T cells such as γδ T cells, CD1-restricted T cells and mucosal-associated-invariant T (MAIT) cells (Chaplin, 2010). Although the precise roles and the interaction mechanisms of these cell types are yet to be defined, it is hypothesised that cross-talk exists among the different elements of 
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the cells and is likely to be upregulated (Nunes-Alves et al., 2014). The detailed roles of CD4+, CD8+ and memory T cells in M. tuberculosis infection are described as follows. 
1.4.2.1. CD4+ T cells CD4+ T cells are critical for M. tuberculosis control and the role of these cells is the most well-characterised among other lymphocyte cell subsets. In humans, the importance of CD4+ T cells in controlling M. tuberculosis is perhaps best described by the fact that patients with CD4+ T cell deficiency from HIV infection have dramatically elevated rates of reactivated TB (Walker et al., 2013). In the mouse model, CD4+ T cell knockout mice are far more susceptible to infection than normal mice and it has been shown that adoptive transfer of mycobacteria-reactive CD4+ T cells into CD8-/- mice restored the protective immunity against subsequent mycobacterial challenge (Caruso et al., 1999, Feng and Britton, 2000). Different subsets of CD4+ T cells appear to play a role in TB 
immunity. Among these subsets, IFNγ producing Th1 cells are essential due to the fact 
that IFNγ is the key mediator in T cell function (Takeuchi and Saito, 2017). IFNγ knockout mice are unable to restrict the growth of bacilli following M. tuberculosis infection and show severe tissue necrosis and succumb to a rapid and fatal course of TB (Flynn et al., 1993, Cooper et al., 1993). In addition, individuals with mutation in 
the IFNγ receptor gene are more susceptible to mycobacterial infection (Fernando and Britton, 2006). However, the frequency of T cells producing IFNγ alone does not appear to be sufficient in generating effective anti-TB protective immunity (Kaufmann, 2013), suggesting that other components and mediators are important. Murine tumour necrosis factor (TNF) was found to synergize with IFNγ to activate macrophages and inhibit the replication of intracellular bacteria (Britton et al., 1998). The production of 
IFNγ and TNF along with interleukin 2 (IL2) is known to promote self-driven expansion of T cells that leads to amplification of T cell responses that correlate to vaccine-mediated protection in Leishmania major infection model (Darrah et al., 2007). 
Furthermore, IFNγ, TNF and IL2 triple positive central memory T cells (TCMs) provides protective responses against TB following BCG vaccination (Maggioli et al., 2016). The association between increased immunity and these polyfunctional T cells is not only due to the fact that these cells possess a broader repertoire of function but is also caused by the ability of these cells express greater magnitude of multiple cytokines as compared to single-cytokine producing T cells (Kannanganat et al., 2007).  
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Figure 1.3. Overview of the immune response generated to control M. 
tuberculosis infection (Kaufmann, 2010). Following infection, M. tuberculosis is taken up by alveolar macrophages where it evades the immune responses. DCs take up antigen and present it on MHC class I and II to activate specific naïve CD4+ and CD8+ T cells. Following their activation, DCs proceed to secret multiple cytokines to induce 
Th1 and Th17 cell responses. Th1 cells produce IFNγ, TNF and IL2 to activate infected macrophages and CD4+ T cells respectively. This has been shown to correlate with protection. Th17 cells secret IL17 to activate polymorphonuclear granulocyte (PNG) and recruit IFNγ secreting CD4+ T cells to the lung. IFNγ producing CD8+ T cells activate macrophage and act as cytolytic T lymphocytes (CTL) to kill infected cells and bacterial cells by secreting granzymes, perforin and granulysin which lyse host cells and directly attack M. tuberculosis. During chronic infection with persistent antigens, CD4+ and CD8+ T cells may become exhausted rendering them less effective against M. 
tuberculosis.   
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Another subset of CD4+ T cells which are thought to play roles in M. tuberculosis infection is Th17 cells. Th17 cells were first described as a distinct population of the 
helper T cells controlled by the transcription factor RORγt (Steinman, 2007). The main effector cytokine of Th17 cells is IL17, although these cells also release other cytokines such as IL22, IL26 and granulocyte-macrophage colony stimulating factor (GM-CSF) (Lyadova and Panteleev, 2015). Although the role of Th17 is less characterized, several studies have been shown that IL17 producing T cells are efficiently generated following vaccination and involved in the memory response to subsequent M. 
tuberculosis challenge (Umemura et al., 2007). It has also been shown that Th17 cells are involved in TB pathology, due to the major source of IL17 was represented by 
IFNγ+IL17+ CD4+ T cells whose proportion directly correlates with the clinical parameters associated with disease severity (Jurado et al., 2012). IL17 is also thought to be responsible for neutrophil recruitment as neutrophils possess a pathogenic role and exacerbate TB disease (Dorhoi et al., 2011). Due to this complex role of Th17 cells, several novel TB vaccines are aimed to induce long-lived Th17 responses in addition to antigen-specific Th1 immunity (Lindenstrøm et al., 2012). In addition, recent studies suggest that there is a degree of plasticity of the Th17 cells in acquiring functional characteristics of Th1 cells. This plasticity is associated with higher in-vivo survival and self-renewal capacity and less senescence than Th1 polarized cells with higher phenotypic stability (Muranski and Restifo, 2013). Therefore, achieving the correct balance between Th1 and Th17 responses may be critical for determining the protective immunity against TB. 
1.4.2.2. CD8+ T cells The evidence for an essential role of CD8+ T cells in controlling M. tuberculosis infection is not quite as compelling as CD4+. The role of this subset of immune cells has been considered less important due to the fact that intracellular mycobacteria principally reside within the phagosome not cytosol of the host macrophages. Experimental M. 
tuberculosis infection of CD4-/- and CD8-/- mice has revealed that while CD4 deficient mice die within a few weeks of infection, CD8 deficient mice have a less dramatic phenotype (Flynn and Chan, 2001). However, presentation of mycobacterial antigens on MHCI molecules to CD8+ T cells occurs during both M. tuberculosis and BCG infection (Woodworth and Behar, 2006), and the increased efficiency of activation of CD8+ T 
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cells by M. tuberculosis is in part due to the secretion of ESAT-6 by the Esx1 secretion system encoded by RD1 deleted in BCG. Selective depletion of CD4+ and CD8+ T cells by neutralizing antibodies has shown that although CD8+ T cells are not required for the control of acute M. tuberculosis infection, they are essential for optimal control of chronic M. tuberculosis in murine infection model (Lin and Flynn, 2015, van Pinxteren et al., 2000). 
CD8+ T cells have the capability to secret multiple cytokines, such as IFNγ and IL4, and these are important in maintaining the balance of Th1 and Th2 phenotypes (Raja, 2004). CD8+ T cells can also differentiate into cytotoxic T lymphocytes (CTL) under the 
influence of helper T cells and contribute to macrophage activation by secreting IFNγ (Bhat et al., 2017, Feng et al., 1999). Furthermore, the process of intracellular killing of 
M. tuberculosis via apoptosis of infected human macrophages is dependent on the production of CD8+ T cell associated granulysin and perforin (Woodworth and Behar, 2006). Mice deficient in various genes involved in the processing and presentation of cytoplasmic antigens such as TAP1 (a transporter associated with antigen processing mediated by MHCI) and several others surface CD8+ molecules show decreased resistance to M. tuberculosis infection (Flynn and Chan, 2001). 
1.4.2.3. Memory T cells The generation of T cell memory following the dynamics of primary immune responses is summarised in three different phases i.e. expansion and effector T cell differentiation (including clonal expansion and acquisition of effector functions), T cell contraction (the majority of activated effector T cells death via apoptosis), and stable memory (the formation of a stable and long-lived population of memory T cells) (Pennock et al., 2013, Cui and Kaech, 2010, Williams et al., 2008).  
Understanding the pathways that lead to optimal generation and maintenance of memory T cells is critical in designing improved vaccine against TB. Several models of latent (i.e. EBV, CMV, HSV) and persistent (i.e. HCV, HIV) viral infections have been developed, however the majority of the viruses do not colonise the lung leading to different type of host-pathogen interactions compared to M. tuberculosis infection (Wherry et al., 2007, Davenport et al., 2009). The relationship between the level and duration of antigen exposure and its influence on memory T cell responses during 
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chronic pulmonary TB is poorly characterised. Studies in viral models of CD8+ T cell immunity have suggested that antigen concentration, cytokine environment, TCR affinity, the type of APCs, helper CD4+ T cells and the degree of co-stimulation influence the development of a robust and long-lived memory T cells (Masopust et al., 2004). Previous in-vitro studies using peptide-activated DCs demonstrated that antigen dose dictates the aptitude of memory CD4+ T cells, in which high levels of antigen resulting in limited survival of the cells following secondary expansion after antigenic re-stimulation (Lozza et al., 2008). Similarly, human memory CD4+ T cells recognise the displayed phenotype of persistent viruses and function as short-lived effector cell rather than memory cells following the stimulation of short-lived protein antigens (Stubbe et al., 2008). These trends are also observed in CD8+ T cells where chronic viral infection appears to favour the generation of antigen-dependent effector CD8+ T cells but not long-lived memory CD8+ T cells (Wherry et al., 2004). 
Based on anatomical location, effector function, expression of cell surface markers and lymph node homing receptors, memory T cells are divided into two distinct subsets i.e. central memory T cells (TCMs) and effector memory T cells (TEMs) (Wherry et al., 2003). TCMs express high level of surface receptor CD62L and a chemokine receptor type 7 (CCR7). Similar to naïve T cells, TCMs primarily guard the secondary lymphoid organs. These cells have limited effector functions, secret IL2 causing high proliferation, and differentiate rapidly to an effector phenotype after specific antigen encounters (Marzo et al., 2005). In contrast, TEMs lack in CD62L and CCR7 expressions and these cells mainly circulate in the peripheral tissues. However, TEMs have a greater capacity to generate cytokines (such as IFNγ and TNF) and possess cytolytic properties when compared to TCMs (Seder and Ahmed, 2003). Effector memory T cells are also thought to act as short-term effectors following antigen exposure, whereas TCMs are considered as the long-term survivors that form the basis of immunological memory (Kaech et al., 2002). 
Several studies have made the correlation between the ratio of antigen-specific TCM and TEM with their ability to contain chronic infection (Harari et al., 2004). In a murine model of M. tuberculosis infection, adoptive transfer of TCM, generated by subunit vaccination conferred protection against M. tuberculosis challenge (Duffy et al., 2009). Another study has also shown that the decrease of BCG protection in chronically 
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infected mice correlates with the loss of TCM (Lindenstrøm et al., 2013). In addition, it has been shown that the enhanced protection conferred by vaccination with a recombinant BCG strain expressing lysteriolysin (BCG ΔureC::hly) correlated with high numbers of TCM, and adoptive transfer of these cells confirmed their critical role in protection (Vogelzang et al., 2014). 
It has been postulated that T cells progressively gain functionality with further differentiation, including the production of IFNγ, IL2 and TNF (Seder et al., 2008). The amount of initial antigen exposure together with the innate immune micro-environment are thought to modulate the extent of T cell differentiation. However, continued and prolonged antigenic stimulation, such as in chronic infections, leads to a loss of TCM and TEM, resulting in terminally differentiated T cells called effector T cells that produce only IFN-γ and are short-lived (Seder et al., 2008). More comprehensive understanding of these parameters regarding memory T cell generation in the context of M. tuberculosis infection may lead to important considerations for rational TB vaccine development in determining the long-term effectiveness of the vaccines. 
1.5. M. bovis BCG: The current TB vaccine Bacillus Calmette–Guérin (BCG) remains the most widely used vaccine in the world given to infants and children to protect against TB. It was originally developed at the Institut Pasteur de Lille by Albert Calmette and Camille Guérin by sub culturing a virulent bovine strain of M. bovis 230 times on bile-glycerine-potato medium over 11 years (Luca and Mihaescu, 2013). Clinical trials in the period 1921 to 1927 revealed that BCG was highly efficient in protecting children against TB infection, suggesting that the continuous passaging of the virulent strain of M. bovis resulted in attenuated virulence yet preserved its immunogenicity (Pym et al., 2002, Andersen and Doherty, 2005). However, the technologies to preserve viable bacteria during this period was not available. Continued supply of bacterial stocks was achieved by in-vitro passage which ultimately led to a variety of genetically different daughter strains (Behr, 2002). It is estimated that the present-day BCG strains have been propagated for more than 1000 times, hence the genetic alterations which contribute to BCG-associated protection and/or adverse effects (Zhang et al., 2013, Behr, 2002). Furthermore, some BCG strains have been reported to be more immunogenic than others, possibly 
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resulting in the inconsistency of the vaccine to provide protective immunity against TB and the variable efficacy in clinical trials (Walker et al., 2010, Agger and Andersen, 2002). Nevertheless, neonatal BCG vaccination provides protection against severe types of disseminated BCG, such as miliary TB and TB meningitis, to which infants and young children are particularly susceptible (Wagner and Young, 2004). In addition, BCG provides limited protection against several non-tuberculous diseases and other inflammatory or autoimmune conditions such as asthma and allergic diseases, 
leishmaniasis, candidiasis, warts, Chron’s disease (CD), insulin-dependent diabetes mellitus (IDDM), and specific cancers (Kaposi sarcoma, cervical cancer, bladder cancer and lymphoproliferative disorders) (Arts et al., 2016, Rousseau et al., 2008).  
Although BCG vaccination shows an excellent safety profile, the efficacy in preventing pulmonary TB in adults is limited. BCG-immunised individuals can still be infected with 
M. tuberculosis and develop active TB or maintain a latent infection which can reactivate later in life (Dockrell and Smith, 2017). BCG protection also wanes with time and is unlikely to persist more than ten years after vaccination (Sterne et al., 1998). Multiple explanations have been proposed for the variable protection induced by BCG vaccine. These include pre-sensitisation with environmental mycobacteria, strain and vaccine batch variations and route of administration (Dockrell and Smith, 2017). Vaccination setting, maternal conditions and genetic backgrounds, co-infections with other pathogens are also some of the factors that are considered to affect BCG-induced immune responses (Dockrell and Smith, 2017). Furthermore, a recent study has shown that young adults receiving BCG vaccination reported to respond in a dichotomous manner where BCG either induced a broad proinflammatory T cell response with local inflammatory reactogenicity or, in contrast, a predominant CD8+ regulatory T cell response with mild local inflammation, poor cytokine induction, and absent of polyfunctional CD4+ T cells (Boer et al., 2015). These heterogenous host responses to BCG hampers the study for correlates of protection in BCG-vaccinated populations. Finally, the continuous passaging of BCG during development has led to the chromosomal deletion of RD1 region in BCG spanning the cfp10-esat6 locus encoding the major antigens ESAT-6 and CFP10 (Pym et al., 2002) thus individual vaccinated with BCG may be exposed to a more limited antigenic profile than the actual M. 
tuberculosis infection (Lambert et al., 2009). 
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1.6. Novel TB vaccine strategies Due to the limitations of BCG, novel TB vaccine candidates have been developed and several have reached clinical trials. These TB vaccine candidates are categorised as: 1) preventive pre-exposure vaccines which are administered prior to first M. tuberculosis exposure (priming vaccines); 2) preventive post-exposure vaccines which are aimed to target adolescents and adults with LTBI prior BCG immunisation (boosting vaccines); and 3) therapeutic vaccines administered in adjunct with canonical TB drugs (Kaufmann et al., 2017). The TB vaccine candidate pipeline incorporates various vaccine platforms including adjuvanted proteins, viral vectored, live attenuated and whole-cell inactivated mycobacterial vaccines. The vaccine categories along with the candidates which are currently under clinical studies are outlined in Table 1.1. and explained below. 
1.6.1. Protein based subunit vaccines Knowledge of the M. tuberculosis genome has allowed rapid progress in identifying novel potential vaccine antigens (Stylianou et al., 2018). A significant amount of research is being conducted in order to develop protein based subunit vaccines using antigens recognised by T cells from TB positive patients (Kaufmann, 2010). The capacity for repeat administration is one of the great advantages of protein-based vaccines, but due to generally poor inherent reactogenicity, this type of vaccine requires the concurrent use of adjuvants that promote Th1-type  immune responses (Kaufmann, 2010). All protein vaccines (outlined in Table 1.1.) currently in clinical trials are delivered via peripheral injection. 
The fusion protein H4 is composed of the highly immunogenic antigens Ag85B and TB10.4, known as one of the three members of the early secretory antigenic target ESAT-6 family of proteins found in M. tuberculosis culture supernatants (Skjøt et al., 2000). Ag85B is a particularly attractive antigen target, it is a highly conserved enzymatic mycolyl transferase crucial for cell wall synthesis. As a member of the Ag85 complex protein family, Ag85B is common to M. tuberculosis, BCG and several other environmental mycobacteria (Prendergast et al., 2016, Huygen, 2014). TB10.4, on the other hand, is an immunodominant M. tuberculosis secreted antigen, shown to induce greater immune responses in T cells isolated from TB patients compared to BCG-vaccinated and non-vaccinated donors (Skjøt et al., 2002).  
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Table 1.1. List of TB vaccine candidates in human clinical trials  
Type Candidate Company Description Phase in 
clinical 
trials* 
Reference 
Adjuvanted protein ID93/GLA-SE IDRI, Aeras Fusion of four M. tuberculosis proteins (Rv1813, Rv2608, Rv3619 and Rv3620) in GLA-SE adjuvant 
Phase IIa Baldwin et al., 2012, Bertholet et al., 2010 M72/AS01E GSK, Aeras A recombinant fusion protein derived from M. tuberculosis Mtb32A (Rv0125) and Mtb39A (Rv1196) in AS01E adjuvant 
Phase IIb Gillard et al., 2016, Fletcher and Schrager, 2016 H56:IC31 SSI, Valneva, Aeras Fusion of M. tuberculosis antigens: Ag85B, ESAT-6 and Rv2660c in IC31 adjuvant Phase IIb Aagaard et al., 2011, Luabeya et al., 2015 Viral vectored Ad5-Ag85A McMaster, CanSino A recombinant replication-deficient human Ad5 vector expressing Ag85A Phase I Smaill and Xing, 2014 ChAdOx1-85A/MVA85A UOXF A ChAd vector expressing M. tuberculosis Ag85A Phase I Ewer et al., 2016 TB/FLU-04L RIBSP An influenza vector-based vaccine expressing Ag85A and ESAT-6 Phase IIa Walker et al., 2016 Live-attenuated mycobacterial MTBVAC Biofabri, TBVI, Zaragoza, Aeras 
A live attenuated M. 
tuberculosis with the deletion of phoP and fadD26 genes Phase IIa Gonzalo-Asensio et al., 2017, Quigley et al., 2017 VPM1002 SII, MPIIB, TBVI A recombinant BCG expressing hly but lacking 
ureC gene (BCG ΔureC::hly HmR)  
Phase III Grode et al., 2013, Spertini et al., 2015 Inactivated whole-cell mycobacterial RUTI
® Archivel Farma A liposomal formulation of M. tuberculosis cell wall fragments Phase IIa Nell et al., 2014 DAR-901 Dartmouth, GHIT SRL172 (non-tuberculous mycobacterium) master cell bank derivative Phase IIb von Reyn et al., 2017, Sharma et al., 2017 
Vaccae™ AZL An injectable form of heat-inactivated M. vaccae Phase III Yang et al., 2011, Dlugovitzky et al., 2006 MIP Cadila, ICMR An inactivated whole-cell derived from M. indicus pranii Phase III Kamal et al., 2017 
 
*Aeras Global Clinical Pipeline (latest revision: August 2018). Abbreviations: IDRI, Infectious Disease Research Institute; GSK, GlaxoSmithKline plc.; SSI, Statens Serum Institute; McMaster, McMaster University; UOXF, University of Oxford; RIBSP, Research institute for Biological Safety Problems; TBVI, TuBerculosis Vaccine Initiative; SII, Serum Institute of India; MPIIB, Max Planck Institute for Infection Biology; GHIT, Global Health Innovative Technology Fund; AZL, Anhui Zhifei Longcom Biologic Pharmacy Co. Ltd.; ICMR, Institute of Leprosy and Other Mycobacterial Diseases. 
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H4 is administered alongside the novel adjuvant IC31, a mixture of a leucine-rich peptide and the oligodeoxynucleotide ODN1a (TLR9 ligand), in a 25:1 ratio which includes a depot that allows prolonged antigen presentation and enhanced Th1 (IFNγ) responses (Schellack et al., 2006). H4:IC31 has so far been assessed in a Phase I with encouraging results and is now currently under a Phase IIa trial (Norrby et al., 2017, Geldenhuys et al., 2015). A more recently developed subunit vaccine candidate, H56, is a fusion protein of three M. tuberculosis antigens i.e. Ag85B, ESAT-6 and an additional antigen expressed during latency Rv2660c (Aagaard et al., 2011). Although the role of Rv2660c is unclear, the increased transcripts of this protein in intracellular M. 
tuberculosis under nutrient stress suggest that Rv2660c contributes to intracellular survival of the bacteria (Betts et al., 2002). Administrated also with IC31, H56 has been shown to induce antigen-specific IgG responses as well as Th1 cytokine-expressing CD4+ T cells (Luabeya et al., 2015). H56:IC31 as a BCG boost offered potential to prevent latently infected individuals from progressing to active disease (Kaufmann, 2011) and is now under Phase IIb clinical trials. 
Another protein-based subunit vaccine candidate, ID93, is a fusion of four M. 
tuberculosis proteins (Rv1813, Rv2608, Rv3619 and Rv3620) belonging to the virulence factor families PE/PPE (proteins containing Pro-Glu/Pro-Pro-Glu motifs), ESX and latency protein categories respectively (Baldwin et al., 2015). ID93 is combined with the adjuvant GLA-SE, a glucopyranosyl lipid adjuvant (synthetic hexa-acylated lipid A analog) formulated in an oil-in-water stable emulsion, that induces in-
vivo innate immune responses and Th1 cellular immunity to coadministered vaccine antigens (Anderson et al., 2010, Coler et al., 2011). In murine studies, ID93/GLA-SE has shown to generate a Th1-response with antigen-specific polyfunctional CD4+ T cells and protect mice against M. tuberculosis H37Rv challenge (Baldwin et al., 2012, Bertholet et al., 2010). When given as a BCG booster in guinea pigs, ID93/GLA-SE showed improved pathology and reduced bacterial load which led to increased survival (Bertholet et al., 2010). The vaccine has just recently completed a Phase IIa trial evaluating safety and immunogenicity in treated adult pulmonary TB patients (CinicalTrials.gov Identifier: NCT02465216). Interestingly, this vaccine is also currently being investigated as a mucosal vaccine in animal models, where it switches the CD4+ T cell responses to a Th17-dominated memory T cell response in the lungs 
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and maintains the same level of protection when observed with parental immunisation (Orr et al., 2015). 
M72/AS01E is a prophylactic vaccine and reported to be the most advanced protein-based subunit vaccines for TB in clinical trials (Gillard et al., 2016, Fletcher and Schrager, 2016). This vaccine is composed of the M72 antigen, which is a recombinant fusion protein derived of M. tuberculosis Mtb32A (Rv0125, a putative secreted serine protease antigen) and Mtb39A (Rv1196) proteins and administered with the AS01E adjuvant system (Montoya et al., 2013, Skeiky et al., 1999, Mortier et al., 2015). Previous intensive studies have shown that M72/AS01E has a clinically acceptable safety profile and induces both humoral and cell-mediated immune responses in healthy, HIV-infected, M. tuberculosis infected and BCG-vaccinated children (Montoya et al., 2013, Leroux-Roels et al., 2013, Day et al., 2013, Penn-Nicholson et al., 2015, Thacher et al., 2014, Idoko et al., 2014). A recent Phase IIa trial has also shown that M72/AS01E was immunogenic in adults who were previously or currently treated for TB although this vaccine seemed to create substantial local adverse reactions at the injection site (Gillard et al., 2016). Despite this, M72/AS01E has entered a Phase IIb efficacy testing (NCT01755598) which is expected to be completed in November 2018. 
1.6.2. Viral vector-based subunit vaccines Viral vectors are tools for vaccine and gene therapy owing to the ability of viruses to infect cells. The main advantages of using viral vectors for vaccines are as follows: high efficiency gene transduction, cell type-specific gene delivery, and induction of robust immune responses (Ura et al., 2014). There are currently three viral vectored vaccines for TB in clinical trials: Ad5-Ag85A (McMaster University, Canada and CanSino, China), ChAdOx1-85A/MVA85A (University of Oxford, England) and TB/FLU-04L (Research Institute for Biological Safety Problems, Kazakhstan), all consist of M. tuberculosis Ag85A protein, a mycolyl transferase enzyme essential for cell wall synthesis. A Phase I trial of TB/FLU-04L (an influenza vector-based TB vaccine expressing Ag85A and ESAT-6) has shown a good safety profile of the vaccine in humans, it was also highly immunogenic with the ability to induce antigen specific memory CD4+ and CD8+ T cell responses (Walker et al., 2016). Ad5-Ag85A, a recombinant replication-deficient human Ad5 vector expressing Ag85A, is now currently under Phase I study. In animal models, pulmonary immunisation with Ad5-Ag85A showed improved protection over 
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BCG alone. Furthermore, Ad5-Ag85A was safe and immunogenic when delivered intramuscularly to humans and stimulated polyfunctional T cell responses, even more potently in previously BCG-vaccinated volunteers (Smaill and Xing, 2014). MVA85A, a replication-deficient modified vaccinia Ankara (MVA) virus encoding Ag85A incorporating human adenovirus vector, was the first viral vectored vaccine to enter human trials (McShane et al., 2004). Multiple Phase I and IIa studies have shown that MVA85 was well-tolerated and induced diverse vaccine-specific T cell responses (Triccas and Counoupas, 2016). The main drawback of adenoviruses is the pre-existing vector-specific immunity. However, this has been effectively overcome by using replication-deficient (E1-deleted) chimpanzee adenoviruses (ChAds) as substitutes (Ewer et al., 2016). This includes a ChAd vector expressing M. tuberculosis Ag85A (ChAdox1-85A) which is being examined with or without MV85A boost in healthy adults (NCT01829490). 
Another vaccine technology that has shown promise in pre-clinical studies is the cytomegalovirus (CMV) vector, which is a live attenuated persistent viral vector able to express multiple M. tuberculosis antigens (Voss et al., 2018). It has been shown that the engineering of the CMV vector leads to constant, low-level replication of the virus, giving sustained antigen expression and long-term immunity (Früh and Picker, 2017, 
Čičin-Šain et al., 2011). Furthermore, over two independent M. tuberculosis challenge studied have demonstrated that subcutaneous vaccination of rhesus macaques with Rhesus Cytomegalovirus vectors encoding M. tuberculosis antigen inserts (RhCMV/TB) elicited and maintained highly effector differentiated, circulating and tissue-resident 
M. tuberculosis-specific CD4+ and CD8+ memory T cell responses (Hansen et al., 2018). RhCMV/TB was also able to reduce the overall (pulmonary and extra-pulmonary) extent of M. tuberculosis infection and disease by 68% compared to unvaccinated controls after intra-bronchial M. tuberculosis challenge. Overall data presented from several studies demonstrated that CMV-based vaccines exhibit significant protection against aggressive M. tuberculosis strain challenge in highly susceptible rhesus macaques (Hansen et al., 2018), making this technology highly favoured for TB vaccine development. 
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1.6.3. Live attenuated mycobacterial vaccines Live attenuated vaccines were originally designed as replacement vaccines and given instead of BCG. However, following the progress of these viable vaccine candidates in clinical settings, some have now been considered as a preventive post-exposure vaccines and therapies (Kaufmann et al., 2017). There are two live mycobacterial (MTBVAC and VPM1002) and four inactivated whole-cell mycobacterial vaccines (RUTI, DAR-901, MIP and Vaccae) in human trials. The most advanced candidate is heat-inactivated M. vaccae (Vaccae™; Anhui Zhifei Longcom Biologic Pharmacy Co. Ltd., China). M. vaccae is a non-pathogenic species of mycobacteria commonly found in soil and water and was first examined as a TB vaccine in the 1980s (Huang and Hsieh, 2017). Vaccae™, an injectable form of heat-inactivated M. vaccae, has already been approved in China as an immunotherapeutic agent to help shorten TB drug therapy and is effective against drug-sensitive and MDR-TB (Yang et al., 2011, Dlugovitzky et al., 2006). 
RUTI® (Archivel Farma, Barcelona, Spain), similar to Vaccae™, is also being investigated as an immunotherapeutic vaccine aimed to reduce the exposure to the TB antibiotic treatment and to increase the current treatment efficacy  (Kaufmann et al., 2017). RUTI® is a liposomal formulation of M. tuberculosis cell wall fragments which has been grown under stress conditions. Its mechanism of action is based on an induction of a poly-antigenic cellular response against non-replicating bacteria (Cardona, 2006). RUTI® has been shown to trigger a specific response against M. 
tuberculosis antigens with good safety in a Phase I human trial (Nell et al., 2014). Later a Phase II trial reported that this vaccine resulted safety and immunogenicity in both HIV-negative and HIV-positive volunteers with LTBI (Nell et al., 2014). A Phase IIa trial is currently planned to assess the safety and immunogenicity of RUTI® therapeutic vaccination in patients with MDR-TB (NCT02711735). 
The SRL172 (an inactivated whole-cell vaccine derived from a non-tuberculous mycobacterium) master cell bank was used to design scalable manufacturing for the booster vaccine now knowns as DAR-901 (Sharma et al., 2017). A Phase I trial has demonstrated safety and tolerability of this vaccine in adults with childhood BCG immunisation. DAR-901 induced statistically significant increases in IFNγ response to DAR-901 and M. tuberculosis lysates, it also induced antibody responses to M. 
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tuberculosis virulence factor-associated glycolipid lipoarabinomannan (von Reyn et al., 2017). A randomized controlled Phase IIb trial is now underway to asses DAR-901 in preventing adult TB infection in Tanzania (NCT00052195). The last vaccine candidate that falls under this whole-cell inactivated vaccine category is M. indicus pranii (MIP), an inactivated non-tuberculous mycobacterial therapeutic vaccine which has been studied as an adjunct to therapy for leprosy (Kamal et al., 2017). A recent randomized trial looking at the efficacy and safety of MIP as an adjunct therapy in pulmonary TB has shown that MIP contributed to clearance of M. tuberculosis bacilli (Sharma et al., 2017). The other two viable live attenuated vaccines that are now under clinical trials are described below. 
1.6.3.1. Recombinant BCG strains A large number of recombinant BCG (rBCG) vaccines are being developed and tested in pre-clinical settings with the purpose of providing improved protective immunity and efficacy of the current vaccine against M. tuberculosis infection (Triccas, 2010). Current strategies to improve the protective efficacy of BCG involve introducing recombinant genetic materials to overexpress immunogenic BCG antigens that are not sufficiently expressed during infection (Horwitz and Harth, 2003) or M. tuberculosis specific antigens that are absent in BCG (Pym et al., 2003). Other approaches aim to replace the deleted genes during the attenuation of BCG, add virulence factors from other pathogens (Andersen and Doherty, 2005) or complement BCG with genes encoding co-factors that potentiate antigen presentation function (Grode et al., 2005, Sun et al., 2009). 
VPM1002, also known as BCG ΔureC::hly HmR, is a recombinant BCG strain expressing listeriolysin encoded by the hly gene of Listeria monocytogenes, lacking the urea C gene (ureC) and containing a hygromycin resistance marker (Grode et al., 2013). Listeriolysin causes perforation of macrophages in pH-dependent manner which leads to acidic pH of phagosomal membranes whereas urease C is involved in neutralization of the phagosome harbouring BCG allowing rapid phagosomal acidification and phagolysosome fusion (Nieuwenhuizen et al., 2017). VPM1002 was well tolerated and 
able to stimulate multifunctional and single IFNγ-producing T cells and generate antibody-producing B cells in BCG-naïve or BCG-immune individuals (Grode et al., 2013). This rBCG vaccine is currently the most advanced TB vaccine candidate and 
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shown to have a better safety and efficacy profile than standard BCG in preclinical models (Grode et al., 2013). VPM1002 protected mice against M. tuberculosis infection in an experimental post-exposure model (Nieuwenhuizen et al., 2017) and was well tolerated in adults (Spertini et al., 2015). VPM1002 has recently completed Phase I and II clinical trials against TB in adults and neonates, it is currently being assessed in HIV-exposed neonates and under development as a preventive post-exposure vaccine for adolescents and adults (Kaufmann et al., 2017). The most recent study of VPM1002 is to assess the efficacy and safety of this rBCG in prevention of TB recurrence in India (NCT03152903) and is estimated to be completed by November 2019. 
1.6.3.2. Attenuated M. tuberculosis strains The ultimate advantage of using attenuated live M. tuberculosis strains as vaccine is that many genetic regions encoding important antigens are absent in BCG but still present in M. tuberculosis (Gonzalo-Asensio et al., 2017). Although chromosomal deletions in the virulence genes of M. tuberculosis provide assurance for safety and genetic stability, several safety concerns including the possibility of conversion back to virulence is to be considered (Walker et al., 2010). MTBVAC is the first and only live attenuated M. tuberculosis vaccine tested in humans and is currently under preparation to enter a Phase IIa study (A-050) in adults (NCT02933281) and neonates (NCT03536117) in South Africa. MTBVAC was constructed by generating two independent stable genetic deletions without antibiotic resistance markers in the genes phoP and fadD26 which encode two major virulence factors in M. tuberculosis (Arbues et al., 2013). The gene phoP encodes the transcription factor of the two-component virulence system PhoP-PhoR, which regulates more than 2% of M. 
tuberculosis genome implicated in virulence (Gonzalo-Asensio et al., 2008). The fadD26 gene participates in biosynthesis and export of phthiocerol dimycocerosates (PDIM), the main virulence-associated cell wall lipids of M. tuberculosis that contributes to phagosomal escape and host cell exit (Domenech and Reed, 2009, Quigley et al., 2017). A recent study has demonstrated that MTBVAC-induced both ESAT-6 and CFP10-specific immune responses that correlate with improved efficacy relative to BCG (Gonzalo-Asensio et al., 2017). 
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1.7. Route of administration for TB vaccines There are several different methods in administrating vaccines i.e. intramuscular, subcutaneous, intradermal, intraperitoneal, intravenous, oral, intratracheal and aerosol. The immune responses generated after immunisation followed by challenge differ depending on the delivery routes. The use of pulmonary delivery in TB vaccination is an increasingly appealing strategy. Delivering a vaccine via aerosol matches the natural primary route of M. tuberculosis infection and may therefore mimic the induction of a local immune response in the pulmonary mucosa followed by systemic immunity (Todoroff et al., 2013). However, BCG is delivered intradermally and the majority of the vaccines in clinical trials against this disease are administrated systemically (Manjaly Thomas and McShane, 2015). 
It has been proposed that the explanation behind the failure of intradermally delivered BCG to prevent TB is the route of delivery. This has been hypothesised and explored since 1960s where Rosenthal and colleagues decided to deliver BCG via aerosol nebulisation to school children and medical students, concluding that this method of administration was well-tolerated and feasible (Rosenthal et al., 1968). Extensive studies in animal models have been conducted to further investigate pulmonary BCG, including in hon-human primates (NHP), the most relevant model that represents TB infection in humans. The general results verified that the pulmonary administration of BCG enhanced the immunogenicity and protective effect of the vaccine (Sharpe et al., 2016). A recent study reported that a powdered BCG vaccine in leucine buffer delivered using an inhaler via the pulmonary route provided increased protection in guinea pigs compared to intradermal injection (Garcia-Contreras et al., 2007). Spray-dried BCG has also been delivered to mice via tracheal intubation with insufflation, which enabled BCG to be delivered in a precise dose and induced local immune responses in the lungs (Morello et al., 2009). Furthermore, aerosol BCG has entered Phase I clinical trials in healthy UK adults assessing the safety and immunogenicity of the vaccine (NCT02709278). 
1.8. Novel antigens for TB vaccine development One of the major challenges in developing vaccine against TB is the lack of antigen diversity included in novel vaccines. Of all the current candidates in clinical development, six of the subunit vaccines contain or express either Ag85A or Ag85B 
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proteins. In order to optimise the potential in finding successful candidates, an expansion of antigen selection is required (Fletcher and Schrager, 2016). Secreted or cell wall associated proteins of M. tuberculosis often become the potential targets of the host immunity (West et al., 2008). Secreted proteins such as Ag85 complex and ESAT-6 are antigens commonly used in novel TB subunit vaccines. This has led to further studies to search for M. tuberculosis proteins that may be useful in vaccine development. In addition, another potential consideration for the use of novel antigens in subunit vaccines is their ability to not impair the diagnostic efficacy of the TST or QuantiFERON®-TB Gold test used to establish M. tuberculosis. 
1.8.1. CysVac Secreted proteins of M. tuberculosis are generally the most common explored antigens for vaccine development due to their ability to be recognised by host cells in early stage of infection. However, M. tuberculosis can alter the metabolic and protein expression patterns during its persistency in a latent phase of infection (Du et al., 2016). This leads to a possible limitation of BCG vaccine owing to its rapid clearance hence the inability to expose the host to latency-associated antigens (Geluk et al., 2007). Many protein antigens expressed during the latent phase of M. tuberculosis infection are intracellular (Counoupas et al., 2016, Singh et al., 2014). Incorporating latency-associated antigens in prophylactic or immunotherapeutic vaccines may allow improved host cell control of infection. 
A study by Pinto, et al. identified a family of intracellular proteins from the sulphate-assimilation pathway (SAP) category in M. tuberculosis i.e. CysD (Rv1285) and CysNC (Rv1286). These proteins were highly expressed under stress conditions including hypoxia and cell starvation experienced during infection of host macrophages (Pinto et al., 2004, Pinto et al., 2012). In addition, CysD and CysNC are highly expressed in the lung of mice during chronic M. tuberculosis infection (Counoupas et al., 2016). The genes that encode SAP of M. tuberculosis are required for the reduction of sulfur and necessary for biosynthesis of cysteine (Pinto et al., 2012). cysD and cysNC genes are also ones of the prime targets of reactive nitrogen intermediates encountered by M. 
tuberculosis in the intracellular environment (Rhee et al., 2005) making them essential for the bacterial survival inside the host. 
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Protein components of SAP pathway are immunogenic and recognised by both murine and human T cells M. tuberculosis infection and when tested as vaccine antigens, these proteins were protective in murine challenge models (Pinto et al., 2012). In further studies conducted by Counoupas, et al., SAP antigen CysD was incorporated with Ag85B to generate the novel fusion protein vaccine antigen CysVac2. When delivered with the liposomal adjuvant MPLA-DDA, CysVac2 was highly immunogenic inducing both CysD and Ag85B-specific polyfunctional Th1 and Th17-type CD4+ T cell responses. Importantly, CysVac2 was also highly protective in both pre- and post-exposure models of M. tuberculosis infection in mice at chronic stage of infection, and when given as BCG-booster, CysVac2 was able to improve protection afforded by prior BCG vaccination (Counoupas et al., 2016). Therefore, CysVac2 is a protein vaccine of great interest with the potential to provide protection against M. tuberculosis at all stages of infection On-going studies in our lab are currently incorporating several other immunogenic antigens with CysD to create novel CysVac fusion protein vaccines for further protective efficacy against M. tuberculosis. 
1.8.2. MPT83 MPT83 (Rv2873), a surface-expressing lipoglycoprotein of M. tuberculosis and analogous to MPB83 in M. bovis (Wiker, 2009), is currently of interest for use in novel subunit vaccine development. The gene mpt83 encodes a precursor protein with signal peptides for export through the general secretory (Sec) pathway. Pre-exported MPT83 is processed by signal peptidase II, the N-terminus of this protein is lipidated at the first cysteine residue, and the lipoprotein then localises to the bacterial cell surface where the lipid tail embeds in the cell wall (Tschumi et al., 2012, Kao et al., 2012, Harboe et al., 2002). The functional role of MPT83 remains unclear and the three-dimensional structure of this protein is yet to be elucidated (Wiker, 2009). The operon that encodes either mpt83 or mpb83 gene is under the control of transcriptional regulator SigK. When cultured in-vitro, an anti-SigK factor shows generally low expression of MPT83 in M. tuberculosis, whereas mutations in the gene encoding anti-SigK in virulent M. bovis lead to high levels of MPB83 expression (Saïd‐Salim et al., 2006). However, in in-vivo infection model of M. tuberculosis, MPT83 is upregulated and functions as a highly immunogenic antigen (Becker and Sander, 2016). It is believed that MPT83 can stimulate human APCs directly in a TLR2-dependent manner 
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due to its N-terminal lipidation. Following recognition, MPT83 induces the production 
of multiple cytokines (IFNγ, IL12, IL6 and TNF) in macrophages that leads to the presentation of MPT83 peptide to CD4+ T cells after immunisation with rMPT83 (Chen et al., 2011). A recent report suggested that MPT83 establishes a proapoptotic effect and induces apoptosis in both human and mouse macrophages (Wang et al., 2017). 
Studies have shown that MPT83 may function as a virulence factor by inducing matrix metalloproteinase type 9 (MMP9), a protein that involved in the breakdown of extracellular matrix of the host and correlates with the severity of the disease (Chambers et al., 2010, Ashhurst et al., 2018). MPT83 is known to be recognised by positive TB patients, with significant levels of antibody and cellular responses. In addition, subcutaneous immunisation with MPT83 protein vaccines also induced a potent immune response with significant protection against aerosol M. tuberculosis challenge in mice (Kao et al., 2012). 
1.9. Adjuvants for novel TB subunit vaccines Purified and recombinant subunit vaccines often require additional components to help stimulate protective effect and enhance the immunogenicity of the vaccine antigens. These additional components are called adjuvants, comes from the Latin 
“adjuvare” meaning “to help” (Coffman et al., 2010). Adjuvants help to improve immunity to vaccine antigens by a variety of mechanism. There are several factors to be considered in selecting adjuvants for vaccines such as the nature of antigen used, the type of immune responses desired, the route of administration and whether the antigen release over an extended period of time is sustained and advantageous (Parida and Kaufmann, 2010). Few adjuvants are currently used in approved human vaccines, including alum, liposomes (Epaxal Crucell NV, The Netherlands), AF03 (Sanofi Pasteur, France), MF59 (a potent oil-in-water emulsion; Novartis Vaccines and Diagnostics Inc., MA), AS03 and AS04 (Glaxosmithkline Biologicals S.A., Belgium). Vaccines against M. 
tuberculosis infection require adjuvants that help to enhance the Th1 response. Several studies and investigations in the use of adjuvants in TB subunit vaccines are further described below. 
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1.9.1. Adjuvants used in TB vaccine trials GLA-SE, AS01E and IC31 are the adjuvants used in subunit TB vaccine candidates which are currently in human clinical trials. GLA-SE, utilised in ID93 vaccine, is TLR4 agonist and known to promote strong Th1 and balanced IgG1/IgG2 responses to vaccine antigens (Cauwelaert et al., 2016). AS01E, used in M72 vaccine, is a liposome-based adjuvant containing  two immunostimulants (3-O-desacyl-4’-monophosphoryl lipid A and saponin QS-21), reported to enhance adaptive immunity and is efficient at promoting CD4+ T cell-mediated immune responses (Didierlaurent et al., 2017). IC31 (a two-component adjuvant consisting of the artificial antimicrobial cationic peptide and the TLR9 stimulatory oligodeoxynucleotide ODN1a) is an adjuvant utilised in H56 vaccine and known to induce peptide specific cytotoxic T cells (CTL) in a type 1 interferon and Stat1 dependent manner (Szabo et al., 2013). 
Several other adjuvants reveal promising results in pre-clinical testings for TB subunit vaccines. The formulation of a pattern recognition receptor (PRR) agonist monophosphoryl lipid A (MPLA) and dimethyldioctadecylammonium bromide (DDA) has been used in a wide range of use in TB vaccine trials. DDA forms a cationic depot at the site of infection as a results of the net positive surface charge and/or the particle size of the liposomes and stimulates mixed Th1/Th17 responses (Nordly et al., 2011). MPLA is a synthetic and less toxic form of a lipopolysaccharide (LPS) lipid A derived from Salmonella minnesota R595 and has been used extensively in clinical trials as a component in prophylactic and therapeutic vaccines targeting infectious diseases, cancers and allergies (Evans et al., 2003). MPLA utilises both TLR2 and TLR4 to activate NF-κB p65 in human monocytes that leads to an upregulation of co-stimulatory molecules CD80 and CD86 helping T-helper cells to polarize secreting cytokines such as TNF, IL10 and IL12 (Martin et al., 2003). The combination of DDA and MPLA as an adjuvant formulation in TB subunit vaccines provides a benefit in generating comprehensive protective immune responses. A recent study combining MPLA-DDA and a glycolipid trehalose-6,6-dibehenate (TDB), a synthetic analog of trehalose-6,6-dimycolate (TDM), was used as a novel liposomal adjuvant to deliver CMFO (a novel fusion of four M. tuberculosis multistage antigens: Rv2875, Rv3044, Rv2073c and Rv0577). Following the immunisation of pCMFO/MPLA-DDA-TDB in mice, improved Th1 and significant CFMO-specific IL2 central memory T cell responses 
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were observed (Tian et al., 2018). However, as a potent immunostimulant, safety concerns still need to be further investigated regarding the use of such adjuvant formulations. 
1.9.2. Advax 
Advax™ (Vaxine Pty Ltd.), a delta inulin-derived microparticle, is a novel adjuvant used for peripheral and pulmonary delivery of subunit vaccines against wide variety of infectious diseases and immunological conditions. Advax is a microparticle derived from polyfructofuranosyl-D-glucose (delta-inulin), a storage form of carbohydrate in the plant family of Compositae (Petrovsky and Cooper, 2015). Inulin (all linear fructans with β-(2→1) fructosyl-fructose glycosidic bonds) was first isolated from elecampane plant (Inula helenium) (Meyer and Blaauwhoed, 2009). The delta form of this substance (β-D-[2 → 1] poly(fructo-furanosyl) α-D-glucose) has been manufactured as Advax™, a novel adjuvant with EU GMP grade and is approved for clinical trials (Cooper and Petrovsky, 2010) against several immunological conditions including seasonal and pandemic influenza virus (Gordon et al., 2016, Gordon et al., 2012), hepatitis B (Gordon et al., 2014) and insect sting anaphylaxis (Hannah et al., 2011, Fok et al., 2014). Interestingly, unlike other adjuvants, Advax does not require adsorption or direct association with an antigen to mediate its effect and still maintains its adjuvant capabilities to enhance immune responses 24 hours post administration (Saade et al., 2013, Hayashi et al., 2017). Additionally, Advax can magnify both humoral and cellular responses of a broad range of antigens (Petrovsky and Cooper, 2015). 
Despite the broad range of use, Advax mechanism of action is not fully understood as the recognition receptors of this adjuvant are yet to be identified (Petrovsky, 2015). The mechanism underlying Advax activity as an adjuvant has been the subject of intense investigation (Petrovsky and Cooper, 2015). Recent studies have shown that the use of Advax as an adjuvant for pulmonary influenza vaccination induced a more balanced Th1/Th2 response and potent systemic immunity (Murugappan et al., 2015). Furthermore, the addition of TLR9 agonist CpG oligonucleotide to Advax adjuvant when delivered with CysVac2 vaccine led to an improved immunogenicity and protective efficacy of the vaccine against TB (Counoupas et al., 2017). Therefore, this adjuvant offers potential use in subunit TB vaccines as a well-tolerated yet potent activator of adaptive immunity against the disease. 
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1.10. Current study: Hypotheses and aims 
1.10.1. Hypotheses 
• Vaccines expressing multiple, novel antigenic components may provide improved protective immunity against M. tuberculosis infection compared to the existing BCG vaccine. 
• Overexpressing in BCG components of protein transport systems will increase antigen abundance and the protective efficacy of the vaccine. 
• Pulmonary vaccination of live recombinant BCG directly targeting dendritic cells will promote more efficient and stronger immune responses against M. tuberculosis infection. 
 
1.10.2. Aims 
• To determine the immunogenicity and protective efficacy of a novel subunit protein vaccine CysVac5 against M. tuberculosis infection in several murine strains. 
• To examine the protective effect of recombinant BCG strains overexpressing components of the mycobacterial Sec protein export pathway. 
• To determine whether pulmonary vaccination of BCG engineered to target antigen presenting cells improves immunity and protective capacity against M. tuberculosis in mice. 
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2.1. Reagents 
2.1.1. General chemicals and buffers 
• Phosphate-buffered saline (PBS) (pH 7.2) was prepared by dissolving 8.00 g NaCl, 0.20 g KCl, 1.44 g Na2HPO4 and 0.24 g KH2PO4 in 1 L triple distilled water (TDW) and kept sterile. 
• PBS-Heparin was prepared by dissolving a stock solution of heparin sulphate in PBS (5000U/mL) to a final concentration of 50 U/mL and stored at 4qC until use. 
• PBS-Tween (PBS-T) (0.05%, v/v) was prepared by adding 5 mL of Tween-20 (Sigma, St. Louis, MO) to a final volume of 10 L PBS. 
• Tris-buffered saline (TBS) was prepared by dissolving 6.05 g Tris and 8.76 g NaCl in 800 mL of TDW. pH was adjusted to 7.5 by adding 1 M HCl and the solution volume was made up to 1 L with TDW. 
• TBS-Tween (TBS-T) 0.05%, v/v was prepared by adding 5 mL of Tween-20 (Sigma, St. Louis, MO) to a final volume of 10 L TBS. 
• Fluorescence activated cell sorting (FACS) buffer was aseptically prepared by dissolving 5 mL of foetal calf serum (Trace, Sydney, Australia) and 0.1 g NaN3 per 100 mL PBS. Ethylene-diamine-tetra-acetic acid (EDTA) was added to a final concentration of 5 mM. 
• ACK lysis buffer was prepared by dissolving 8.29 g NH4Cl, 1.00 g KHCO3 and 37.2 mg Na2EDTA in 800 mL TDW and adjusted to pH 7.2 with 1 M HCl. The solution was adjusted to 1 L with sterile TDW, sterilised by passage through 0.2 µm filter, and stored at 4 °C. 
• Trypsin/Trypsin-LE was used according to the manufacturer’s instructions (Calbiochem, USA). 
• 10% (v/v) neutral buffered formalin (10% formalin) was purchased from Fronine, (Sydney, Australia). 
• Transformation Storage Solution (TSS) buffer was prepared by dissolving 5 g of 10% polyethylene glycol in 2.5 mL of 5% dimethyl sulfoxide and 1 mL of 20mM MgCl2 and brought the volume to 50 mL by adding autoclaved LB broth and then filter sterilized it.    
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2.1.2. Tissue culture media 
• Complete RPMI Tissue Culture Media (cRPMI) was prepared by supplementing RPMI 1640 (Gibco®) with 10% (v/v) heat inactivated (56°C, 30 minutes) FCS, 0.5 mM 2-β-mercaptoethanol (Sigma), 100 U/mL penicillin (Trace) and 0.1% (w/v) streptomycin (CSL, Melbourne, Australia). Complete RPMI was used for most of tissue culture experiments in this study. 
• RPMI with DNAse/collagenase [0.1 mg/mL DNAse I (Worthington, Freehold, USA), 10 U/mL Collagenase Type I (Worthington)] was used to assist degradation of connective tissue and cellular debris in harvested lung samples. 
• Serum-free RPMI 1640 was used to label cells with CFSE, according to the 
manufacturer’s instructions (Life Technologies, Carlsband, USA). 
 
2.1.3. Mycobacterial culture media 
• Complete 7H9 broth was prepared by dissolving 0.47% (w/v) powdered 7H9 broth (Difco, Detroit, USA) in TDW, then autoclaved and supplemented with filter-sterilised 0.2% (v/v) glycerol, 0.02% (v/v) tyloxapol (Sigma) or 0.05% (v/v) Tween 20 (Sigma) and 10% (v/v) albumin-dextrose-catalase (ADC, see Table 2.1.). 
• Complete 7H9 broth without bovine serum albumin (BSA) (ADC/BSA-) was prepared by dissolving 0.47% (w/v) powdered 7H9 broth (Difco) in TDW, then autoclaved and supplemented with filter-sterilised 0.2% (v/v) glycerol, 0.02% (v/v) tyloxapol (Sigma) and 10% (v/v) albumin-dextrose-catalase (ADC) without BSA (see Table 2.1.). 
• Complete 7H11 agar was prepared by dissolving 2.1% (w/v) powdered 7H11 agar (Difco) in TDW with 0.2 % (v/v) glycerol (MP Biochemicals, Santa Ana, USA) and then autoclaved. The resulting medium was then further supplemented with 10% (v/v) oleic-acid-albumin-dextrose-catalase (OADC). 
• The antibiotic kanamycin (50 μg/mL, Sigma), ampicillin (100 μg/mL, Sigma), 
hygromycin (50 μg/mL, Life Technologies) were added when required for plasmid maintenance. 
 
 
 
 
40 Chapter 2. Materials and Methods 
Table 2.1. Bacto Middlebrook ADC and OADC Supplement 
Reagent Company ADC ADC/BSA- OADC Bovine serum albumin (BSA) Moregate Biotech, Australia 5% (w/v) - 5% (w/v) Dextrose Sigma 2% (w/v) 2% (w/v) 2% (w/v) Catalase Sigma 0.003% (w/v) 0.003% (w/v) 0.004% (w/v) Oleic Acid Sigma - - 0.05% (w/v) NaCl Sigma - - 0.85% (w/v) TDW - As required As required As required 
 
2.1.4. Bacterial culture media 
• Luria Bertani broth (LB Broth) was prepared by dissolving LB broth powder [1% (w/v) tryptone, 0.5% (w/v) NaCl, 0.5% (w/v) yeast extract] (Difco) in TDW. 
• Luria Bertani agar (LB agar) was prepared by dissolving LB agar powder [1% (w/v) tryptone, 0.5% (w/v) NaCl, 0.5% (w/v) yeast extract and 1.5% (w/v) bacteriological agar] (Difco) in TDW. 
• The antibiotics kanamycin (50 μg/mL) or ampicillin (50 μg/mL); hygromycin; geneticin (G-418, 50 μg/mL; Gibco®) were added when required for plasmid maintenance. 
 
2.2. Bacterial strains and plasmids Bacterial strains and their uses in this study are described in Table 2.2. as well as plasmids utilised in Table 2.3.    
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Table 2.2. Bacterial strains used in this study. 
Bacterial strains Source Description/use 
E. coli DH5α  ATCC700790 Cloning, storage of plasmids in glycerol stocks 
E. coli BL21 (DE3) New England Biolabs Protein expression 
M. bovis BCG Pasteur ATCC35734 (Professor Brigitte Gicquel, Institute Pasteur, France) 
Vaccination of mice 
M. tuberculosis H37Rv ATCC27294 Aerosol challenge for murine TB model described in Chapter 3 only BEI RESOURCES, NIAID, NIH, NR-13648) Aerosol challenge for murine TB model BCGpMOD12 Dr. Rachel Pinto BCG Pasteur with additional component of pMOD12 plasmid (Luo et al., 1996, Chung et al., 2003) BCG∷secDFG6 Dr. Rachel Pinto Novel live recombinant BCG vaccine (Chapter 4) BCG∷secDFG10 Dr. Rachel Pinto Novel live recombinant BCG vaccine (Chapter 4) BCGpMV261 (Stover et al., 1991) BCG Pasteur with additional component of pMV261 plasmid. BCGmCherry Dr Nathalie Winter, INRA Centre de Tours, Nouzilly, France 
BCG with integrative vector carrying mCherry controlled by the M. fortuitum blaF promoter BCG∷DEC20585B Dr. Rachel Pinto BCG containing signal sequence of secreted protein Ag85B scFvDEC205 BCG∷DEC20519kDa Dr. Rachel Pinto BCG containing signal sequence of membrane bound 19kDa scFvDEC205 BCGmCherry∷DEC20585B Dr. Rachel Pinto  BCG∷DEC20585B with mCherry plasmid (pNIP-40) BCGmCherry∷DEC20519kDa Dr. Rachel Pinto and Lucy Baker (2015) BCG∷DEC20519kDa with mCherry plasmid (pNIP-40) 
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Table 2.3. Plasmids utilised in this study 
Plasmid 
name 
Source Gene 
resistance 
Bacterial 
strains 
transformed 
Characteristic 
pET28a-CysVac5 Genescript, USA; Dr. Rachel Pinto 
Kanamycin BCG Pasteur E. coli IPTG inducible expression vector of CysVac5 recombinant fusion protein, encoding N-terminal 10x His-tag pNIP-40 mCherry Dr Nathalie Winter Hygromycin BCG Pasteur, BCG∷DEC20585B, BCG∷DEC20519kDa 
Integrative vector carrying mCherry controlled by the M. 
fortuitum blaF promoter pMOD12-secDFG Dr. Rachel Pinto Kanamycin BCG Pasteur pMV261 derived shuttle plasmid containing two multi cloning sites (MCS or polylinker regions) and two independent, constitutively active promoters HSP60 and HSP70 from BCG (Chung et al., 2003) pMV261-scFvDEC205 Dr. Rachel Pinto Kanamycin BCG Pasteur, BCGmCherry A shuttle mycobacterial replicating vector used to transform scFvDEC205 recombinant protein into BCG pUC57-scFvDEC205 Genscript, USA Kanamycin - PCR cloning vector containing the complete coding sequence of scFv mouse gene  
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2.3. Generation of recombinant E. coli strains and purification of recombinant 
proteins 
2.3.1. Preparation of E. coli competent cells Competent E. coli DH5α or BL21 (DE3) cells were prepared by inoculating 10 mL of LB broth and incubating overnight at 37°C in shaking conditions (200 rpm). The pre-inoculum was then diluted 1/50 in 50 mL of fresh LB broth and grown at 37°C shaking until the OD600 was between 0.5 and 0.6. The culture was incubated on ice for 15 minutes, then transferred to a 50 mL tube (BD Bioscience, San Diego, USA) and centrifuged at 4500 g for 10 minutes at 4°C. The pellet was resuspended in 1 mL of Transformation Storage Solution (TSS) buffer [10% (w/v) PEG-8000, 30 mM MgCl2, 5% (v/v) dimethyl sulfoxide, 10% (v/v) glycerol, in autoclaved LB broth]. 
 
2.3.2. Plasmid production, extraction and purification 
Competent E. coli DH5α cells were transformed with plasmid DNA via heat-shock. Plasmid DNA (100 ng; Table 2.3.) was added to the bacterial cells and the mixture incubated on ice for 30 minutes. The cells were then incubated for 45 seconds at 42°C to heat-shock the bacteria and facilitate uptake of plasmid DNA. The cells were put on ice for 2 minutes, recovered in LB broth and the resulting culture incubated at 37°C for 60 minutes shaking (200 rpm). The culture was then plated out onto LB agar containing the appropriate antibiotics and cultured at 37°C overnight. A single colony was then cultured in selective LB broth at 37°C, shaking at 200 rpm overnight. The culture was processed, and the plasmid extracted using a Wizard Plus MiniPreps DNA Purification System (Promega Biosciences, Madison, USA). The concentration and purity of the eluted plasmid was determined with a NanoDrop Spectrometer (Thermo Fisher Scientific, Waltham, USA). 
 
2.3.3. Plasmid screening Screening of purified plasmids was carried out by restriction enzyme digestion and subsequent agarose gel electrophoresis. All restriction enzymes and buffers were purchased from New England Biolabs (Ipswich, USA). The specific restriction enzymes used are stated in the relevant chapters. 100bp and 1kb GelPilot DNA ladders (Qiagen, Hilden, Germany) were used to determine the size of digested fragments. 
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2.3.4. E. coli recombinant protein expression Chemically competent E. coli BL21 (DE3) were transformed with the appropriate protein expression vector, cultured overnight, sub cultured and grown until mid-log phase (OD600 of 0.5-0.6) and then treated with 0.5 M of isopropyl β-D-1-thiogalactopyranoside (IPTG) shaking at 37 °C overnight to induce protein expression. The bacterial culture was pelleted by centrifugation (4000 g, 15 minutes, RT) and resuspended in lysis buffer (50 mM KPO4, 4 mM KCl, 5 mM b-ME, lysozyme 0.1 mg/mL, pH 8) and sonicated 10 times for 30 seconds with a probe sonicator (Branson, USA) to disrupt the cells. The soluble and insoluble fractions were separated at 12000 rpm for 1 hour at 4 °C (Eppendorf, Hamburg, Germany). The insoluble fraction was resuspended overnight at 4 °C in urea buffer (8 M urea, pH 8), and then passed through a his-tag affinity chromatography column (Clontech, Mountain View, USA). After several washes with urea buffer with increasing concentrations of imidazole, the his-tagged protein was eluted from the column in urea buffer containing 200 mM imidazole, and then dialysed overnight in a refolding buffer (25 mM HEPES, 0.1 M KCl, 1.5 mM DTT, 5% glycerol, pH 7.5). The protein concentration was then measured by Bradford Assay and the protein expression was confirmed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot. 
 
2.3.5. SDS-PAGE Protein samples were prepared with denaturing sample buffer and heated to 95 °C for 5-10 minutes. Along with a molecular weight standard (Bio-Rad), samples were separated on a two phase 4%/12% or 4%/15% sodium dodecyl sulphate-polyacrylamide stacking/resolving gel and visualized by Coomassie blue staining. 
 
2.3.6. Western blotting SDS-PAGE separated protein samples were electroblotted onto a nitrocellulose PVDF membrane (GE Healthcare, UK) using a Bio-Rad Mini Transblot system for 15 minutes at voltage of 140V in transfer buffer (12 % methanol, 12 mM Tris HCl, pH 8.3 and 85 mM glycine). The membrane was then blocked overnight at 4 °C in BSA (1% w/v in TBS-T) before His-tagged proteins were detected with nickel-conjugated horseradish peroxidase (1:10,000) (Ni-HRP His detect; KPL, Inc., MD). Alternatively, when c-Myc or human influenza haemagglutinin (HA) tagged proteins were to be detected specifically, 
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appropriate antibody staining was utilised (see Chapter 4 Section 4.2.1 and Chapter 5 Section 5.2.1). The membrane was then blocked in 5% w/v skim milk in PBS, and protein identified using donkey anti-mouse IgG-HRP antibody (Santa Cruz Biotechnology, Inc., Dallas, TX). Blots were developed with SuperSignal West Pico Chemiluminescent substrate (Thermo Fisher Scientific) and visualized using a ChemiDoc MP imaging system (Bio-Rad). 
 
2.4. Generation of recombinant BCG strains 
2.4.1. Mycobacterial culture Mycobacterial strains used in this study (outlined in Table 2.2.) were grown in complete 7H9 broth media in tissue culture flasks (Corning, NY) and incubated at 37 °C. At an OD600 of 0.5-0.6, 25% glycerol stocks were made and stored at -80 °C until required. For infection experiments, stocks were thawed and centrifuged (3600 g, 10 minutes, 4 °C) and the pellet resuspended in 1 mL of sterile PBS-T (0.01%). Prior to injection, bacteria were briefly sonicated (30% amplitude, 15 seconds) using a sonicator (Branson, Danbury, USA) to disperse aggregated mycobacteria. The bacterial counts for stocks were determined by plating out a serial dilution on supplemented Middlebrook 7H11 agar media (Difco). M. tuberculosis H37Rv (ATCC27294; BEI Resources) was grown similarly to other mycobacterial strains, except all procedures were conducted in a PC3 facility.  
2.4.2. Preparation of electro-competent mycobacterial cells Recombinant BCG strains were grown in complete 7H9 media until mid-log phase (OD600 of 0.5-0.6). The bacterial cells were centrifuged (3600 g, 10 minutes, RT), supernatant removed, and cells washed in 10% (v/v) sterile glycerol. Cells were washed three times before being resuspended in 10% sterile glycerol and 200 μL aliquots were stored at -80 °C until further use. 
 
2.4.3. Transformation of competent mycobacterial cells 
Frozen aliquots of competent mycobacteria were defrosted and incubated with 1 μg of appropriate purified plasmid DNA (Table 2.3). This mixture was transferred to a 0.2 cm electroporation cuvette (Bio-Rad) and cells were pulsed twice with 2.5 kV voltage in a MicroPulser (Bio-Rad). Cells were recovered by adding complete 7H9 media and 
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incubated as a standing culture (37 °C, overnight). The transformed mycobacterial cells were centrifuged (3600 g, 10 minutes, RT), resuspended in 1 mL of complete 7H9 media and plated onto 7H11 agar plates with selective appropriate antibiotics. Plates were then incubated for 2-3 weeks (37 °C, 5% CO2) and screened for appropriate protein expression as described below.  
2.4.4. Screening of recombinant BCG strains Expression of recombinant protein fusion secDFG (Chapter 4 Section 4.2.1) and recombinant protein scFv DEC205 (Chapter 5 Section 5.2.1) was confirmed by SDS-PAGE and Western blot (as described in Section 2.3.5 and 2.3.6) using appropriate antibody sera. Cell lysates were collected from cultures of individual transformed colonies using a Mini BeadBeater (BioSpec Products, Bartlesville, OK) whereas crude supernatants from each colony were concentrated using a centrifugal filter unit (Amicon Ultra-15, Millipore, Darmstadt, Germany). Cell lysates and concentrated supernatants were then separated by SDS-PAGE on a 12% polyacrylamide gel (Mini-
Protean® TGX™ Bio-Rad, Hercules, CA) and further protein expression was confirmed by Western blot as described in Section 2.3.6. For mCherry expression, bacterial cells were fixed in 10% neutral buffered formalin for a minimum of 30 minutes prior to acquisition by flow cytometry (see Section 2.11). The level of fluorescence was examined on the YG610 channel in an LSR Fortessa machine (BD Biosciences).   
2.5. In-vitro experiments 
2.5.1. Preparation of cell cultures Frozen cell stocks of RAW 264.7 (ATCC TIB-71) and CHO (a kind gift of Dr Irina Caminschia, Burnet Institute, Melbourne, VIC) were taken from liquid nitrogen, thawed and grown in cell culture flasks containing 25 mL of complete RPMI media. The flasks were then incubated (5% CO2, 37 °C) until a confluency of ~80% reached. To passage the cells, a cell scraper or 0.25% trypsin-EDTA (Thermo Fisher Scientific, Australia) was used to detach cells from the side of the flask and the cell suspensions were transferred to a 50 mL falcon tube. The cell suspensions were then pelleted by centrifugation (1500 rpm, 5 minutes, 4 °C) and supernatants removed. The cells were resuspended in 5 mL complete RPMI and then split amongst four cell culture flasks containing 25 mL complete RPMI media. Once cells had reached ~80% confluency, a 
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cell scraper or 0.25% trypsin-EDTA was used to detach the cells from the side of the flask and the cell suspensions were transferred to a 50 mL falcon tube. Falcon tubes containing cell suspensions were centrifuged (1500 rpm, 5 minutes, 4 °C) and the supernatant was removed. The cells were resuspended in 10 mL complete media and 10 µL of this resuspension was added into a well of a sterile 96-well round-bottomed plate (BD Biosciences) containing 90 µL of trypan blue (0.4%; Sigma-Aldrich). The resuspension was mixed by pipetting up and down gently before 10 µL was taken and pipetted under the coverslip of a haemocytometer. The number of cells was counted, and the following equation used to calculate the number of cells per mL:  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 # 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑞𝑢𝑎𝑑𝑟𝑎𝑛𝑡 𝑥 104 𝑥 101 = # 𝑐𝑒𝑙𝑙𝑠/𝑚𝐿  where 104 represents the volume and 101 represents the factor by which cells have been diluted in media or dye prior to counting. 
 
2.5.2. Macrophage infection RAW 264.7 murine macrophage cells (ATCC TIB-71) were grown to ~80% confluency in a cell culture flask and then dispensed into 24-well plates at 2x105 cells/well. BCG Pasteur, BCG∷secDFG6, BCG∷secDFG10 were then added to the cells at a multiplicity of infection (MOI) of 1:1 or 1:5 in FCS supplemented RPMI media. The plates were incubated (37 °C, 5% CO2) for 4 hours and then washed three times with PBS to remove extracellular bacteria. Cells were incubated for a further 20, 68, and 164 hours after which they were lysed and colony forming units (CFU) were determined by growth at 37 °C on supplemented 7H11 medium. 
 
2.5.3. DEC205 transfected CHO-cell infection Normal CHO and DEC205-transfected CHO cells were provided as a kind gift of Dr Irina Caminschia, Burnet Institute, Melbourne, VIC. The cells were grown to ~80% confluency in complete RPMI media with geneticin (G-418, Gibco) antibiotic for transfected cells and plain supplemented media for normal cells. Cells were then transferred to a 24-well plate (approximately 2x105 cells/well) and BCG∷DEC20585B and BCG∷DEC20519kDa were added into each well with MOI 1:1; 1:5; and 1:10 and incubated at 4 and 37 °C. Approximately 4 hours post infection, cells were washed with 
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complete RPMI media to remove extracellular bacteria. A cell scraper was used to detach cells from the bottom of the plate and the cell suspension was transferred to a 96 well round-bottom plate. Cells were then pelleted by centrifugation (1500 rpm, 5 minutes, 4 °C) and prepared for surface and intracellular cytokine staining (Appendix 6) for flow cytometry analysis as described in Section 2.11. 
 
2.6. Preparation and assessment of vaccines 
2.6.1. Preparation of MPLA-DDA liposomal vaccines Dimethyl dioctadecyl ammoniumbromide (DDA; 5mg/mL; Sigma) was prepared in sterile water and heated to 80 °C with regular stirring for 20 minutes whereas MPLA (InvivoGen, San Diego, CA) was resuspended in 1 mL of DMSO and vortexed to allow complete solubilisation. The formulation of MPLA-DDA adjuvant was prepared in a ratio of 1:10 (w/w; 25 µg of MPLA with 250 µg of DDA). 
 
2.6.2. Preparation of Advax™ based vaccines AdvaxCpG used in this study was kindly provided by Vaxine Pty Ltd (courtesy of Professor Nikolai Petrovsky, Flinders University). Recombinant fusion protein CysVac2 (Ag85B-CysD) was provided by Dr. Claudio Counoupas and Dr. Diana Quan, the laboratory of Professor Jamie Triccas, University of Sydney and CysVac5 (Ag85B-CysD-MPT83) was produced and purified in this study (Chapter 3.). AdvaxCpG (1 mg of 
Advax and 10 μg of CpG7909 per dose) preparations were resuspended and mixed with appropriate protein in a formulation of 1 mg AdvaxCpG adjuvant and 3 µg protein was delivered per immunisation. 
 
2.6.3. Preparation of live recombinant mycobacterial vaccines BCG Pasteur and other recombinant BCG strains utilised in this study (Table 2.2.) were grown in 7H9 broth media with appropriate antibiotics to mid-log phase (OD600 of 0.5-0.6). Bacterial cultures were then transferred into a 50 mL falcon tube and pelleted by centrifugation (3500 rpm, 10 minutes, RT). Supernatant was removed, and the bacterial cell pellet was resuspended in 1 mL of sterile PBS. Prior to infection, the cells were briefly sonicated (30 % amplitude, 15 seconds; Barnson, Danbury USA) to disperse aggregated mycobacteria.  
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2.7. Mice Female C57BL/6 and BALB/c mice were obtained from the Australian Research Centre (Perth, W.A.) or Animal BioResources (Moss Vale, NSW, Australia). All other mice used in this study were bred within the Centenary Institute animal facility and maintained under specific pathogen-free conditions with unrestricted access to food and acidified water. To examine CD4+ T cell responses to M. tuberculosis protein Ag85B, P25 mice with transgenic expression of a TCR specific for I-Ab-Ag85B240-254 peptide generated on a C57BL/6 were utilized (Tamura et al., 2004). Mice were used between 6-8 weeks of age. Mice infected with M. tuberculosis were housed in a PC3 lab facility at the Centenary Institute. All animal experiments were approved by the Sydney Local Health District Animal Welfare Committee under the protocol numbers 2013/047 and 2017/011.  
2.8. Mouse immunisation 
2.8.1. Subcutaneous (s.c.) Six to eight weeks old female mice were anaesthetised with gaseous isofluorane (Veterinary companies of Australia, Kings Park, Australia) and injected with 5x105 CFU 
of BCG/rBCGs in 200 μL of PBS or 200 μL of subunit vaccine solution formulated in MPLA-DDA (Sigma-Aldrich; 25 μg subunit vaccine protein in 250 μg MPLA-DDA per dose, three times, two weeks apart) at the base of the tale with an insulin syringe.  
2.8.2. Intramuscular (i.m.) Six to eight weeks old female mice were anaesthetised with gaseous isofluorane and 
injected with 50 μL of subunit vaccine formulation in AdvaxCpG (1 mg of Advax and 10 
μg of CpG7909 per dose, three times, two weeks apart) into the thigh muscle of each hind limb.  
2.8.3. Intranasal (i.n.) 
Six to eight weeks old female mice were anaesthetised with 200 μL of ketamine/xylazine solution (50 mg/6.25 mg/kg). 20 μL vaccine in isotonic solution (PBS) was applied to the nares and mice were allowed to inhale the solution.   
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2.9. Mouse organ harvesting and preparation of single cell suspension Mice were sacrificed via CO2 asphyxiation and the relevant tissues removed utilising aseptic techniques. Leukocytes isolated from mice were enumerated using a haemocytometer or by an automated cell counter, Countess (Invitrogen). Viability of the cells was determined by trypan blue exclusion (Sigma-Aldrich).  
2.9.1. Lungs Prior to collection of the lung lobes, circulating blood was removed by injection of cold PBS-heparin (20 U/mL; Sigma) into the right atrium of the heart to inflate and perfuse the lungs. The lung lobes were then transferred into RPMI media (Gibco®) for the isolation of leukocytes. Diced lung tissue was digested with collagenase type 4197 (50 
U/mL; Freehold NJ) and DNAse I (13 μg/mL; Sigma) at 37 °C for 30 minutes before 
homogenisation and multiple filtration steps using a 40 μm cell strainer (BD Biosciences). Erythrocytes were lysed by resuspending the pellet in 1 mL of ACK lysis buffer for 1 minute before 10 mL of FCS supplemented RPMI media added. Leucocytes were then counted by trypan blue exclusion and diluted to the desired concentration.  
2.9.2. Lymph nodes and spleen 
Lymph nodes and spleens were homogenized by passing through a 40 μm cell strainer (BD Biosciences) in RPMI media and then pelleted by centrifugation (5 minutes, 4 °C, 1500 rpm). Erythrocytes were removed using ACK lysis buffer and single cell suspensions were prepared and counted as described for lungs previously.  
2.9.3. Peripheral blood Prior to CO2 asphyxiation, mice were held in a restrainer and a scalpel blade was used 
to puncture the tail lateral vein. Approximately 200 μL of blood was collected in a 5 mL tube containing 2mL of PBS-heparin (20 U/mL; Sigma). The blood suspension was stratified on 3 mL of Histopaque 1083 (Sigma) and centrifuged at room temperature, 300 g for 30 minutes. The peripheral blood mononuclear cells (PBMCs), formed as a cloudy white ring at the interface between the aqueous and histopaque phase, was collected and washed twice with complete RPMI media. Erythrocytes were removed using ACK lysis buffer and single cell suspensions were prepared and counted as described for lungs previously. 
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2.9.4. Ears Both ears were removed and immediately split into dorsal and ventral halves using surgical forceps. These parts of the ear tissue were then diced with scissors, transferred into RPMI media then digested with collagenase type 4197 (50 U/mL; 
Freehold NJ) and DNAse I (13 μg/mL; Sigma) at 37 °C for 45 minutes. Digestion was stopped by adding cold complete RPMI media and passed through a 40 μm cell strainer (BD Biosciences). Single cell suspensions were then prepared and counted as described for lungs previously.  
2.10. Transgenic T-lymphocyte isolation and adoptive transfer Spleens from donor female P25 mice (CD45.1 background) were harvested and filtered 
using a 40 μm cell strainer (BD Biosciences) then pelleted by centrifugation (5 minutes, 4 °C, 1500 rpm). Erythrocytes were lysed by resuspending the pellet in 1 mL of ACK lysis buffer for 1 minute and then recovered by adding 10 mL of complete RPMI media. Cells were then counted by tryphan blue exclusion and plated at the desired concentration for further assays. After the preparation of single cell suspension, cells were washed in warm RPMI without FCS and resuspended at a concentration of 5x107 cells/mL. Cells were incubated with 5mM carboxyfluorescein-diacetate-succinimidyl-ester (CFSE; Life Technologies) at 37 °C for 10 minutes with inversion every 3 minutes to ensure a homogenous suspension.  CFSE is an intracellular dye used to track cell division. Each time a CFSE-labelled cell divides, the proportion of CFSE is equally distributed to each of the two daughter cells (Lyons and Parish, 1994). Cells were then washed thoroughly and resuspended in complete RPMI media to a final concentration of 2.5x106 cells/mL. Wild type C57BL/6 recipient mice (CD45.2 background) were placed under a warm lamp to allow the vasodilatation of the lateral tail veins and were restrained using the appropriate restrainer apparatus. Approximately 5x105 CFSE-
labelled cells in 200 μL RPMI media were injected intravenously (i.v.) into the lateral tail veins of recipient mice. 
 
2.11. Flow cytometry 
2.11.1. Surface staining Approximately 2x106 cells, prepared as described in Section 2.10., were transferred into a 96-well round bottom plate (BD Biosciences) and pelleted by centrifugation at 
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1500 rpm (5 minutes, 4 °C). The supernatant was decanted, and cells were resuspended in FACS wash (PBS with 2% FCS). Fc receptors were blocked with anti-mouse CD16/CD32 (BD Biosciences; 1:200, 20 minutes on a shaker, 4 °C). Cells were 
then washed twice with 200 μL FACS wash and incubated with 30 μL of appropriate antibody mix (diluted in FACS wash) for 30 minutes (on a shaking block, 4 °C). Cells were washed thoroughly with FACS wash to remove unbound antibody and then fixed by resuspending the pellet in 10% neutral buffered formalin. The plates were kept covered and stored at 4 °C until acquisition.  
2.11.2. Intracellular staining Single cell suspensions were prepared at a concentration of 2-5x106 cells/mL as described in Section 2.10. in complete RPMI media. The cells were incubated (4 hours, 37 °C, 5% CO2) with the addition of relevant protein recall antigens (10 μg/mL) or media alone as controls. This was then followed by the addition of Brefeldin A (10 
μg/mL; Sigma) and further incubation (16 hours, 37 °C, 5% CO2) to allow intracellular accumulation of cytokines. Cells were collected following the incubation by centrifugation (1500 rpm, 5 minutes, 4 °C) and removing the supernatant. Non-specific 
Fc receptor bindings were blocked with 50 μL of anti-mouse CD16/CD32 (20 minutes, 4 °C). Cells were then washed with 200 μL FACS wash followed by surface staining described in Section 2.11.1. using appropriate antibody mix. After the incubation with surface markers, cells were washed twice with FACS wash and then fixed by adding 
100 μL Cytofix solution (BD Biosciences) and left incubated for 20-30 minutes at 4 °C. Using Cytoperm wash (BD Biosciences), cells were washed thoroughly then stained using appropriate antibody mix prepared in Cytoperm wash and incubated for 30 minutes (on a shaking block, 4 °C). Cells were washed twice using Cytoperm and then resuspended in 10% neutral buffered formalin and stored away from the light at 4 °C until acquisition.  
2.11.3. Flow cytometry analysis Flow cytometry data acquisition of all samples was conducted using an LSR-Fortessa or LSR-II 5L flow analyser (BD Biosciences) and analysed with BD FACSDiva™ software (BD Biosciences). Cell samples were filtered, and single colour compensation controls were generated by immunostaining BD CompBeads with the same antibody utilised in 
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the experimental panel (Appendix 2), except for live/dead staining, CFSE/VPD labelled cells, or where the antibody utilised would not bind to compensation beads, in which case murine leukocytes were labelled with the appropriate markers in the same manner as experimental cell samples. All immunostained cells and beads were fixed in 10% neutral buffered formalin prior to data acquisition. Samples processed in PC3 
were fixed overnight and further addition of 50 μL neutral buffered formalin was required. The acquisition of the data was performed by collecting the cells at a rate no faster than 9000 events per second to minimise the electronic abort counts and sample blockages. Single-cell flow cytometry analysis was performed using FlowJo® software (FlowJo, LLC). Appendix 2-7 shows the antibodies and appropriate gating strategies utilised for each panel that are also references in the relevant result chapters.  
2.12. IFNγ ELISPOT Antigen-specific IFNγ secreting lymphocytes from mice were measured by ELISPOT as previously described by Kao et al., 2012. Membranes of a 96-well ELISPOT plate (MultiScreen-IP, Millipore) were wet with 35% ethanol and washed thoroughly with PBS. The wells were then coated (overnight, 4 °C) with anti-IFNγ antibody (AN18 10 
μg/mL in PBS), washed and blocked with complete RPMI media (2 hours, 37 °C). The blocking solution was decanted, and purified vaccine peptides or relevant proteins added as recall antigens (10 μg/mL) with Concanavalin A (ConA; 3 μg/mL) or media alone as controls. Splenocyte suspension were plated at 2 x 105 cells per well and incubated for 20 hours, at 37 °C in 5% CO2. The cells were decanted, and the plates were washed 6 times with PBST (0.1 % Tween 20). Captured IFNγ was then detected with biotinylated anti-IFNγ antibody (XMG1.2-biotin 5 μg/mL in PBS/0.5% BSA, incubated overnight, 4 °C). Plates were washed thoroughly with PBST (0.1 % Tween 20) followed by the addition of avidin alkaline phosphatase (Sigma; 1:1000 v/v in PBS/0.5% BSA, 45 minutes, RT). Plates were washed thoroughly with PBST (0.1 % Tween 20) and then PBS. The presence of IFNγ producing cells was visualised by the addition of alkaline phosphatase substrate solution (in NPP buffer; 0.01% Substrate A, 0.01% Substrate B; AP conjugate substrate kit, Biorad). Developed spots were then counted using an automated ELISPOT reader (AID EliSpot Reader software v 6.0; Autoimmun Diagnostika GmbH, Germany) and reported as frequency per million cells.  
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Table 2.4. List of antigens for ex-vivo cell stimulation in this study 
Antigens Concentration Source Description Ag85A 10 μg/mL BEI Resources (NR-14871) Recombinant form of the antigen 85 complex A of M. tuberculosis expressed in E. coli Ag85B 10 μg/mL Dr. Rachel Pinto Recombinant form of the antigen 85 complex B of M. tuberculosis expressed in E. coli BEI Resources (NR-14870) Ag85C 10 μg/mL BEI Resources (NR-14858) Recombinant form of the antigen 85 complex C of M. tuberculosis expressed in E. coli CysD 10 μg/mL Dr. Rachel Pinto Recombinant protein expressed in 
E. coli MPT83 10 μg/mL Dr. Anneliese Ashhurst Recombinant protein expressed in E. coli CysVac2 10 μg/mL Dr. Claudio Counoupas and Dr. Diana Quan Recombinant fusion protein (Ag85B-CysD) CysVac5 10 μg/mL Chapter 3 Section 3.2.1. Recombinant fusion protein (Ag85B-CysD-MPT83) P25 10 μg/mL Sigma Immunodominant peptide I-A(b) MTB280-294 (FQDAYNAAGGHNAVF) BCG lysate 10 μg/mL Centenary Institute Lysate of BCG Pasteur pellet cells resuspended in PBS Recombinant BCG crude supernatants 20 μg/mL Chapter 4 Section 4.2.1 Crude supernatants collected from recombinant BCG cultures in media without BSA PstS1 10 μg/mL BEI Resources (NR-14859) Native protein purified from M. tuberculosis H37Rv CFP fraction GroES 10 μg/mL BEI Resources (NR-14861) Native protein purified from M. tuberculosis H37Rv CFP fraction MPT32 (Apa) 10 μg/mL BEI Resources (NR-14862) Native protein purified from M. tuberculosis H37Rv CFP fraction TB10.4 10 μg/mL Dr. Rachel Pinto EsxH from ESX-3 of M. tuberculosis (ESAT-6 like protein)  CFP10 10 μg/mL Dr. Rachel Pinto EsxB of M. tuberculosis (ESAT-6 like protein) CFP 10 μg/mL Centenary Institute Concentrated culture filtrate proteins (CFP) secreted by M. 
tuberculosis BEI Resources (NR-14827) Concanavalin A (ConA) 3 μg/mL Sigma Lymphocyte mitogen  
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2.13. M. tuberculosis aerosol infection Mice were challenged with M. tuberculosis H37Rv (BEI Resources, Manassas, VA) by low-dose aerosol infection (with approximately 108 CFU bacteria which resulted in a final infective dose of 100 viable bacilli per mouse) in an inhalation exposure apparatus (Glas-Col, Terre Haute, IN). The infectious dose was verified 24 hours post infection by plating lung homogenates onto supplemented Middlebrook 7H11 media. Four and/or 20 weeks after the infection, lungs and spleen were harvested and homogenised. Bacterial loads were then determined by plating serial dilutions of the tissue homogenate onto supplemented Middlebrook 7H11 media, and then incubating at 37 °C for approximately 21 days. Colony forming units (CFU) were counted and expressed as Log10 CFU.  
2.14. Histopathology The middle right lobe of murine lungs was harvested and then perfused with 10% neutral buffered formalin and processed at the Veterinary Pathology Diagnostic Services (Sydney School of Veterinary Science, the University of Sydney) for paraffin embedding, slide mounting and haematoxylin and eosin (H&E) staining. Slides were then visualised and observed using Leica DM600B microscope (Leica Microsystem©) with a magnification of 40x.  
2.15. Statistical analysis Statistical analysis was performed using GraphPad Prism 7 software (GraphPad Software, La Jolla CA, USA). The significance of differences between experimental groups was evaluated by one- or two-way analysis of variance (ANOVA), with pairwise comparison of multi grouped data sets achieved using Tukey’s honest significant difference (HSD) post-hoc test and was considered significant when the P values were 
≤ 0.05 (* p<0.1; ** p<0.01; *** p<0.001; **** p<0.0001).    
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CHAPTER	3:	The	 Immunogenicity	 and	 Protective	Efficacy	against	Tuberculosis	of	a	Triple-Antigen	Subunit	Vaccine		 	
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3.1. Introduction	and	aims	Tuberculosis	 (TB)	 is	 a	 leading	global	 cause	of	death	 from	 a	 single	 infectious	 agent,	causing	 up	 to	 1.7	 million	 deaths	 annually	 (WHO,	 2017).	 New	 estimate	 suggests	 a	quarter	of	 the	world’s	population	 is	 latently	 infected	with	M.	tuberculosis,	 this	state	allows	the	bacteria	to	survive	and	enter	a	quiescent	phase	which	can	reactivate	later	in	life	(WHO,	2017).		
Mycobacterium	 bovis	 Bacillus	 Calmette-Guérin	 (BCG)	 is	 the	 only	 licensed	 vaccine	available	 for	 humans.	 BCG	 vaccine	 is	 among	 the	most	widely	 used	 vaccines	 in	 the	world;	 more	 than	 3	 billion	 individuals	 have	 been	 vaccinated	 with	 BCG	 since	 its	introduction	in	1921	(Franco-Paredes	et	al.,	2006,	WHO,	2016)	and	over	100	million	doses	of	BCG	are	administrated	annually	(Liu	et	al.,	2009).	However,	despite	being	able	to	provide	good	protection	for	newborns	and	children	against	disseminated	forms	of	TB,	BCG	displays	a	high	variation	in	its	degrees	of	protection	against	pulmonary	TB	infection	in	adolescences	and	adults	(ranging	from	0-80%),	the	population	that	bears	the	highest	burden	of	the	disease	(Colditz	et	al.,	1994,	Fine,	1995).	Therefore,	improved	vaccines	that	offer	efficient	and	consistent	protection	against	this	disease	are	urgently	needed.		
There	are	two	major	strategies	that	have	been	used	to	develop	new	vaccines	against	TB	infection.	The	first	strategy	is	the	substitution	of	the	current	vaccine,	BCG,	in	a	form	of	 an	 improved	modified	 version	 of	 the	 strain	 (Kaufmann	 et	 al.,	 2014a)	 or	 a	 new	attenuated	live	of	the	pathogen	M.	tuberculosis	itself	(Arbues	et	al.,	2013).	The	other	strategy	is	to	develop	prime-boost	vaccines	in	which	BCG	continues	to	be	given,	and	later	an	additional	new	vaccine	is	delivered	as	a	booster	that	can	improve	and	extend	BCG’s	 initial	 priming	 and	 protective	 effects	 (Villela	 et	 al.,	 2014).	 Based	 on	 these	approaches,	 several	 novel	 vaccine	 candidates	 against	 TB	 are	 now	 currently	 in	preclinical	 and	clinical	 trials,	 including	 recombinant	BCG	strains,	 live	attenuated	M.	
tuberculosis	 strains,	 mycobacterial	 extracts,	 recombinant	 viral-vectored	 platforms,	and	protein-adjuvant	combinations	(Villela	et	al.,	2014).	
While	the	current	vaccine	available	BCG	is	likely	to	be	retained	due	to	its	efficacy	to	provide	protection	against	TB	 in	 infants	and	young	children,	protein-based	 subunit	vaccines	may	offer	the	potential	to	elicit	the	protective	effects	of	BCG	in	adolescents	
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and	adults	and	provide	better	safety	especially	in	immunocompromised	individuals.	Subunit	vaccines	can	also	be	a	safer	alternative	compared	to	live	vaccine	vectors	and	may	be	better	when	given	as	multiple	doses.	Pre-clinical	and	clinical	works	have	shown	that	 the	 ability	 of	 protein	 based	 subunit	 vaccines	 to	 induce	 long-lasting	 T	 cell	responses	 therefore	 able	 to	 provide	 long-term	 protection	 against	 M.	 tuberculosis	infection	(Kaech	et	al.,	2002,	Doherty	et	al.,	2007).		
Determining	antigens	for	use	in	new	generation	of	subunit	vaccines	is	critical	for	their	efficacy	as	M.	tuberculosis	expresses	a	great	number	of	antigens	that	are	considered	immunodominant,	i.e.	secreted	Ag85	protein	family	and	ESAT6	protein.	There	is	also	no	 clear	 consensus	 among	 the	 antigens	 combinations	 that	 are	 required	 to	 provide	optimal	protection.	One	very	important	consideration	is	the	ability	of	this	pathogen	to	remain	 dormant	 in	 macrophages	 and	 then	 reactivate	 later	 under	 immune-compromised	 condition.	 During	 this	 shift	 from	 aerobic	 growth	 to	 dormancy,	 M.	
tuberculosis	 undergoes	 physiological	 changes	 in	 its	 energy	 and	 metabolic	 status	(Gopinath	et	al.,	2015).	Environmental	stresses	such	as	hypoxia,	nutrient	deprivation,	iron	 restriction,	 mild	 acidity,	 and	 reactive	 nitrogen	 and	 oxygen	 species	 induce	dormancy	(Tan	et	al.,	2010)	and	these	factors	cause	the	expression	pattern	of	proteins	to	differ	from	that	in	active	phase	(Counoupas	et	al.,	2016).	This	is	argued	to	be	one	of	the	 limitations	 of	 BCG	 vaccine	 as	 the	 persistence	 of	 BCG	 bacilli	 in	 the	 host	 is	inadequately	defined	(Kaveh	et	al.,	2014)	and	the	vaccine	may	be	rapidly	cleared	from	the	host	before	entering	 the	dormant	phase,	 thus	 limiting	 the	vaccine	 responses	 in	latently	infected	individuals.	
The	 clinical	 features	 of	 TB	 infection	 include	 multi	 processes	 of	 primary	 infection,	latency	and	reactivation.	In-vitro	models	of	M.	tuberculosis	that	mimic	environmental	conditions	 of	 different	 in-vivo	 stages	 have	 demonstrated	 expression	 of	 several	different	antigens	expressed	by	M.	tuberculosis	under	these	conditions	(Ma	et	al.,	2016).	In	the	past	few	years,	TB	subunit	vaccine	research	has	made	substantial	progress	with	several	vaccine	candidates	in	clinical	trials.	However	most	of	these	vaccine	candidates	are	 constructed	 based	 on	 the	 antigens	 that	 are	 secreted	 by	 rapidly	 growing	 M.	
tuberculosis	during	acute	primary	infection,	such	as	the	fusion	proteins	Ag85B-TB10.4	(H4:IC31)	and	MTB32A-MTB39A	 (M72+AS01E)	 (Aeras,	2018),	with	many	 fusion	or	protein	 combinations	 in	 preclinical	 development.	 More	 recently,	 fusion	 protein	
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vaccines	that	include	antigens	expressed	by	the	bacilli	in	various	metabolic	stages	have	been	 developed;	 these	 include	 candidates	 now	 in	 clinical	 trials	 such	 as	 Ag85B-Rv2660c-ESAT6	 (H56:IC31)	 (Lin	et	 al.,	 2012)	and	Rv2608-Rv3619-Rv3620-Rv1813	(ID93+GLA-SE)	 (Baldwin	 et	 al.,	 2012)	 in	 clinical	 trials	 (Aeras,	 2018);	 whereas	preclinical	candidates	under	investigation	include	TB10.4-HspX,	ESAT6-RpfE	(Xin	et	al.,	2013),	the	poly-epitope	derived	from	the	Hsp65-Ag85B-19kDa	lipoprotein	–Hsp16	and	 Rv1733c	 (Geluk	 et	 al.,	 2012).	 However,	 it	 is	 unknown	 if	 these	 candidates	 can	induce	protection	against	TB	 in	humans.	Therefore,	 further	 research	 in	discovering	more	combinations	of	antigens	that	are	recognised	at	both	active	and	latent-stage	of	infection	is	crucial	in	TB	vaccine	development.	
Our	 laboratory	 has	 previously	 identified	 a	 protein	 family	 compromising	 the	 M.	
tuberculosis	 sulphate-assimilation	 pathway	 (SAP)	 whose	 members	 are	 highly	upregulated	 during	 conditions	 of	 intracellular	 stress	 (Pinto	 et	 al.,	 2004)	 and	recognised	 during	 the	 course	 of	M.	 tuberculosis	 infection	 in	 both	mice	 and	humans	(Pinto	et	al.,	2012).	Most	importantly,	SAP	antigens	such	as	CysD	and	CysNC	are	highly	expressed	during	the	chronic	phase	of	M.	tuberculosis	infection	(Pinto	et	al.,	2012).	This	makes	 these	 antigens	 potential	 candidates	 for	 TB	 subunit	 vaccines	 that	 target	 all	tubercle	bacilli	populations	in	various	metabolic	states	of	infection.	
Exploring	 alternative	 antigens	 from	 M.	 tuberculosis	 as	 candidates	 for	 TB	 subunit	vaccines	 along	with	 different	 adjuvant	 combinations	 can	 contribute	 to	 enhance	 the	efficacy	and	aid	 in	 the	development	of	TB	vaccines.	 In	 this	chapter,	a	SAP-based	TB	subunit	vaccine	is	examined.	A	novel	candidate	termed	CysVac5	is	the	newest	member	of	CysVac	vaccine	family	developed	in	our	laboratory.	It	is	a	fusion	protein	vaccine	that	consists	of	Ag85B,	CysD,	and	MPT83	proteins.	Here	we	examined	the	capability	of	this	candidate	 to	provide	protection	 in	 comparison	 to	CysVac2	 (Counoupas	et	 al.,	 2016,	Counoupas	et	al.,	2017),	the	first	generation	of	CysVac	vaccine	family.	The	following	aims	will	therefore	be	addressed	in	this	chapter:	
(i) To	examine	 in	mice	the	 immunogenicity	 induced	by	the	novel	 fusion	protein	subunit	vaccine	CysVac5,	both	pre-	and	post-M.	tuberculosis	infection.	(ii) To	 determine	 if	 CysVac5	 can	 protect	 mice	 against	 aerosol	 infection	 with	virulent	M.	tuberculosis.	
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(iii) To	 determine	 if	 the	 novel	 polysaccharide	 adjuvants	 Advax	 can	 provide	increased	 safety	and	efficacy	against	M.	 tuberculosis	 in	 combination	with	 the	CysVac5	subunit	vaccine.		
3.2. Results	
3.2.1. Construction,	 expression	 and	 purification	 of	 the	 CysVac5	 fusion	
protein	The	recombinant	prokaryotic	expression	plasmid	pET28a-CysVac5	was	constructed	by	 Dr.	 Rachel	 Pinto.	 The	 gene	 encoding	 the	 secreted	 antigen	 FbpB	 (Ag85B),	 an	immunodominant	antigen	expressed	early	during	M.	tuberculosis	infection	(DeJesus	et	al.,	2017)	was	 fused	with	cysD	gene,	which	encodes	the	 first	enzyme	involved	 in	M.	
tuberculosis	sulphate	assimilation	pathway	(Pinto	et	al.,	2012,	Counoupas	et	al.,	2016)	and	the	coding	region	of	MPT83,	a	secreted	lipoprotein	recognised	during	human	TB	(Kao	et	al.,	2012).	The	recombinant	CysVac5	was	expressed	as	the	fusion	form	of	three	antigens	with	a	molecular	weight	of	approximately	100	kDa	(Figure	3.1.B)	and	purified	from	pET28a-CysVac5-transformed	E.	 coli	 BL21(DE3)	 using	 a	 cobalt	 affinity	 cation	exchange	 chromatography	 column	 under	 denaturing	 conditions.	 SDS-PAGE	 (Figure	3.1.C)	and	Western	blot	using	a	His-tag	monoclonal	antibody-HRP	conjugate	(Figure	3.1.D)	were	then	used	to	further	verify	the	purity	and	the	specificity	of	recombinant	fusion	protein	after	chromatography.	
3.2.2. CysVac5/MPLA-DDA	 vaccination	 induces	 high	 frequency	 of	
polyfunctional	 CD4+	 T	 cells	 before	 and	 after	 M.	 tuberculosis	
infection	In	 order	 to	 assess	 early	 immune	 responses	 generated	 by	 CysVac5	 subunit	 vaccine,	CysVac5	or	CysVac2	purified	protein	was	delivered	subcutaneously	to	C57BL/6	mice	formulated	 in	 the	 adjuvant	 combination	 of	 monophosphoryl	 lipid-A	 and	dimethyldioctadecylammonium	bromide	 (MPLA-DDA),	 as	detailed	 in	Figure	3.2.	 Six	and	10	weeks	after	the	first	injection	was	given,	peripheral	blood	mononuclear	cells	(PBMCs)	were	collected	as	described	in	Chapter	2,	section	2.8	and	restimulated	ex	vivo	with	CysVac5	protein.	Cytokine	production	was	examined	by	intracellular	staining.		
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Figure 3.1. Expression, purification and analysis of the CysVac5 recombinant 
protein. (A) Structural diagram of the recombinant prokaryotic expression plasmid pET28a-CysVac5. (B) Expression of CysVac5 in E. coli BL21(DE3) induced by 0.5 mM isopropyl β-D-thiogalactopyranoside (IPTG) and purified using a His-affinity column chromatography. Coomassie Blue-stained 12% SDS-PAGE: E. coli BL21 lysate (lane 1), 
E. coli BL21 expressing CysVac5 lysate (lane 2), molecular weight ladder (M); (C) Purification of CysVac5 via Coomassie Blue-stained SDS-PAGE. E. coli BL21 expressing CysVac5 lysate (lane 1) was subjected to His-affinity column chromatography and CysVac5 isolated (lane 2, 3), molecular weight ladder (M). (D) Purified CysVac5 was verified by immunoblot with His-tag monoclonal antibody-HRP conjugate (lane 1), molecular weight ladder (M).   
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Figure 3.2. Summary of the immunisation schedule to investigate the 
immunogenicity and protective efficacy of CysVac5 vaccine in C57BL/6 mice. C57BL/6 mice (n = 6-8) were vaccinated once subcutaneously (s.c.) with 5x105 CFU of BCG, or 3 times s.c. with 3 Pg of either CysVac2 or CysVac5 vaccines formulated in MPLA/DDA with 2-week intervals. Six and 10 weeks after the first vaccination, the mice were bled to collect peripheral blood mononuclear cells (PBMCs) to assess the early immune responses after the vaccination. Twelve weeks after the BCG vaccine was given, mice were challenged with aerosol M. tuberculosis H37Rv (100 CFU/mice). Four and 20 weeks after the challenge, mice were euthanised to examine the immune responses and assess the bacterial loads in both lungs and spleen  
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0 2 4 16 
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At	week	6	post	vaccination,	the	triple	positive	CD4+	T	cell	population	secreting	IFNg,	IL2	 and	 TNF	 was	 significantly	 increased	 in	 BCG	 vaccinated	 group,	 with	 higher	frequencies	observed	in	both	CysVac2	and	CysVac5	vaccinated	mice	(Representative	flow	cytometry	plots	are	shown	in	Figure	3.3A).	This	trend	was	maintained	when	the	population	was	observed	at	week	10	after	vaccination	and	there	was	a	slight	increase	in	the	percentage	of	CD4+IFNg+IL2+TNF+	T	cells	across	the	3	groups.	There	was	also	a	significant	increase	in	the	frequencies	of	IFN-g	and	TNF	positive	as	well	as	single	TNF	producing	CD4+	T	cells	in	groups	vaccinated	with	CysVac2	and	CysVac5,	with	a	slightly	higher	magnitude	for	both	populations	in	CysVac5	group.	The	increased	frequency	was	also	 observed	 in	 the	 CD4+	T	 cell	 population	 producing	 IL17	 in	 CysVac5	 vaccinated	groups	at	both	6	and	10	weeks	after	the	first	vaccination,	indicating	that	CysVac5	also	generated	strong	Th17-type	responses	(Figure	3.4).	Additionally,	the	total	number	of	cells	producing	multiple	cytokines	in	response	to	CysVac5	ex	vivo	stimulation	was	also	greater	 for	 the	CysVac5	vaccinated	mice	 in	 comparison	 to	 those	 that	 received	BCG.	Therefore,	subcutaneous	immunisation	with	CysVac5	fusion	protein	vaccine	led	to	a	sustained	increase	in	the	frequency	of	multi-cytokine	producing	T	cells	in	the	blood.	
The	next	series	of	experiments	was	to	determine	the	type	of	immunity	generated	by	CysVac5	vaccination	after	M.	tuberculosis	infection.	C57BL/6	mice	were	vaccinated	as	detailed	in	Figure	3.2	and	then	challenged	with	a	low	dose	aerosol	of	M.	tuberculosis	H37Rv	 (100	CFU	per	mouse)	 twelve	weeks	 after	 the	 first	 vaccination.	Four	and	20	weeks	after	the	infection,	pulmonary	cells	were	collected	and	restimulated	ex	vivo	with	CysVac5	 single	 protein	 components	 (Figure	 3.5	 -	 3.7).	 Overall,	 mice	 that	 received	CysVac5	 vaccination	 showed	 the	 greatest	 frequency	 of	 pulmonary	 CD4+	 T	 cells	producing	multiple	 cytokines	 (IFNg,	 IL2,	 IL17	 and	 TNF)	 upon	 recalling	 to	 singular	components	 of	 CysVac5	 protein	 vaccine	 (Ag85B,	 CysD	 or	MPT83)	 in	 both	 short	 (4	weeks	post	challenge)	and	extended	time	point	(20	weeks	post	challenge).	
Closer	examination	revealed	that	at	4	weeks	after	M.	tuberculosis	H37Rv	infection,	the	response	to	the	CysVac5	fusion	protein	vaccine	in	the	lung	seemed	to	be	majorly	driven	by	Ag85B	component	as	upon	stimulation	with	this	single	protein,	about	12%	of	the	total	CD4+	T	cells	in	the	lungs	were	quadruple	positive	for	IFNg,	IL2,	IL17	and	TNF.	
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Figure	3.3.	CysVac5/MPLA-DDA	induction	of	polyfunctional	CD4+	T	cells	before	
M.	 tuberculosis	 challenge.	Mice	 were	 vaccinated	 as	 described	 in	 Figure	 3.2.	 (A)	Representative	flow	plots	demonstrating	changes	in	the	frequency	of	IFNγ,	IL2,	and/or	TNF	positive	CD4+	T	cells	in	murine	PBMCs	after	CysVac5/MPLA-DDA	delivery.	Two	
(B)	 and	 6	 (C)	 weeks	 after	 the	 last	 vaccination,	 PBMCs	 were	 isolated	 from	 the	peripheral	 blood.	 Intracellular	 cytokine	 staining	 was	 performed	 after	 4	 hours	stimulation	with	CysVac5	protein	and	16	hours	stimulation	with	Brefeldin	A.	Data	are	a	representative	of	2	independent	experiments	and	show	cytokine	frequency	±	SEM	for	 each	 group.	 Significance	 of	 differences	 between	 the	 groups	was	 determined	 by	ANOVA	(*	p<0.1;	**	p<0.01;	***	p<0.001;	****	p<0.0001).			 	
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Figure 3.4. Production of IL-17 producing CD4+ T cells after subcutaneous 
delivery of CysVac5/MPLA-DDA. Mice were vaccinated as described in Figure 3.2. 
(A) Representative flow plots demonstrating changes in the frequency of IL17 producing CD4+ T cells in murine PBMCs after CysVac5/MPLA-DDA delivery. Two (B) and 6 (C) weeks after the last vaccination, PBMCs were isolated from the peripheral blood. Intracellular cytokine staining was performed after 4 hours stimulation with CysVac5 protein and 16 hours stimulation with Brefeldin A. Data are a representative of 2 independent experiments and show cytokine frequency r SEM for each group. Significance of differences between the groups was determined by ANOVA (* p<0.1; ** p<0.01). 
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This	number	was	significantly	higher	compared	to	those	shown	in	mice	that	received	only	BCG	or	left	unvaccinated.	High	frequencies	of	other	important	subsets	reported	to	be	important	in	combating	TB	infection	were	also	observed	in	CysVac5	vaccinated	mice,	this	vaccination	was	able	to	generate	significantly	greater	frequencies	of	triple-cytokine	positives	CD4+	T	cells	populations	(i.e.	IFNg+IL2+TNF+;	IFNg+IL17+TNF+;	and	IL2+IL17+TNF+)	even	when	compared	to	its	well-studied	relative	CysVac2.	The	similar	trend	was	maintained	when	these	subsets	were	observed	after	stimulated	ex-vivo	with	the	other	vaccine	 component	CysD	 (Figure	3.6)	although	 the	population	 sizes	were	smaller	than	those	seen	upon	recalling	to	Ag85B.	As	for	MPT83	stimulation,	CysVac5	vaccinated	was	the	only	group	that	showed	proportion	of	polyfunctional	CD4+	T	cells	producing	 IFNg,	 IL2,	 IL17	 and	 TNF	 as	 well	 as	 triple	 positive	 (IFNg+IL2+TNF+;	IFNg+IL17+TNF+;	and	IL2+IL17+TNF+)	and	double	positive	(IFNg+IL17+;	and	IL17+TNF+)	CD4+	T	cells	populations	(Figure	3.7).	
Further	investigation	of	the	immunity	generated	by	CysVac5	fusion	protein	vaccine	at	20	weeks	after	M.	tuberculosis	infection	revealed	that	the	mice	that	received	CysVac5	had	the	highest	frequency	of	CD4+	T	cells	producing	IFNg,	IL2,	IL17	and	TNF	compared	to	other	groups,	 including	 those	 that	 received	CysVac2	after	 recalling	 to	 the	Ag85B	component	(Figure	3.8).	Other	important	phenotypes	of	these	CD4+	T	cells	generated	by	 the	 CysVac5	 vaccine	 were	 IFNg+IL2+TNF+;	 IFNg+IL17+TNF+;	 and	 IL2+IL17+TNF+	positive	 cells	 as	well	 as	 those	 producing	 IFNg	 and	 TNF	 only.	 In	 addition,	 cytokine	production	by	CysD	or	MPT83-specific	CD4+	T	cells	 in	 the	 lungs	of	 immunised	mice	reflected	the	same	patterns	of	responses	seen	at	4	weeks	after	the	infection,	although	responses	were	relatively	low	(Figure	3.9,	3.10).	Together,	these	results	indicate	that	CysVac5	vaccination	 formulated	 in	MPLA-DDA	adjuvant	was	 able	 to	 stimulate	both	Th1	and	Th17	responses.	
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Figure 3.5. CysVac5/MPLA-DDA vaccination induces Ag85B-specific 
polyfunctional pulmonary CD4+ T cells after M. tuberculosis infection. Antigen-specific cells were detected by intracellular immunostaining and flow cytometry after 
ex-vivo stimulation with Ag85B protein (10 Pg/mL). (A) Representative flow plots of Ag85B-specific CD4+ T cells producing multiple cytokines. (B) Frequency of cytokine-producing CD4+ T-lymphocytes in the lungs was assessed at 4 weeks after M. 
tuberculosis infection. Data are the means r SEM (n = 6-8) and are a representative of 2 independent experiments. Statistically significant differences among groups are shown as determined by ANOVA with Tukey’s honest significant difference (HSD) post hoc test (** p<0.01; *** p<0.001; **** p<0.0001).  
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Figure 3.6. CysVac5/MPLA-DDA vaccination induces CysD-specific 
polyfunctional pulmonary CD4+ T cells after M. tuberculosis infection. Antigen-specific cells were detected by intracellular immunostaining and flow cytometry after 
ex-vivo stimulation with CysD protein (10 Pg/mL). (A) Representative flow plots of CysD-specific CD4+ T cells producing multiple cytokines. (B) Frequency of cytokine-producing CD4+ T-lymphocytes in the lungs was assessed at 4 weeks after M. 
tuberculosis infection. Data are the means r SEM (n = 6-8) and are a representative of 2 independent experiments. Statistically significant differences among groups are 
shown as determined by ANOVA with Tukey’s honest significant difference (HSD) post hoc test (**** p<0.0001)    
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Figure 3.7. CysVac5/MPLA-DDA vaccination induces MPT83-specific 
polyfunctional pulmonary CD4+ T cells after M. tuberculosis infection. Antigen-specific cells were detected by intracellular immunostaining and flow cytometry after 
ex-vivo stimulation with MPT83 protein (10 Pg/mL). (A) Representative flow plots of MPT83-specific CD4+ T cells producing multiple cytokines. (B) Frequency of cytokine-producing CD4+ T-lymphocytes in the lungs was assessed at 4 weeks after M. 
tuberculosis infection. Data are the means r SEM (n = 6-8) and are a representative of 2 independent experiments. Statistically significant differences among groups are shown as determined by ANOVA with Tukey’s honest significant difference (HSD) post hoc test (* p<0.1; **** p<0.0001).    
IF
N
γ 
IL
2 
TNF 
IL17 
Unvaccinated BCG CysVac2 CysVac5 
A. 
0.0
0.5
5
10
15
%
 o
f C
D4
+  T
 c
el
ls
IFNg
IL2
TNF
+
+
+
+
+
+
+
-
+
+
-
+
IL17
+
+
-
-
+
-
+
+
+
-
+
-
+
-
-
+
+
-
-
-
-
+
+
+
-
+
+
-
-
+
-
+
-
+
-
-
-
-
+
+
-
-
+
-
-
-
-
+
****
*
****
Unvaccinated
BCG
CysVac2
CysVac5
B. 
 
71 Chapter 3. CysVac5 
                                    
Figure 3.8. CysVac5/MPLA-DDA vaccination induces Ag85B-specific 
polyfunctional pulmonary CD4+ T cells after M. tuberculosis infection. Antigen-specific cells were detected by intracellular immunostaining and flow cytometry after 
ex-vivo stimulation with Ag85B protein (10 Pg/mL). (A) Representative flow plots of Ag85B-specific CD4+ T cells producing multiple cytokines. (B) Frequency of cytokine-producing CD4+ T-lymphocytes in the lungs was assessed at 20 weeks after M. 
tuberculosis infection. Data are the means r SEM (n = 6-8) and are a representative of 2 independent experiments. Statistically significant differences among groups are 
shown as determined by ANOVA with Tukey’s honest significant difference (HSD) post hoc test (* p<0.1; ** p<0.01; *** p<0.001; **** p<0.0001). 
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Figure 3.9. CysVac5/MPLA-DDA vaccination induces CysD-specific 
polyfunctional pulmonary CD4+ T cells after M. tuberculosis infection. Antigen-specific cells were detected by intracellular immunostaining and flow cytometry after 
ex-vivo stimulation with CysD protein (10 Pg/mL). (A) Representative flow plots of CysD-specific CD4+ T cells producing multiple cytokines. (B) Frequency of cytokine-producing CD4+ T-lymphocytes in the lungs was assessed at 20 weeks after M. 
tuberculosis infection. Data are the means r SEM (n = 6-8) and are a representative of 2 independent experiments. Statistically significant differences among groups are 
shown as determined by ANOVA with Tukey’s honest significant difference (HSD) post hoc test (* p<0.1; ** p<0.01).   
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Figure 3.10. CysVac5/MPLA-DDA vaccination induces MPT83-specific 
polyfunctional pulmonary CD4+ T cells after M. tuberculosis infection. Antigen-specific cells were detected by intracellular immunostaining and flow cytometry after 
ex-vivo stimulation with MPT83 protein (10 Pg/mL). (A) Representative flow plots of MPT83-specific CD4+ T cells producing multiple cytokines. (B) Frequency of cytokine-producing CD4+ T-lymphocytes in the lungs was assessed at 20 weeks after M. 
tuberculosis infection. Data are the means r SEM (n = 6-8) and are a representative of 2 independent experiments. Statistically significant differences among groups are shown as determined by ANOVA with Tukey’s honest significant difference (HSD) post hoc test (* p<0.1; **** p<0.0001).  
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3.2.3. CysVac5/MPLA-DDA	vaccination	 increases	 the	number	of	antigen	
specific	IFNg	splenocytes	produced	after	M.	tuberculosis	infection	In	 order	 to	 further	 assess	 antigen-specific	 responses	 to	 CysVac5	 vaccination,	 IFNg-secreting	T	lymphocyte	responses	were	analysed	by	ELISPOT	using	splenocytes	from	vaccinated	and	control	mice.	Significantly	higher	frequencies	of	antigen-specific	IFNg-secreting	cells	were	observed	in	the	spleen	of	both	CysVac2	and	CysVac5	vaccinated	mice	 at	 both	 short	 (4	weeks)	 and	 extended	 (20	weeks)	 time	 points	 post	 infection	(Figure	3.11.A,	B).	Splenocytes	from	CysVac2	and	CysVac5	vaccinated	mice	secreted	significantly	 increased	 amount	 of	 IFNg	 in	 response	 to	 all	 antigens	 compared	 to	splenocytes	 collected	 from	 unimmunised	 mice	 or	 those	 that	 received	 BCG	 alone.	Notably,	there	were	significantly	higher	number	of	splenocytes	secreting	IFNg	upon	re-stimulation	 with	 MPT83	 antigen	 in	 the	 CysVac5	 vaccinated	 group	 across	 the	experiment	time-points,	suggesting	that	this	specific	response	is	driven	by	the	MPT83	component	of	CysVac5	fusion	protein	vaccine,	that	CysVac2	does	not	possess.	
3.2.4. CysVac5/MPLA-DDA	 reduces	 the	 bacterial	 burden	 in	 M.	
tuberculosis	infected	mice	CysVac2	vaccination,	the	first	generation	of	CysVac	family	vaccine	candidates,	is	more	protective	 against	 TB	 infection	 compared	 to	 BCG	 in	 murine	 models	 with	 lower	bacterial	 loads	 and	 less	 severe	 immunopathology	 (Counoupas	 et	 al.,	 2016).	 To	determine	if	the	addition	of	MPT83	in	CysVac5	could	improve	this	protective	effect,	C57BL/6	mice	(n=	6-8)	were	immunised	subcutaneously	3	times	with	either	CysVac2	or	CysVac5	(3	μg	per	mouse)	in	MPLA-DDA.	5x105	CFU	of	subcutaneous	BCG	was	given	once	as	controls.	Twelve	weeks	after	the	first	vaccination,	the	mice	were	challenged	with	M.	 tuberculosis	 H37Rv	 and	 bacterial	 numbers	 in	 both	 spleen	 and	 lungs	were	enumerated	at	4-	and	20	post-	infection.	
In	 the	 lungs,	CysVac5	was	able	 to	 confer	a	 significant	 level	of	protection	against	M.	
tuberculosis	infection	at	the	early	time	point	(4	weeks	post	challenge)	compared	to	the	unvaccinated	group	with	0.9	Log10	CFU	reduction,	and	slightly	lower	bacterial	counts	than	those	that	received	BCG	or	CysVac2	vaccinations	(Figure	3.12.A).		
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Figure	3.11.	Splenic	antigen-specific	IFNg-secreting	cells	following	subcutaneous	
CysVac5/MPLA-DDA	vaccination.	C57BL/6	mice	were	s.c.	3	 times	2	week-interval	with	3	µg	of	CysVac2	or	CysVac5	formulated	in	MPLA-DDA,	or	s.c.	once	with	5x105	CFU	of	BCG.	Twelve	weeks	after	the	first	vaccination,	mice	were	aerosol	challenged	with	a	low	dose	of	M.	tuberculosis	H37Rv	(approximately	100	CFU/mouse).	The	number	of	antigen-specific	IFNg-secreting	cells	were	enumerated	by	ELISPOT.	(A)	Representative	results	from	the	ELISPOT	assay	of	murine	splenocytes	after	ex-vivo	restimulated	with	respective	antigens	(10	µg/mL	each)	showing	the	number	of	spots	formed	per	well.	Spot	forming	units	(SFU)	were	determined	at	four	(B)	and	20	(C)	weeks	post-infection.	The	 data	 are	 the	 means	 ±	 SEM	 and	 are	 representative	 of	 2	 repeat	 experiments.	Statistical	 significance	was	 calculated	by	ANOVA	with	Tukey’s	HSD	post	hoc	 test	 (*	p<0.1;	**	p<0.01;	***	p<0.001;	****	p<0.0001).				 	
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Figure 3.12. Protection afforded by CysVac5/MPLA-DDA following aerosol M. 
tuberculosis infection. C57BL/6 mice were vaccinated as described in Figure 3.2. and 12 weeks after the first vaccination, mice were aerosol challenged with a low dose of 
M. tuberculosis H37Rv (100 CFU/mouse). Mice were euthanised after weeks post challenge to harvest the lungs and spleen. The bacterial loads were enumerated at 4 
(A, E) and 20 (B, F) weeks post-challenge in the lungs (A, B) or spleen (E, F). Data are the means r SEM and are representative of 2 independent experiments. Statistical significance was determined by ANOVA with Tukey’s HSD post hoc test (* p<0.1; ** p<0.01; **** p<0.0001). Lung pathology was observed at 4 (C) and 20 (D) weeks post 
M. tuberculosis challenge after formalin fixing and hematoxylin-eosin (H&E) staining.   
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As	previously	reported	(Sterne	et	al.,	1998,	Brandt	et	al.,	2002,	Rodrigues	et	al.,	2011,	Counoupas	 et	 al.,	 2016),	 BCG	 protection	waned	 over	 time,	 however	 the	 protection	provided	by	CysVac5	was	maintained	at	the	extended	time	point	in	the	lung	(20	weeks	post	challenge;	Figure	3.12.B).	In	the	spleen	there	were	no	significant	differences	in	protection	 observed	 across	 the	 vaccinated	 groups	 at	 4	 weeks	 post-M.	 tuberculosis	infection	 due	 to	 wide	 variability	 of	 the	 bacterial	 counts	 in	 several	 groups	 (Figure	3.12.E).	However,	at	20	weeks	post	challenge,	CysVac2	and	CysVac5	immunised	mice	had	significantly	lower	numbers	of	bacterial	CFU	compared	to	unvaccinated	and	BCG	immunised	mice	(Figure	3.12.F).	
Histopathological	 analysis	 of	 the	 lungs	 also	 confirmed	 a	 better	 containment	 of	 the	infection	 indicated	 by	 more	 compact	 aggregate	 of	 macrophages	 that	 formed	granulomas	 (Figure	 3.12.C,	 D).	 At	 early	 time	 point,	 the	 lung	 section	 of	 CysVac5	vaccinated	 mice	 appeared	 less	 inflamed	 with	 darker	 and	 smaller	 granulomas	indicating	more	lymphocytes	infiltration	to	the	sites	of	infection	and	better	bacterial	containment.	Lung	sections	of	CysVac5	vaccinated	mice	 for	 the	extended	time	point	showed	 even	 cleaner	 areas	 compared	 to	 those	 collected	 from	 mice	 that	 were	 left	unvaccinated	 or	 received	 only	 BCG	 vaccination.	 Overall,	 CysVac5	 vaccination	 was	protective	against	M.	tuberculosis	infection	at	both	short	(4	weeks)	and	extended	(20	weeks)	 time	 points	 after	 challenge.	 Although	 there	 were	 no	 significant	 statistical	differences,	there	was	a	trend	that	CysVac5	provided	better	protection	than	BCG	and	CysVac2	against	M.	tuberculosis	infection.	These	results	correlate	with	the	significantly	greater	immune	responses	driven	by	this	novel	subunit	protein	vaccine	both	pre-	and	post-M.	tuberculosis	exposure.	
3.2.5. CysVac5/MPLA-DDA	 induces	 protective	 immunity	 in	 different	
variants	of	MHC	haplotypes	(BALB/c	mice)	The	variety	of	different	genetic	factors	in	humans	is	one	of	the	biggest	challenges	in	developing	vaccines	against	TB.	Effective	vaccines	should	be	able	to	impart	protection	against	infection	in	populations	with	different	genetic	background.	In	order	to	examine	the	protective	immunity	afforded	by	CysVac5	vaccination	in	different	mouse	strains,	BALB/c	(H2d)	mice,	a	distinct	strain	to	C57BL/6	(H2b),	were	either	left	unvaccinated	or	vaccinated	according	to	the	same	schedule	described	in	Figure	3.2.		
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Figure 3.13. CysVac5/MPLA-DDA induction of polyfunctional CD4+ T cells in 
BALB/c mouse PBMCs before M. tuberculosis challenge. Mice were vaccinated as described in Figure 3.2. (A) Representative flow plots demonstrating changes in the frequency of IFNγ, IL2, and/or TNF positive CD4+ T cells in murine PBMCs after CysVac5/MPLA-DDA delivery. (B) Six weeks after the last vaccination, PBMCs were isolated from the peripheral blood. Intracellular cytokine staining was performed after 4 hours stimulation with CysVac5 protein and 16 hours stimulation with Brefeldin A. Data are a representative of 2 independent experiments and show cytokine frequency 
r SEM for each group. Significance of differences between the groups was determined by ANOVA (* p<0.1; ** p<0.01; **** p<0.0001).    
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Figure 3.14. Generation of IL-17 producing CD4+ T cells after subcutaneous 
delivery of CysVac5/MPLA-DDA in BALB/c mouse PBMCs. Mice were vaccinated as described in Figure 3.2. (A) Representative flow plots demonstrating changes in the frequency of IL17 producing CD4+ T cells in murine PBMCs after CysVac5/MPLA-DDA delivery. (B) Six weeks after the last vaccination, PBMCs were isolated from the peripheral blood. Intracellular cytokine staining was performed after 4 hours stimulation with CysVac5 protein and 16 hours stimulation with Brefeldin A. Data are a representative of 2 independent experiments and show cytokine frequency r SEM for each group. Significance of differences between the groups was determined by ANOVA (*** p<0.001; **** p<0.0001).     
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Ten	 weeks	 after	 the	 first	 injection,	 PBMCs	 were	 collected	 to	 assess	 the	 immunity	induced	 by	 the	 vaccines	 prior	 to	 M.	 tuberculosis	 challenge.	 At	 12	 weeks	 post	immunisation	mice	were	 infected	with	 low	dose	aerosol	M.	 tuberculosis	H37Rv	and	immunity	examined	4	weeks	later.	
Analysis	 of	 cytokine	 production	 by	 ICS	 and	 flow	 cytometry	 revealed	 that	 s.c.	vaccination	of	CysVac5/MPLA-DDA	was	able	to	induce	immunity	in	BALB/c	mice	prior	to	 the	 M.	 tuberculosis	 infection	 (Figure	 3.13).	 Although	 the	 magnitude	 of	 these	responses	 was	 small	 compared	 to	 that	 observed	 in	 C57BL/6	 mice,	 it	 was	 still	distinguishable	 from	 the	 unvaccinated	 group.	 CysVac2	 and	 CysVac5	 vaccinations	induced	Th17	responses	indicated	by	the	high	frequency	of	IL17+	CD4+	T	cells	in	the	PBMCs	(Figure	3.14).	After	recalling	to	each	protein	component	of	the	vaccine,	mice	that	have	been	 immunised	by	CysVac2	or	CysVac5	tended	to	show	greater	Th1	and	Th17-type	 responses	 compared	 to	 those	 that	 received	 BCG	 or	 left	 unvaccinated	observed	at	4	weeks	following	M.	tuberculosis	aerosol	challenge	(Figure	3.15	–	3.17).	
To	 assess	 antigen-specific	 responses	 to	 CysVac5	 vaccination,	 IFNg-secreting	 T-lymphocyte	 responses	were	 analysed	 by	 ELISPOT.	 Significantly	 higher	 numbers	 of	antigen-specific	IFNg-secreting	cells	were	observed	in	the	spleen	to	each	of	the	single	component	 and	 the	 whole	 fusion	 proteins	 of	 the	 vaccine	 of	 CysVac2	 and	 CysVac5	subcutaneously	 immunised	 mice.	 In	 particular,	 there	 was	 a	 significantly	 increased	number	 of	 MPT83	 specific	 T-lymphocytes	 producing	 IFNg	 cytokine	 found	 in	 the	splenocytes	of	BALB/c	mice	that	received	CysVac5	compared	to	the	other	three	groups	(Figure	3.18).	
The	 next	 experiment	 assessed	 the	 protective	 efficacy	 of	 CysVac5/MPLA-DDA	 in	BALB/c	mice.	Mice	were	vaccinated	as	summarised	in	Figure	3.2.	and	then	challenged	by	aerosol	infection	with	M.	tuberculosis	H37Rv.	Four	weeks	later,	the	bacterial	loads	in	the	lungs	and	spleen	were	enumerated	to	determine	the	protective	efficacy	of	the	vaccine.	CysVac5/MPLA-DDA	was	able	 to	reduce	the	bacterial	burden	 in	both	 lungs	and	 spleen	 (0.63	 and	 0.32	 log10	 of	 reduction	 respectively)	 compared	 to	 the	unvaccinated	mice	(Figure	3.19).	These	results	were	consistent	with	the	pre	and	post-
M.	tuberculosis	challenge	immunogenicity,	in	which	CysVac5	could	generate	stronger	immune	responses	against	M.	tuberculosis	infection.	
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Figure 3.15. CysVac5/MPLA-DDA vaccination induces Ag85B-specific 
polyfunctional pulmonary CD4+ T cells after M. tuberculosis infection in BALB/c 
mice. Antigen-specific cells were detected by intracellular immunostaining and flow cytometry after ex-vivo stimulation with Ag85B protein (10 Pg/mL). (A) Representative flow plots of Ag85B-specific CD4+ T cells producing multiple cytokines. 
(B) Frequency of cytokine-producing CD4+ T-lymphocytes in the lungs was assessed at 4 weeks after M. tuberculosis infection. Data are the means r SEM (n = 6-8) and are a representative of 2 independent experiments. Statistically significant differences 
among groups are shown as determined by ANOVA with Tukey’s honest significant difference (HSD) post hoc test (* p<0.1; ** p<0.01; *** p<0.001; **** p<0.0001).  
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Figure 3.16. CysVac5/MPLA-DDA vaccination induces CysD-specific 
polyfunctional pulmonary CD4+ T cells after M. tuberculosis infection in BALB/c 
mice. Antigen-specific cells were detected by intracellular immunostaining and flow cytometry after ex-vivo stimulation with CysD protein (10 Pg/mL). (A) Representative flow plots of CysD-specific CD4+ T cells producing multiple cytokines. (B) Frequency of cytokine-producing CD4+ T-lymphocytes in the lungs was assessed at 4 weeks after 
M. tuberculosis infection. Data are the means r SEM (n = 6-8) and are a representative of 2 independent experiments. Statistically significant differences among groups are 
shown as determined by ANOVA with Tukey’s honest significant difference (HSD) post hoc test (* p<0.1; ** p<0.01; *** p<0.001; **** p<0.0001).  
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Figure 3.17. CysVac5/MPLA-DDA vaccination induces MPT83-specific 
polyfunctional pulmonary CD4+ T cells after M. tuberculosis infection in BALB/c 
mice. Antigen-specific cells were detected by intracellular immunostaining and flow cytometry after ex-vivo stimulation with MPT83 protein (10 Pg/mL). (A) Representative flow plots of MPT83-specific CD4+ T cells producing multiple cytokines. 
(B) Frequency of cytokine-producing CD4+ T-lymphocytes in the lungs was assessed at 4 weeks after M. tuberculosis infection. Data are the means r SEM (n = 6-8) and are a representative of 2 independent experiments. Statistically significant differences 
among groups are shown as determined by ANOVA with Tukey’s honest significant difference (HSD) post hoc test (* p<0.1; ** p<0.01; *** p<0.001; **** p<0.0001).  
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Figure 3.18. Splenic antigen-specific IFNJ-secreting cells following subcutaneous 
CysVac5/MPLA-DDA vaccination in BALB/c mice. Mice were s.c. 3 times 2 week-interval with 3 µg of CysVac2 or CysVac5 formulated in MPLA-DDA, or s.c. once with 5x105 CFU of BCG. Twelve weeks after the first vaccination, mice were aerosol challenged with a low dose of M. tuberculosis H37Rv (approximately 100 CFU/mouse). The number of antigen-specific IFNJ-secreting cells were enumerated by ELISPOT. (A) Representative results from the ELISPOT assay of murine splenocytes after ex-vivo restimulated with respective antigens (10 Pg/mL each) showing the number of spots formed per well. Spot forming units (SFU) were determined at 4 weeks post-infection 
(B). The data are the means r SEM and are representative of 2 repeat experiments. Statistical significance was calculated by ANOVA with Tukey’s HSD post hoc test (* p<0.1; ** p<0.01; *** p<0.001; **** p<0.0001).  
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Figure 3.19. Protection afforded by CysVac5/MPLA-DDA following aerosol M. 
tuberculosis infection in BALB/c mice. Mice were vaccinated as described in Figure 3.2. and 12 weeks after the first vaccination, mice were aerosol challenged with a low dose of M. tuberculosis H37Rv (100 CFU/mouse). Mice were euthanised four weeks post challenge (A) to harvest the lungs (B) and spleen (C) for bacterial load enumeration. Data are the means r SEM and are representative of 2 independent 
experiments. Statistical significance was determined by ANOVA with Tukey’s HSD post hoc test (* p<0.1; ** p<0.01; **** p<0.0001).    
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3.2.6. The	 use	 of	 the	 polysaccharide	 adjuvant	 AdvaxCpG	 to	 improve	
CysVac5	 vaccine-induced	 protection	 against	 M.	 tuberculosis	
infection	In	the	next	set	of	experiments,	the	ability	of	Advax	formulations	to	enhance	protective	immune	 responses	 against	M.	 tuberculosis	 infection	 when	 combined	 with	 CysVac5	subunit	vaccine	was	 tested.	Using	 the	 same	vaccination	 schedule	as	 summarised	 in	Figure	 3.2,	 mice	 were	 vaccinated	 intramuscularly	 (i.m.)	 with	 CysVac2/AdvaxCpG	 or	CysVac5/AdvaxCpG	(3	µg/1mg	per	dose	respectively)	or	AdvaxCpG	alone	(1	mg	per	dose).	AdvaxCpG	differs	from	regular	Advax	in	the	addition	of	oligonucleotide	CpG7909	(10	µg	per	 dose),	 further	 improved	 protection	 against	 TB	 infection	 in	 murine	 models	compared	to	Advax	alone	(Counoupas	et	al.,	2017).	Six	weeks	after	the	last	vaccination	mice	were	bled	 for	 immunogenicity	assessment,	and	2	weeks	 later	were	challenged	with	M.	tuberculosis	H37Rv	and	assessed	for	bacterial	loads	as	described	in	Figure	3.2.	
The	 immunogenicity	 of	 CysVac5	 vaccine	 formulated	 in	 AdvaxCpG	 was	 assessed	 by	examining	CysVac5-specific	 responses	 in	PBMCs	6	weeks	after	 the	 last	vaccination.	Intracellular	staining	confirmed	a	higher	percentage	of	cytokine	producing	CD4+	T	cells	in	the	CysVac5/AdvaxCpG	group	upon	restimulation	with	CysVac5	recombinant	protein	(Figure	 3.20).	 The	 CysVac5/AdvaxCpG	 group	showed	 the	highest	 frequency	 of	 triple	positive	 IFNg+IL2+TNF+	 and	 double	 positive	 IFNg+IL2+	 and	 IL2+TNF+	 cells	 (Figure	3.20.B).	 There	was	 also	 a	 high	 percentage	 of	 cells	 producing	 IFNg	 and	 IL2	 in	 both	CysVac2/AdvaxCpG	and	CysVac5/AdvaxCpG	vaccinated	groups.	A	high	number	of	TNF+	CD4+	T	cells	was	also	observed	among	all	groups,	while	there	was	no	significant	IL17	production	detectable	from	any	of	the	vaccinated	mice	with	either	CysVac2/AdvaxCpG	or	CysVac5/AdvaxCpG	before	M.	tuberculosis	challenge.	Together	these	results	showed	that	vaccination	with	CysVac5/AdvaxCpG	was	able	to	induce	greater	Th1-like	responses	in	mice	 compared	 to	 those	vaccinated	with	BCG,	However,	 the	Th17-like	 responses	were	not	detectable	after	Advax	formulated	vaccine	delivery.	
The	next	experiment	examined	the	vaccine	induced	immunity	4	weeks	post	aerosol	M.	
tuberculosis	 challenge	 after	 restimulation	with	 singular	 components	 of	 the	 vaccine	(Ag85B,	CysD,	or	MPT83)	in	the	lungs.		
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Figure 3.20. CysVac5/AdvaxCpG induction of polyfunctional CD4+ T cells before M. 
tuberculosis challenge. Mice were vaccinated as described in Figure 3.2. (A) Representative flow plots demonstrating changes in the frequency of IFNγ, IL2, and/or TNF positive CD4+ T cells in murine PBMCs after CysVac5/AdvaxCpG delivery. (B) Six weeks after the last vaccination, PBMCs were isolated from the peripheral blood. Intracellular cytokine staining was performed after 4 hours stimulation with CysVac5 protein and 16 hours stimulation with Brefeldin A. Data are a representative of 2 independent experiments and show cytokine frequency r SEM for each group. Significance of differences between the groups was determined by ANOVA (** p<0.01; *** p<0.001).  
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Figure 3.21. CysVac5/AdvaxCpG vaccination induces Ag85B-specific 
polyfunctional pulmonary CD4+ T cells after M. tuberculosis infection. Antigen-specific cells were detected by intracellular immunostaining and flow cytometry after 
ex-vivo stimulation with Ag85B protein (10 Pg/mL). (A) Representative flow plots of Ag85B-specific CD4+ T cells producing multiple cytokines. (B) Frequency of cytokine-producing CD4+ T-lymphocytes in the lungs was assessed at 4 weeks after M. 
tuberculosis infection. Data are the means r SEM (n = 6-8) and are a representative of 2 independent experiments. Statistically significant differences among groups are 
shown as determined by ANOVA with Tukey’s honest significant difference (HSD) post hoc test (* p<0.1; *** p<0.001; **** p<0.0001).  
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Figure 3.22. CysVac5/AdvaxCpG vaccination induces CysD-specific polyfunctional 
pulmonary CD4+ T cells after M. tuberculosis infection. Antigen-specific cells were detected by intracellular immunostaining and flow cytometry after ex-vivo stimulation with CysD protein (10 Pg/mL). (A) Representative flow plots of CysD-specific CD4+ T cells producing multiple cytokines. (B) Frequency of cytokine-producing CD4+ T-lymphocytes in the lungs was assessed at 4 weeks after M. tuberculosis infection. Data are the means r SEM (n = 6-8) and are a representative of 2 independent experiments. Statistically significant differences among groups are shown as determined by ANOVA 
with Tukey’s honest significant difference (HSD) post hoc test (* p<0.1; *** p<0.001; **** p<0.0001).   
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Figure 3.23. CysVac5/AdvaxCpG vaccination induces MPT83-specific 
polyfunctional pulmonary CD4+ T cells after M. tuberculosis infection. Antigen-specific cells were detected by intracellular immunostaining and flow cytometry after 
ex-vivo stimulation with MPT83 protein (10 Pg/mL). (A) Representative flow plots of MPT83-specific CD4+ T cells producing multiple cytokines. (B) Frequency of cytokine-producing CD4+ T-lymphocytes in the lungs was assessed at 4 weeks after M. 
tuberculosis infection. Data are the means r SEM (n = 6-8) and are a representative of 2 independent experiments. Statistically significant differences among groups are shown as determined by ANOVA with Tukey’s honest significant difference (HSD) post hoc test (* p<0.1; ** p<0.01; **** p<0.0001).    
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At	 the	 cellular	 level,	 when	 recalled	 to	 Ag85B	 protein,	 both	 groups	 that	 received	CysVac2/AdvaxCpG	 and	 CysVac5/AdvaxCpG	 vaccination	 were	 able	 to	 generate	 high	frequencies	of	polyfunctional	CD4+	cells	in	the	lungs	that	secreted	IFNg,	IL2,	IL17	and	TNF	after	challenged	with	aerosol	M.	tuberculosis	(Figure	3.21).	Unlike	the	immunity	driven	by	the	vaccine	pre–M.	tuberculosis	exposure,	the	immune	responses	observed	after	 challenge	 showed	 a	 significant	 Th17	 like	 response	 indicated	 by	 the	 high	frequency	of	quadruple	positive	CD4+	T	cells	producing	IFNg,	IL2,	IL17,	and	TNF	after	
ex-vivo	 stimulation	 with	 Ag85B	 protein.	 In	 addition,	 a	 clear	 population	 of	 Ag85B-specific	 CD4+	 T	 cells	 producing	 IL17	 alone	 was	 observed	 in	 the	 lungs	 of	 mice	immunised	intramuscularly	with	CysVac5/AdvaxCpG	(Figure	3.21).	
Similar	trends	were	observed	upon	recall	to	other	protein	components	of	the	vaccine	(CysD	 and	 MPT83).	 CysVac2/AdvaxCpG	 and	 CysVac5/AdvaxCpG	 vaccinated	 groups	showed	 a	 high	 proportion	 of	 CD4+	 T	 cells	 displaying	 a	 triple	 positive	 phenotype	(IFNg+IL2+TNF+)	 or	 producing	 IFNg/TNF	 only	 after	 CysD	 stimulation	 (Figure	 3.22),	with	slightly	higher	percentages	of	these	subsets	in	the	CysVac5/AdvaxCpG	group	upon	recall	 to	MPT83	 (Figure	 3.23).	 Additionally,	 a	 significantly	 increased	 proportion	 of	single	positive	TNF+-secreting	CD4+	T	cells	was	observed	among	all	the	groups	after	stimulation	with	each	of	the	singular	component	of	CysVac5	protein	vaccine.	
Analysis	 of	 IFNg-secreting	 antigen-specific	 T-lymphocyte	 responses	 in	 the	 spleen	revealed	for	mice	immunised	i.m.	with	CysVac5/AdvaxCpG	mice	vaccinated	with	BCG,	CysVac2/AdvaxCpG	and	CysVac5/AdvaxCpG	were	able	to	generate	greater	numbers	of	IFNg-secreting	 antigen-specific	 T-lymphocytes	 compared	 to	 those	 that	 received	AdvaxCpG	only	or	left	unvaccinated	in	response	to	Ag85B,	CysD	or	the	entire	CysVac2	or	 CysVac5	 proteins	 (Figure	 3.24).	 Only	 minimal	 responses	 were	 observed	 upon	MPT83	restimulation	in	CysVac5/AdvaxCpG	vaccinated	mice.	Levels	of	IFNg-producing	cells	in	response	to	Ag85B	or	CysD	was	comparable	between	CysVac2/AdvaxCpG	and	CysVac5/AdvaxCpG	 groups	 (Figure	 3.24.B).	 The	 small	 IFNg	 responses	 observed	 in	control	groups	were	most	likely	driven	by	the	pathogen	M.	tuberculosis	itself.	
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Figure	3.24.	Splenic	antigen-specific	IFNg-secreting	cells	following	subcutaneous	
CysVac5/AdvaxCpG	vaccination.	C57BL/6	mice	were	s.c.	3	times	2	week-interval	with	3	µg	of	CysVac2	or	CysVac5	formulated	in	AdvaxCpG,	or	s.c.	once	with	5x105	CFU	of	BCG.	Twelve	weeks	after	the	first	vaccination,	mice	were	aerosol	challenged	with	a	low	dose	of	M.	 tuberculosis	H37Rv	 (approximately	100	CFU/mouse).	The	number	of	 antigen-specific	IFNg-secreting	cells	were	enumerated	by	ELISPOT.	(A)	Representative	results	from	 the	 ELISPOT	 assay	 of	 murine	 splenocytes	 after	 ex-vivo	 restimulated	 with	respective	antigens	(10	µg/mL	each)	showing	the	number	of	spots	formed	per	well.	Spot	 forming	units	(SFU)	were	determined	at	 four	(B)	and	20	weeks	post-infection.	The	 data	 are	 the	 means	 ±	 SEM	 and	 are	 representative	 of	 2	 repeat	 experiments.	Statistical	significance	was	calculated	by	ANOVA	with	Tukey’s	HSD	post	hoc	test	(**	p<0.01;	***	p<0.001;	****	p<0.0001).			 	
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Figure 3.25. Protection afforded by CysVac5/AdvaxCpG following aerosol M. 
tuberculosis infection in. C57BL/6 were vaccinated as described in Figure 3.2. and 12 weeks after the first vaccination, mice were aerosol challenged with a low dose of M. 
tuberculosis H37Rv (100 CFU/mouse). Mice were euthanised four weeks post challenge (A) to harvest the lungs (B) and spleen (C) for bacterial load enumeration. Data are the means r SEM and are representative of 2 independent experiments. 
Statistical significance was determined by ANOVA with Tukey’s HSD post hoc test (* p<0.1; ** p<0.01; **** p<0.0001).   
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The	 final	 set	 of	 the	 experiments	 examined	 the	 bacterial	 burden	 in	 both	 lungs	 and	spleen	of	M.	tuberculosis	 infected	mice	after	CysVac5/AdvaxCpG	delivery.	Four	weeks	after	the	low	dose	aerosol	challenge	of	M.	tuberculosis	H37Rv,	lungs	and	spleen	were	harvested	and	the	bacterial	loads	in	each	of	the	organ	were	enumerated	to	determine	the	 protective	 efficacy	 of	 the	 vaccine.	 Vaccination	 of	 C57BL/6	 mice	 with	CysVac5/AdvaxCpG	resulted	in	an	approximate	of	0.64	and	0.48	log10	reduction	in	the	lungs	and	spleen	respectively	(Figure	3.28).	The	level	of	protection	provided	by	either	CysVac5	or	CysVac2	formulated	in	AdvaxCpG	was	comparable	to	that	provided	by	BCG	vaccination.	 The	 bacterial	 burdens	 in	 the	 lungs	 and	 spleen	 of	 mice	 from	 CysVac	immunised	groups	were	significantly	lower	compared	to	those	treated	with	AdvaxCpG	only	or	left	unvaccinated	(Figure	3.25).	Overall	the	immunogenicity	results	observed	pre-	and	post-aerosol	M.	tuberculosis	challenge	showed	that	the	use	of	AdvaxCpG	with	CysVac5	 vaccination	 generated	 high	 frequency	 of	multifunctional	 CD4+	 T	 cells	 and	elicited	 strong	 antigen-specific	 T-lymphocytes	 responses	 that	 led	 to	 improved	protective	efficacy	against	M.	tuberculosis	infection.	
3.3. Discussion	
3.3.1. CysVac5:	 A	 novel	 fusion	 protein	 subunit	 vaccine	 against	 M.	
tuberculosis	infection	The	selection	of	novel	and	optimal	antigens	for	inclusion	in	subunit	vaccines	is	a	critical	step	 in	 the	 TB	 vaccine	 development.	 However,	 the	 choice	 of	 antigens	 used	 in	M.	
tuberculosis	 vaccine	 candidates	 that	 are	 now	 in	 clinical	 trials	 has	 been	 primarily	focusing	on	a	small	subset	of	immunodominant	proteins,	such	as	antigen	85	complex,	ESAT6	and	TB10.4	(Aeras,	2018,	Kaufmann	et	al.,	2014b).	The	focus	of	this	Chapter,	CysVac5,	 consists	 of	 three	 different	 protein	 components,	 namely	 Ag85B,	 CysD	 and	MPT83.	 The	 vaccine	 was	 based	 on	 CysVac2	 (Ag85B-CysD),	 the	 first	 generation	 of	CysVac	multistage	vaccine	family	whose	components	are	expressed	at	different	stages	of	 the	 M.	 tuberculosis	 life	 cycle	 and	 provided	 significant	 protection	 against	 M.	
tuberculosis	infection	in	several	murine	strains	(Counoupas	et	al.,	2016).	
In	 the	current	study,	protective	antigen	MPT83	was	added	to	CysVac2	recombinant	protein	to	form	a	novel	subunit	vaccine	candidate	termed	CysVac5.	MPT83	(Rv2873)	is	 a	 secreted	mycobacterial	 lipoprotein	 expressed	 on	 the	 surface	 of	M.	 tuberculosis	(Hewinson	et	al.,	1996).	Although	its	function	is	not	well	characterised,	this	antigen	is	
 
97 Chapter 3. CysVac5 
recognised	by	T	 cells	of	TB	 infected	murine	and	humans,	 and	when	given	as	either	protein	or	DNA	vaccine,	MPT83	confers	significant	levels	of	protection	in	both	lungs	and	spleen	against	aerosol	M.	tuberculosis	infection	with	strong	IFNg	CD4+	and	CD8+	T	cell	responses	(Kao	et	al.,	2012).	With	the	addition	of	another	immunogenic	antigen	MPT83	to	the	fusion	vaccine,	it	was	hypothesised	that	CysVac5	provides	an	improved	immune	 responses	 and	 protective	 efficacy	 against	 TB	 infection	 compared	 to	 its	previous	relative	CysVac2.	
CysVac5	 recombinant	 protein	 was	 constructed	 by	 fusing	 a	 chronic	 stage-specific	antigen	of	M.	tuberculosis	sulphate	assimilation	pathway	(SAP)	protein	member,	CysD	with	 two	major	 immunodominant	 mycobacterial	 antigens	 Ag85B	 and	 MPT83.	 The	recombinant	 fusion	 protein	 vaccine	 was	 purified	 using	 a	 cobalt	 affinity	 cation	exchange	chromatography	column	under	denaturing	conditions.	However	as	shown	in	Figure	3.1.C,	the	purification	process	reduced	the	total	amount	of	the	protein.	This	was	thought	to	be	caused	by	sizeable	fractions	of	CysVac5	recombinant	protein	might	be	lost	by	formation	of	insoluble	aggregates	in	the	so-called	inclusion	bodies	(Yang	et	al.,	2011)	 hence	 the	 faint	 bands	 observed	 with	molecular	 weight	 lower	 than	 CysVac5	protein.	For	 future	work,	some	of	 these	aggregated	proteins	may	be	recoverable	by	using	one	or	more	cycles	of	denaturation-renaturation.	However,	the	latter	approach	can	also	 lead	 to	 inactivation	of	 the	protein	and	 reduced	yield.	Low	yields	may	also	result	 from	proteolytic	degradation	of	 the	target	protein	during	one	or	more	of	 the	purification	steps	(Meredith,	2006).	
3.3.2. CysVac5/MPLA-DDA	 affords	 significant	 protection	 against	
pulmonary	M.	tuberculosis	infection	In	this	study,	CysVac5	recombinant	protein	vaccine	has	been	successfully	produced	and	 purified.	 It	 was	 formulated	 in	 MPLA-DDA	 (dimethyldioctadecylammonium	bromide	–	monophosphoryl	lipid	A)	adjuvant	before	subcutaneously	injected	into	the	mice.	 Formulation	 of	 CysVac5	 in	 this	 specific	 liposome	 construction	 resulted	 in	 a	vaccine	that	induced	polyfunctional	CD4+	T	cells	secreting	multiple	cytokines	in	mice	both	pre-	and	post-	M.	tuberculosis	challenge	and	a	reduced	bacterial	number	in	the	lungs	and	spleen.	
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Subcutaneous	 injection	 of	 CysVac5	 formulated	 in	MPLA-DDA	 adjuvant	 in	 C57BL/6	mice	resulting	in	the	generation	of	Th1	and	Th17-like	responses	both	before	and	after	
M.	 tuberculosis	 infection	 indicated	 by	 high	 frequencies	 of	 CD4+	 T	 cells	 producing	multiple	cytokines	(IFNγ,	IL2,	IL17	and	TNF).	The	induction	of	T	cells	producing	IFNγ,	IL2,	and	TNF	(Th1-like	response)	observed	in	CysVac5	vaccinated	mice	(Figure	3.3)	was	thought	to	be	correlated	with	vaccine-induced	Th1-mediated	protection,	as	these	polyfunctional	cells	were	reported	to	be	a	crucial	protective	immunity	in	combating	TB	infection.	As	Darrah	et	al.	(2007)	pointed	out	that	the	magnitude	of	the	vaccine-induced	 polyfunctional	 CD4+	 T	 cells	 responses	 was	 significantly	 correlated	 with	protection	 against	 infection.	 In	Leishmania	major	 infection	model,	 several	 different	vaccine-induced	 CD4+	T	 cells	with	 distinct	multiple	 cytokines	 profiles	were	 able	 to	protect	mice	against	the	infection	(Darrah	et	al.,	2007).	
Upon	recalling	to	each	of	the	CysVac5	component,	triple	positive	pulmonary	CD4+	T	cells	producing	IFNγ,	IL2	and	TNF	observed	at	4-	and	20-weeks	post	M.	tuberculosis	infection	 showed	 the	 percentage	 of	 this	 cell	 subset	 was	 significantly	 increased	 in	CysVac5	 vaccinated	mice.	 In	 addition,	 after	 restimulation	with	MPT83,	 the	 antigen	CysVac2	does	not	have,	mice	that	received	CysVac5	vaccination	generated	the	highest	frequency	of	triple	positive	CD4+	T	cells	although	the	magnitude	was	rather	low	(below	0.5%	of	the	total	cell	numbers;	Figure	3.7	and	3.10).	There	is	substantial	amount	of	evidence	in	the	literature	derived	from	studies	of	murine	TB	models	and	humans	that	T	 cells	 co-producing	 IFNγ,	 IL2,	 and	 TNF	 are	 necessary	 to	 control	 TB	 infection	(Lewinsohn	et	al.,	2017,	Wang	et	al.,	2015,	Smith	et	al.,	2016,	Ritz	et	al.,	2012).	
In	humans,	polyfunctional	CD4+	T	cells	have	been	studied	with	reference	to	severity	of	diseases	 due	 to	 intracellular	 infections	 (Cardona,	 2012).	 For	 example,	 slower	AIDS	progression	in	patients	with	HIV-2	than	those	with	HIV-1	infection	(Duvall	et	al.,	2008)	and	 control	 of	 HIV-1	 without	 anti-retroviral	medications	 are	 associated	 with	 high	frequency	of	polyfunctional	HIV-gag	specific	CD4+	T	cells	(Kannanganat	et	al.,	2007).	In	comparison,	the	studies	of	multifunctional	CD4+	T	cells	regarding	host	containment	of	M.	 tuberculosis	 infection	 are	 contradictory.	On	 one	 hand,	 it	 has	 been	 shown	 that	stronger	mycobacteria-specific	polyfunctional	CD4+	T	cells	were	found	in	adults	with	smears	negative	sputum	for	acid	fast	bacilli	(AFB)	than	those	with	AFB	smear	positive	TB.	 In	addition,	successful	TB	 treatments	 that	rapidly	 reduce	 the	bacterial	 load	are	
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associated	 with	 increased	 proportion	 of	 this	 polyfunctional	 subset.	 The	 increased	population	 of	 PPD-specific	 polyfunctional	 (IFNγ+IL2+TNF+)	 CD4+	 T	 cells	 were	 also	reported	to	correlate	significant	inhibition	of	mycobacterial	growth	in	BCG-vaccinated	infants	(Smith	et	al.,	2016).	On	the	other	hand,	several	studies	have	also	demonstrated	that	polyfunctional	CD4+	T	cells	responses	correlate	with	increased	bacterial	counts	(Caccamo	et	al.,	2010,	Qiu	et	al.,	2012).	
Other	 major	 subsets	 of	 CD4+	 T	 cells	 observed	 after	 restimulation	 with	 single	components	of	CysVac5	vaccine	were	cells	that	were	able	to	produce	both	IFNγ	and	TNF	or	 cells	 that	 are	either	 IFNγ	or	TNF	phenotype	positive.	 IFNγ	 is	known	 for	 its	essential	role	in	host	defense,	Cooper,	et	al.	(1993)	and	Flynn,	et	al.	(1993)	used	IFNγ-deficient	 murine	 model	 to	 define	 the	 critical	 role	 of	 this	 particular	 cytokine	 in	controlling	TB	infection	(Cooper	et	al.,	1993,	Flynn	et	al.,	1993).	IFNγ+	T	cells	can	also	mediate	 its	 effector	 functions	 through	 macrophage	 activation	 that	 lead	 to	 the	inhibition	of	mycobacterial	growth	via	iNOS	induction	and	autophagy	(Lewinsohn	et	al.,	2011).	On	the	other	hand,	mice	deficient	in	TNF	receptor	are	highly	susceptible	to	
M.	tuberculosis	infection	(Flynn	et	al.,	1995,	Bean	et	al.,	1999).	The	deficiency	of	TNF	expression	in	mouse	model	leads	to	poor	control	of	M.	tuberculosis	chronic	infection	by	T	cells	(Allie	et	al.,	2013).	It	has	also	been	demonstrated	in	both	murine	and	humans	that	 TNF	 promotes	 granuloma	maturation	 and	 similar	 to	 IFNγ,	 TNF	 also	 activates	infected	 macrophages	 to	 keep	 the	 infection	 contained	 (Lewinsohn	 et	 al.,	 2011).	Although	 all	 groups	 in	 this	 study	 showed	 increased	 population	of	 double	 or	 single	positive	 of	 either	 IFNγ	 or	 TNF	 CD4+	 T	 cells,	 taking	 other	 and	more	 heterogenous	cytokines	producing	cells	into	account,	CysVac5-specific	T	cells	producing	IFNγ	and/or	TNF	led	to	reduction	of	bacterial	number	in	M.	tuberculosis	infected	mice.	
The	next	important	responses	that	CysVac5	vaccine	was	able	to	significantly	induce	in	this	 study	 was	 Th-17	 like	 response.	 The	 frequency	 of	 quadruple	 positive	(IFNγ+IL2+IL17+TNF+)	 as	 well	 as	 single	 positive	 (IL17+)	 CD4+	 T	 cells	were	 seen	 in	CysVac5	 vaccinated	mice	 upon	 recalling	 to	 single	 component	 of	 the	 vaccine.	 These	subsets	were	not	observed	in	BCG	vaccinated	mice	or	those	left	unvaccinated.	Although	CysVac2	pronounced	a	similar	immunity	pattern,	it	is	clear	that	the	addition	of	another	immunogenic	antigen	MPT83	contributed	to	the	increased	frequencies	of	important	T	cell	subsets	observed	in	CysVac5	vaccinated	mice.	It	has	previously	shown	after	all	that	
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MPT83/MPLA-DDA	induced	protective	immunity	in	the	murine	lungs	against	aerosol	TB	infection	(Kao	et	al.,	2012).	
CysVac5	vaccination	in	this	study	appeared	to	favor	the	induction	of	Th17	CD4+	T	cell	responses	indicated	by	the	increased	population	of	IL17+	CD4+	T	cells	before	and	after	challenge.	 The	 role	 of	 IL17	 in	 vaccine-induced	 protection	 against	 M.	 tuberculosis	infection	is	not	fully	characterized	and	rather	controversial	(Cooper,	2010,	Uranga	et	al.,	 2016).	 IL17	 induces	 the	 expression	 of	 several	 pro-inflammatory	 cytokines	 and	chemokines	 such	 as	 granulocyte	 colony-stimulating	 factor	 (G-CSF),	 IL6	 and	 IL8,	promotes	 neutrophils	 recruitment	 and	 granuloma	 formation	 (Ouyang	 et	 al.,	 2008,	Yoshida	et	al.,	2010).	 IL17	 is	reported	to	also	 induce	the	expression	of	CXCL10	that	leads	to	IFNg	producing	cells	recruitment	to	the	site	of	infection	(Khader	et	al.,	2007).	Contrarily,	 it	has	been	 reported	 that	 a	disproportionate	 IL17	 response	may	 lead	 to	excessive	recruitment	of	neutrophils	resulting	immunopathological	injuries	(Cruz	et	al.,	 2006,	 Desvignes	 and	 Ernst,	 2009).	 A	 recent	 study	 has	 also	 shown	 that	 a	 Th17	response	alone	induced	by	a	vaccine	antigen	was	not	able	to	provide	protection	against	
M.	tuberculosis	infection	(Ashhurst	et	al.,	2018).	However,	intra-nasal	BCG	vaccination	is	reported	to	be	dependent	on	the	anti-M.	tuberculosis	Th17	responses	in	controlling	TB	infection	(Aguilo	et	al.,	2015).	It	is	also	suggested	that	the	correct	balance	between	Th1	 and	Th17	 response	 is	 essential	 for	 optimal	 protection,	 as	 CysVac2	 vaccination	generates	a	strong	Th17	response	that	leads	to	reduction	of	mycobacterial	number	in	the	lungs	and	spleen	of	TB	infected	mice	(Counoupas	et	al.,	2016).	In	addition,	these	increased	Th17-like	immune	responses	could	also	be	driven	by	the	adjuvant	CysVac5	was	 formulated	 in.	 Previous	 studies	 reported	 that	MPLA-DDA	 formulation	 induces	antigen-specific	IFNγ	and	IL17	responses	(Agger	et	al.,	2008)	as	well	as	elicits	mainly	the	 polyfunctional	 CD4+	T	 cells	 secreting	 IFNγ,	 IL2,	 and	TNF	 (Aagaard	 et	 al.,	 2011)	hence	the	observed	high	frequencies	of	these	subsets	in	CysVac5	vaccinated	mice.	
3.3.3. CysVac5	induces	protection	in	mice	with	several	MHC	haplotypes	There	are	 linked	effects	of	host	genetic	background	and	mycobacterial	pathogen	on	infection	susceptibility	(Di	Pietrantonio	et	al.,	2011).	Several	epidemiological	studies	have	shown	that	genetic	factors	have	significant	contributions	to	TB	disease	in	humans.	A	 long	series	and	extensive	experimental	studies	 in	various	animal	models	has	also	established	the	importance	of	host	genetic	background	in	assessing	the	outcomes	of	M.	
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tuberculosis	infection	(Abel	et	al.,	2014).	In	order	to	show	whether	CysVac5	vaccination	could	 provide	 protection	 against	 TB	 infection	 in	 mice	 with	 different	 genetic	background,	 CysVac5/MPLA-DDA	 was	 given	 to	 BALB/c	 (H2d)	 subcutaneously	 to	assess	its	immunogenicity	and	protective	effect	before	and	after	the	infection.	
In	 BALB/c	 murine	 strain,	 it	 was	 observed	 that	 CysVac5	 was	 able	 to	 elicit	 strong	Th1/Th17-like	 responses	 both	 before	 and	 after	 challenge.	 This	 was	 shown	 by	 the	increased	populations	of	multifunctional	CD4+	T	cells	producing	IFNg,	IL2,	TNF	as	well	as	 IL17	 in	 the	 PBMCs	 or	 lungs	 of	 vaccinated	 mice	 (Figure	 3.15	 –	 3.19).	 Further	investigation	revealed	the	pattern	of	immunity	elicited	by	this	novel	subunit	vaccine	where	an	 increase	was	observed	 in	the	number	of	antigen	specific	 IFNg-secreting	T	cells	in	the	spleen	(Figure	3.20.)	of	the	mice	vaccinated	by	CysVac5	in	comparison	to	those	vaccinated	with	BCG	only.	This	trend	of	increased	immunity	was	translated	into	the	protection	against	TB	 infection	 in	both	 lungs	and	 the	 spleens	of	M.	 tuberculosis	infected	mice,	 although	there	was	no	statistical	difference	reached,	CysVac5/MPLA-DDA	was	able	to	reduce	the	bacterial	numbers	in	both	organs	examined	at	4	weeks	after	challenge.	This	indicates	that	protection	correlated	with	the	increased	population	of	multifunctional	cytokine-secreting	CD4+	T	cells	after	CysVac5	vaccination	in	BALB/c	mice	 indicating	that,	similar	 to	what	observed	 in	CysVac2	(Counoupas	et	al.,	2016),	CysVac5	was	capable	to	provide	protective	immunity	across	multiple	murine	strains.	
3.3.4. AdvaxCpG	 formulated	CysVac5	 induces	polyfunctional	CD4+	T	cells	
and	protect	C57BL/6	mice	against	M.	tuberculosis	infection	Although	MPLA-DDA	is	a	potent	and	strong	adjuvant	combination,	 the	use	of	MPLA	with	 other	 immunostimulatory	 substances	 often	 causes	 adverse	 events	 and	 local	reactogenicity	 such	 as	 inflammation	 and	 ulceration	 at	 the	 site	 of	 injection	 after	delivery	(Chen	et	al.,	2012).	Therefore,	it	is	important	to	consider	using	safer	and	more	effective	adjuvants	in	human	vaccine	trials	such	as	Advax™,	a	polysaccharide	adjuvant	derived	from	delta-inulin	(Petrovsky	and	Cooper,	2011).	
A	 formulation	 of	 delta	 inulin	 adjuvant,	 Advax™	 polysaccharide	 combined	with	 low	amount	(approximately	10	µg	per	dose)	of	the	TLR9	agonis	CpG	oligodeoxynucleotide	(CpG)	named	AdvaxCpG	was	tested	as	a	safer	platform	to	deliver	the	novel	CysVac5	to	prevent	the	reactogenicity	caused	by	MPLA-DDA.	Counoupas	et	al.	(2017)	proved	that	
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the	addition	of	CpG	in	Advax	formulation	improved	both	the	immunogenicity	and	the	protective	efficacy	of	CysVac2	vaccine	against	M.	tuberculosis	infection,	increased	the	release	of	several	chemo-attractants	(CXCL1	and	CCL3)	and	promoted	the	rapid	influx	of	monocytes	and	neutrophils	to	the	site	of	vaccination.	
In	this	study,	CysVac5	was	formulated	in	AdvaxCpG	and	then	injected	to	C57BL/6	mice	intramuscularly	to	assess	its	immunogenicity	and	protective	efficacy	pre-	and	post-	M.	
tuberculosis	challenge.	In	this	plant-derived	adjuvant	formulation,	CysVac5/AdvaxCpG	vaccination	was	 able	 protect	 C57BL/6	mice	 against	M.	 tuberculosis	 infection	 in	 the	spleen	to	the	same	extent	as	CysVac2/AdvaxCpG	and	BCG.	It	conferred	about	0.48	log10	protection	compared	to	the	unvaccinated	mice	(Figure	3.28.B.).	However,	looking	at	the	bacterial	numbers	in	the	lungs	at	4	weeks	after	the	infection,	BCG	vaccinated	mice	had	the	lowest	CFU	count	(1.4	log10	reduction)	while	mice	that	received	either	CysVac2	or	CysVac5/AdvaxCpG	had	about	0.61	and	0.64	 log10	 reduction	 in	bacterial	numbers	respectively	in	comparison	the	mice	that	were	left	unvaccinated.	However,	these	levels	of	 protection	 were	 actually	 aligned	 with	 those	 shown	 by	 vaccine	 candidates	 in	preclinical	 studies	 that	 are	 currently	 now	 under	 clinical	 trials.	 For	 example,	H56/CAF01	provided	1.25	log10	protection	(Aagaard	et	al.,	2011),	ID93/GLA-SE	0.48	(Bertholet	et	al.,	2010),	and	M72/AS02	0.60	(Skeiky	et	al.,	2004).	This	indicates	that	CysVac5/AdvaxCpG,	 although	 the	 log	protection	was	 slightly	 lower	 than	 its	previous	relative	CysVac2,	matches	the	protective	effect	provided	by	vaccine	candidates	that	are	currently	 in	 human	 trials.	 Further	 investigation	 of	 CyaVac5/AdvaxCpG	 in	 order	 to	provide	protection	at	an	extended	time-point	after	infection	would	be	a	nice	addition	to	the	study	considering	the	latent	antigen	component	in	CysVac5.	
CysVac5/AdvaxCpG	was	observed	to	have	better	 immune	responses	indicated	by	the	generation	of	polyfunctional	CD4+	T	cells	producing	cytokines	in	various	combinations.	Although	the	percentages	of	these	multiple	cytokine	positive	T	cells	were	not	as	great	as	those	promoted	when	this	novel	vaccine	was	formulated	in	MPLA-DDA,	compared	to	mice	that	received	only	BCG,	CysVac5/AdvaxCpG	generated	higher	numbers	of	these	important	cell	subsets	(IFNg+IL2+TNF+;	IFNg+IL2+;	and	IL2+TNF+	positive	CD4+	T	cells),	slightly	greater	than	those	seen	in	CysVac2/AdvaxCpG	vaccinated	mice	(Figure	3.23.).	Direct	 comparison	 between	 CysVac5	 and	 its	 previous	 relative	 CysVac2	 when	formulated	 in	 AdvaxCpG	 adjuvant	 showed	 no	 statistical	 difference.	 Looking	 at	 the	
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frequency	of	multifunctional	CD4+	pulmonary	T	 cells	before	and	after	 the	 infection,	mice	 that	 received	 either	 of	 these	 subunit	 vaccines	 had	 significantly	 greater	percentages	 compared	 to	 those	 that	 received	AdvaxCpG	 or	 BCG	 only	 (Figure	 3.23.	 –	3.26.).	However,	this	trend	of	increased	immunogenicity	did	not	necessarily	translate	into	better	protection	even	 though	AdvaxTM	was	proven	 to	be	protective	 in	 several	models	of	 infection	(Feinen	et	al.,	2014,	Honda-Okubo	et	al.,	2012).	Similar	 findings	were	reported	in	previous	studies	of	CysVac2	vaccine	candidate	that	when	formulated	in	 AdvaxCpG,	 this	 vaccine	 promoted	 the	 generation	 of	 polyfunctional	 CD4+T	 cells	responses	and	significant	protection	against	TB	infection	although	not	better	than	BCG.	This	indicates	that	the	protective	capacity	of	the	Advax-adjuvanted	vaccine	protective	capacity	may	differ	depending	on	the	nature	of	the	target	pathogens	and	the	type	of	immunity	required	for	optimal	protection.	
Further	analysis	of	post-infection	 immune	 responses	 showed	 increased	numbers	of	antigen-specific	 IFNg-secreting	 T	 cells	 in	 the	 mouse	 splenocytes	 following	 the	intramuscular	 CysVac5/AdvaxCpG	 vaccination	 upon	 single	 antigen	 or	 recombinant	CysVac2/5	 protein	 restimulation	 (Figure	 3.27.)	 which	 were	 far	 greater	 than	 those	observed	in	mice	that	received	BCG.	The	ability	of	Advax	in	inducing	IFNg	response	has	been	seen	in	various	different	models	of	infection	such	as	influenza	(Honda-Okubo	et	al.,	2012)	and	hepatitis	B	(Saade	et	al.,	2013).	To	look	more	closely	at	various	cytokines	production	induced	by	CysVac5/AdvaxCpG	measured	by	intra-cellular	immunostaining	and	 flow	 cytometry,	 in	 the	 PBMCs	 of	 CysVac5	 immunised	 mice,	 there	 was	 a	significantly	increased	populations	of	IFNg+IL2+TNF+	and	IFNg+IL2+	CD4+	T	cells.	The	triple	 positive	 IFNg+IL2+TNF+	 T	 cells	 were	 also	 observed	 in	 greater	 magnitude	(approximately	5%	of	the	total	CD4+	pulmonary	T	cells)	in	the	lungs	of	vaccinated	mice	after	the	infection	(Figure	3.23.)	along	with	increased	Th17-like	response	indicated	by	the	production	of	IL17	(Figure	3.24.	–	3.26.).	The	numbers	of	polyfunctional	CD4+	T	cells	 producing	 multiple	 cytokines	 have	 been	 shown	 to	 correlate	 with	 better	protection	(hence	the	0.64	log10	reduction	of	bacterial	counts	in	the	lung	4	weeks	post	TB	 infection)	 in	many	 studies	with	 different	 infection	models	 (Darrah	 et	 al.,	 2007,	Lindenstrøm	 et	 al.,	 2009).	 It	 has	 also	 been	 suggested	 that	 the	 optimal	 protection	against	 TB	 infection	 can	 be	 achieved	 by	 the	 generation	 of	 pooled	 triple-positive	IFNg+IL2+TNF+	T	cells	as	this	phenotype	mediates	rapid	effector	functions	(Seder	et	al.,	
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2008).	 The	 other	 main	 phenotype	 that	 was	 significantly	 increased	 by	CysVac5/AdvaxCpG	 vaccination	 upon	 recalling	 to	 all	 three	 single	 components	 of	CysVac5	protein	vaccine	(Ag85B,	CysD,	or	MPT83)	was	double	positive	IFNg	and	TNF	producing	T	cells.	This	subset	is	known	to	be	an	effector	type	of	cells	(Seder	et	al.,	2008).	Interesting	 from	 previous	 study,	 CysVac2/AdvaxCpG	 was	 reported	 to	 elicit	 more	IL2+TNF+	CD4+	T	cells	which	is	known	to	be	a	characteristic	of	central	memory	T	cells	(Counoupas	et	al.,	2017).	Further	studies	will	aim	to	examine	the	generation	of	specific	T	cell	memory	generated	by	CysVac5/AdvaxCpG	considering	the	capacity	of	this	Advax	formulation	in	inducing	persistent	memory	T	cell	response	has	yet	to	be	characterised.	
Overall,	 the	 intramuscular	 vaccination	 of	 CysVac5/AdvaxCpG	 conferred	 fairly	 strong	immunogenicity	and	protection	against	M.	tuberculosis	 infection	comparable	to	 that	shown	by	CysVac2	in	mouse	model.	Knowing	the	safety	profile	of	Advax	in	humans,	CysVac5/AdvaxCpG	 combination	 becomes	 a	 good	 candidate	 for	 further	 studies	 in	combating	TB.	Additionally,	as	this	part	of	study	was	a	preliminary,	there	are	several	aspects	 that	 need	 to	 be	 further	 investigated	 such	 as	 the	 post-challenge	 immune	responses	 at	 extended	 time-point	 (chronic	 phase	 of	 infection)	 as	 well	 as	 the	 cell	recruitment	and	early	T	cell	priming	induced	by	CysVac5/AdvaxCpG.	
3.4. Conclusions	and	future	directions	This	study	demonstrates	that	CysVac5	can	protect	mice	at	extended	time	points	after	M.	 tuberculosis	 infection,	 provided	 protective	 immunity	 across	 multiple	 murine	strains,	 and	 induced	 both	 Th1	 and	 Th17-like	 responses	 that	 correlate	 with	 the	reduction	 of	 bacterial	 burden	 in	 the	 lungs	 and	 spleen	 of	 infected	 mice.	 Therefore,	CysVac5	is	a	strong	candidate	that	warrants	further	investigation	to	control	pulmonary	TB	in	humans.	
A	 vaccine	 candidate	 has	 to	 demonstrate	 consistent,	 robust,	 and	 high-level	 efficacy	across	a	range	of	animal	models	before	it	advances	to	clinical	testing,	and	the	testing	of	this	vaccine	in	additional	models	such	as	the	guinea	pig	is	warranted	(add	reference).	Further,	 the	 immune	 responses	 generated	 after	 M.	 tuberculosis	 challenge	 differ	depending	 on	 the	 routes	 of	 vaccine	 delivery.	 In	 TB	 vaccine	 research,	 the	 use	 of	pulmonary	delivery	is	an	increasingly	compelling	strategy.	Delivery	of	the	vaccine	into	the	respiratory	tract	follows	the	natural	primary	route	of	TB	infection	in	humans,	it	
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may	mimic	the	induction	of	an	immediate	local	immune	response	followed	by	systemic	immunity	 (Todoroff	 et	 al.,	 2013)	 Therefore,	 pulmonary	 administration	 of	 CysVac5	subunit	vaccine	with	a	suitable	adjuvant	formulation	might	overcome	disadvantages	related	to	administration	by	needle	and	 induce	both	systemic	and	mucosal	immune	responses	against	M.	tuberculosis	infection.	
As	a	major	purpose	of	developing	subunit	vaccines	against	M.	tuberculosis	infection	is	to	boost	BCG-derived	 immunity,	 the	ability	of	CysVac5	to	enhance	the	BCG	induced	protection	warrants	 further	 investigation.	 Such	 novel	 vaccines	with	 the	 capacity	 to	boost	 the	 protective	 immunity	 of	 BCG-vaccinated	 individuals	 against	 TB	 infection	would	be	ideal	candidates	for	clinical	trials	in	humans.	It	would	also	be	of	interest	to	examine	 the	 changes	 in	 bacterial	 burden	 in	 the	 murine	 models	 caused	 by	 CysVa5	vaccination	when	administered	post	M.	tuberculosis	exposure,	as	the	CysD	component	of	the	vaccine	is	upregulated	during	the	late	stage	of	infection	(Counoupas	et	al.,	2016,	Pinto	 et	 al.,	 2004).	 Finally,	 given	 the	 difficulties	 in	 purifying	 the	 fusion	 protein	 of	CysVac5	 subunit	 protein	 vaccine,	 altering	 the	 construction	 by	 rearranging	 the	component	order	of	CysVac5	recombinant	protein	might	create	a	more	stable	form	of	the	 fusion	 protein	 that	 leads	 to	 a	 simplified	 purification	 processes	 and	 improved	protective	immunity.	
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CHAPTER	4:	Characterisation	 of	 the	 Protective	Immunity	afforded	by	Recombinant	BCG	Overexpressing	 the	 Components	 of	 M.	
tuberculosis	Major	Protein	Export	System		 	
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4.1. Introduction	and	aims	
M.	tuberculosis,	the	causative	agent	of	TB,	continues	to	spread	due	to	the	existence	of	a	large	 reservoir	 of	 latently	 infected	 individuals	 that	 can	 reactivate	 at	 any	 time.	 The	current	 TB	 vaccine	 BCG	 is	 described	 to	 be	 protective	 against	 severe	 forms	 of	 TB	(meningitis	and	miliary	TB)	in	children,	but	with	inconsistent	and	variable	protection	against	pulmonary	TB	in	adolescents	and	adults	which	represents	the	transmissible	form	 of	 the	 disease	 (Ottenhoff	 and	 Kaufmann,	 2012,	 Aguilo	 et	 al.,	 2017).	 The	insufficiency	of	BCG	to	provide	protection	against	adult	pulmonary	TB	makes	new	and	more	effective	TB	vaccines	 critically	 important.	Although	BCG	protective	efficacy	 is	variable	in	humans,	it	remains	the	sole	available	vaccine	for	TB.	The	ability	of	BCG	to	induce	some	level	of	protective	immunity	against	TB	in	children,	as	well	as	its	potent		immunostimulatory	 capacity	 (Triccas,	2010),	has	maintained	 interest	 in	developing	BCG	into	a	novel	vaccine	vehicle	with	the	capacity	to	express	recombinant	antigens	and	other	 immunostimulatory	molecules	 to	 create	a	more	effective	TB	vaccine	 (Triccas,	2010).	
M.	tuberculosis,	similar	to	many	other	pathogens,	is	widely	known	for	its	capacity	to	produce	and	secrete	numerous	virulence	proteins	into	the	extracellular	environment	(Pieters,	 2008,	 Gupta	 and	 Rodriguez,	 2018).	Mycobacteria	 possess	 five	 specialised	protein	 transport	 systems	 (ESX-1	 to	 ESX-5)	 and	 two	 conserved	 protein	 export	pathways	 including	 the	 general	 secretion	 (Sec)	 and	 the	 twin-arginine	 translocation	(Tat)	pathways	(Feltcher	et	al.,	2010).	In	M.	tuberculosis,	the	general	Sec	pathway	is	an	essential	cellular	process	and	responsible	for	exporting	the	majority	of	proteins	across	the	 cytoplasmic	 membrane	 (Feltcher	 et	 al.,	 2010,	 Feltcher	 et	 al.,	 2013).	 A	comprehensive	 analysis	has	 revealed	 that	 the	majority	 of	 exported	 proteins	 (62%)	identified	in	the	culture	filtrate	of	M.	tuberculosis	H37Rv	were	exported	through	Sec	pathway	(Målen	et	al.,	2007).	Major	proteins	exported	by	this	pathway	are	members	of	 the	 antigen	 85	 (Ag85)	 complex,	 the	 most	 abundant	 proteins	 secreted	 by	 M.	
tuberculosis	 which	 are	 potent	 immunoprotective	 antigens	 (Palma	 et	 al.,	 2007,	Karbalaei	et	al.,	2017).	
The	 Ag85	 complex	 comprises	 three	 homologous	 major	 secretory	 proteins	 of	 M.	
tuberculosis,	which	have	been	the	focus	of	extensive	research	for	several	years:	Ag85A	(Rv3804c,	35.68	kDa),	Ag85B	(Rv1886c,	34.58	kDa)	and	Ag85C	(Rv0129c,	36.77	kDa)	
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(Wiker	and	Harboe,	1992,	Kruh-Garcia	et	al.,	2014).	Among	the	secretory	proteins,	the	Ag85	complex	members	are	the	most	common	proteins	of	M.	tuberculosis	secreted	into	culture	 fluids	 (Karbalaei	 et	 al.,	 2017).	Due	 to	 their	 ability	 to	 induce	 a	 strong	T	 cell	proliferation	response	(Launois	et	al.,	2010),	a	large	number	of	studies	have	utilised	the	Ag85	complex	to	develop	vaccines	against	TB	infection	in	various	forms	including	recombinant	BCG	(rBCG),	subunit	and	DNA	vaccines.	In	addition,	there	are	currently	six	of	the	total	eight	subunit	TB	vaccines	in	clinical	trials	containing	an	Ag85	protein	(Fletcher	and	Schrager,	2016).	
Previous	reports	have	investigated	the	impact	of	heterologous	expression	of	protein	secretion	machinery	to	increase	the	quality	and	magnitude	of	the	immune	responses	against	M.	tuberculosis	infection	(Gröschel	et	al.,	2017,	Bottai	et	al.,	2015).	Due	to	the	absence	of	a	9.5	kb	genomic	region	termed	RD1	(Region	of	Difference	1),	BCG	lacks	the	type	VII	(T7S)	protein	secretion	ESX-1.	ESX-1	is	responsible	for	the	export	of	proteins,	such	as	ESAT-6,	that	play	crucial	roles	in	host-pathogen	interactions	(Gröschel	et	al.,	2017).	 A	 recombinant	 BCG	 with	 ESX-1	 reconstitution	 has	 shown	 to	 have	 superior	protection	 relative	 to	 parental	 BCG	 against	 highly	 virulent	 M.	 tuberculosis	 with	increased	proportion	of	polyfunctional	CD4+	T	 cells	 and	 strong	CD8+	T	 cell	 effector	responses	(Gröschel	et	al.,	2017,	Bottai	et	al.,	2015).	Thus,	these	findings	support	the	concept	of	altering	the	protein	secretion	system	to	increase	the	transport	of	beneficial	proteins	 leading	 to	 better	 host-pathogen	 interaction	 for	 the	 development	 of	recombinant	BCG	vaccines	has	a	great	potential	to	be	explored	further.	
The	Sec	pathway	in	M.	tuberculosis	consists	of	a	total	16	protein	components	(Ligon	et	al.,	 2012).	While	 some	of	 the	 components	are	essential	 in	 transporting	 cytoplasmic	proteins	into	the	extracellular	environment,	several	others	are	expendable,	including	SecD,	 SecF	 and	 SecG	 (Feltcher	 et	 al.,	 2010).	 SecD	 and	 SecF,	 along	 with	 YajC,	 are	accessory	Sec	proteins	that	contribute	to	the	efficiency	of	mycobacterial	protein	export	(Feltcher	and	Braunstein,	2012).	SecG	forms	a	highly	conserved	heterotrimeric	protein	complex	 with	 SecY	 and	 SecE	 that	 creates	 a	 channel	 in	 the	 cytoplasmic	membrane	through	which	 cytoplasm-synthesised	 proteins	 are	 transported	 to	 the	 extracellular	environment.	Unlike	SecY	and	SecE,	SecG	is	dispensable	and	not	required	for	bacterial	viability,	but	 its	presence	 increases	translocation	efficiency	by	stabilizing	the	SecYE	complex	or	assisting	the	conformational	changes	of	SecA,	a	central	component	of	the	
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Sec	transport	system	(Feltcher	et	al.,	2010).	In	E.	coli,	overexpression	of	SecDF	led	to	increased	membrane	association	of	SecA	resulted	in	increased	protein	translocation	efficiency	(a	Nijeholt	and	Driessen,	2012).	
In	 this	 Chapter,	 it	 was	 hypothesised	 that	 the	 overexpression	 of	 the	 SecD,	 F,	 and	 G	proteins	in	BCG	would	improve	the	efficiency	of	Sec-dependent	export	and	increase	secretion	of	immunogenic	proteins	into	the	extracellular	environment.	This	would	lead	to	improved	immune	recognition	of	secreted	antigens	which	may	in	turn	improve	the	protective	effect	of	the	vaccine.	The	following	aims	will	be	addressed	in	this	chapter:	
(i) To	determine	the	persistency	of	BCG	overexpressing	auxiliary	components	of	
M.	tuberculosis	Sec	pathway	following	vaccination	both	in-vitro	and	in-vivo.	(ii) To	 assess	 the	 ability	 of	 BCG∷SecDFG	 in	 inducing	 T	 cell	 immunity	 after	vaccination	in	mice.	(iii) To	determine	whether	BCG∷SecDFG	vaccination	 improves	protective	efficacy	against	aerosol	M.	tuberculosis	challenge	at	early	and	extended	time	points	post-infection.	
	
4.2. Results	
4.2.1. Construction	 of	 rBCG	 strains	 overexpressing	 the	 combination	 of	
SecDFG	components	from	M.	tuberculosis	Sec	export	system	The	 construction	 of	 recombinant	 BCG	 strains	 overexpressing	 recombinant	 protein	SecDFG	was	performed	by	Dr.	Rachel	Pinto	(2010)	using	a	dual-promoter	expression	plasmid,	 pMOD12.	 Derived	 from	 pMV261,	 pMOD12	 is	 a	 shuttle	 plasmid	 capable	 of	replicating	and	expressing	recombinant	proteins	in	both	E.	coli	and	mycobacteria.	It	contains	two	independent	and	constitutively	active	promoters	from	BCG,	HSP60	and	HSP70,	with	 two	disparate	multiple	 cloning	 sites	 (MCSs)	 (Chung	et	 al.,	 2003).	DNA	fragment	coding	for	the	hexa-histidine	tagged	M.	tuberculosis	protein	SecD	(Rv2587c)	and	 Sec	 F	 (Rv2586c)	 were	 inserted	 to	 the	MCS1	 of	 pMOD12	 under	 the	 control	 of	Phsp60,	whereas	the	purified	c-Myc	tagged	SecG	(Rv1440)	was	ligated	into	the	MCS2	of	the	plasmid	under	Phsp70	promoter	(Figure	4.1.A).	The	new	recombinant	plasmid	containing	SecDF	and	SecG	was	used	to	transform	competent	BCG	to	create	the	desired	strains.	 The	 transformed	 BCG	 cells	were	 then	 plated	 on	 supplemented	 solid	 7H11	media	with	kanamycin	antibiotic	(25	μg/mL).	
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Figure 4.1. Construction and expression of recombinant BCG strains 
overexpressing M. tuberculosis SecDFG protein. (A) A schematic diagram of the recombinant prokaryotic expression plasmid pMOD12-SecDFG. (B) Western blot demonstrating expression of recombinant SecD or SecF protein in BCG. Cell lysates (20 
μg) from 2 clones of BCG∷SecDFG were prepared, separated on a 12% SDS-PAGE gel and transferred to nitrocellulose membrane. Polyhistidine-tagged SecDF was detected using Ni-HRP His-detect conjugate (Lane 1: BCGpMOD12, Lane 2: BCG∷SecDFG6, Lane 3: BCG∷SecDFG10).  
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Correct	 sequence	 and	 alignment	 were	 determined,	 and	 the	 expression	 of	 the	recombinant	 protein	 confirmed	 by	 SDS-PAGE	 and	Western	 blotting.	 Two	 separate	immunoblots	were	run	to	detect	SecDF	and	SecG	expression	in	the	cell	lysates	of	rBCG	strains	 using	 anti-His	 (Sigma	 Aldrich)	 or	 anti-C-myc	 antibody	 (Santa	 Cruz	Biotechnology	Inc.)	respectively	as	explained	in	Chapter	2	Section	2.3.6.	Bands	of	the	expected	size	for	SecD	(60.23	kDa)	and	Sec	F	(47.01	kDa)	were	detected	with	higher	intensity	 in	 the	 lysates	of	both	BCG∷SecDFG	clones	used	 in	 this	 study	compared	 to	parental	BCG,	confirming	the	overexpression	in	the	recombinant	strains	(Figure	4.1.B).	However,	the	expression	of	c-Myc	tagged	SecG	(8.16	kDa)	was	not	able	to	be	detected	across	all	strains	tested,	possibly	due	to	the	small	size	of	SecG	protein	as	conventional	Western	 blotting	 is	 known	 to	 be	 inadequate	 in	 detecting	 low	 molecular	 weight	proteins	and	peptides	efficiently	(Tomisawa	et	al.,	2013).	
The	 next	 experiment	 aimed	 to	 confirm	 whether	 the	 recombinant	 strains	 of	 BCG	overexpressing	SecDFG	were	able	to	increase	the	secretion	of	the	antigen	85	protein	family	members	(Ag85A,	Ag85B	and	Ag85C).	Both	clones	of	BCG∷SecDFG	strain	were	grew	 in	 7H9	 broth	 media	 in	 the	 absence	 of	 BSA,	 supernatants	 concentrated	immunoblot	performed	using	polyclonal	anti-Ag85	antibody	to	confirm	the	presence	of	Ag85	proteins	in	the	extracellular	milieu.	A	band	with	a	size	of	~34	kDa	was	detected	with	higher	intensity	in	both	clones	of	BCG∷SecDFG	strain	compared	to	normal	BCG	(Figure	4.2.A),	indicating	that	the	overexpression	of	SecDFG	altered	the	secretion	of	Ag85	 proteins	 to	 the	 extracellular	 environment.	 In	 addition,	 prior	 to	 culture	supernatant	collection,	the	growth	rate	of	BCG∷SecDFG	in	7H9	Broth	media	without	BSA	 was	 measured	 at	 the	 optical	 density	 (OD)	 of	 600	 nm.	 It	 appeared	 that	 the	recombinant	strains	engineered	for	this	study	grew	at	a	slower	rate	compared	to	the	wild	type	BCG	with	lower	bacterial	density	in	stationary	phase	(Figure	4.2.B).	
4.2.2. The	capacity	of	BCG∷SecDFG	 to	 infect	and	 survive	within	murine	
macrophages	in-vitro	As	a	live	attenuated	vaccine,	BCG	replicates	to	a	limited	extent	inside	host	cells	before	cell-mediated	 immunity	 arrests	 its	 growth	 (Horwitz	 and	 Harth,	 2003).	 It	 was	hypothesised	that	improved	secretion	of	may	alter	interaction	with	host	cells,	either	by	increased	secretion	of	virulence/persistence	determinants	or	enhanced	association	by	secretion	of	receptor-binding	molecules	such	as	Ag85B	(Prendergast	et	al.,	2016).	
  
 
112 Chapter 4. BCG∷SecDFG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Protein secretion and growth rate of BCG∷SecDFG strain in vitro. Two clones of BCG∷SecDFG were grown in 7H9 media in the absence of BSA and cultures incubated at 37°C in 5% CO2 as static cultures. (A) Immunoblot confirming the presence of Ag85B protein in extracellular milieu. Culture supernatants from both clones were collected, concentrated and run for immunoblot against anti-Ag85 complex antibody (Lane 1: BCGpMOD12, Lane 2: BCG∷SecDFG6, Lane 3: BCG∷SecDFG10). 
(B) The growth curves of the strains were generated by measurement of the OD600. Values represent mean of the two independent cultures with standard deviation (SD).    
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RAW	264.7	murine	macrophage	cells	were	infected	with	BCGpMOD12	or	BCG∷secDFG10	and	bacterial	load	determined	at	various	timepoints.	As	shown	in	Figure	4.3,	there	was	no	 increased	 initial	uptake	by	 rBCG	strains,	 as	 indicated	by	 reduced	or	 comparable	bacterial	 counts	 in	 BCG∷SecDFG	 infected	 macrophages	 at	 4	 hours	 post-infection	compared	to	those	infected	by	parental	BCG	at	the	MOI	of	1	and	5	respectively	(Figure	4.3).	However,	rBCG	overexpressing	SecDFG	displayed	enhanced	intracellular	survival	inside	macrophages,	with	a	significant	increase	in	CFU	at	168	hours	following	infection	at	an	MOI	of	1	(Figure	4.3.A)	and	at	72	hours	at	an	MOI	of	5	(Figure	4.3.B)	compared	to	parental	 BCG	 containing	 the	 empty	 plasmid	 pMOD12.	 Thus,	 SecDFG	 expression	appeared	to	alter	the	capacity	of	BCG	to	survive	long-term	within	host	cells.	
4.2.3. In-vivo	 persistence	 and	 immune	 responses	 of	 BCG∷SecDFG	
following	vaccination	of	mice	The	next	series	of	experiments	aimed	to	determine	the	in	vivo	persistence	of	live	rBCG	overexpressing	M.	 tuberculosis	 SecDFG	 protein	 and	 to	 characterise	 the	 associated	cellular	immune	response	to	this	strain.	To	do	this,	mice	were	vaccinated	with	either	BCGpMOD12	or	BCG∷SecDFG	and	the	kinetics	of	BCG	growth	and	persistence	measured	at	certain	time	points	by	enumerating	the	BCG	bacterial	load	in	several	organs	of	the	mice	(Figure	4.4.A).	In	the	inguinal	lymph	nodes	(iLNs),	similar	numbers	of	BCG	were	observed	in	both	vaccinated	groups	at	day	1	following	the	vaccination.	However,	when	the	 bacterial	 loads	were	measured	 at	 later	 time	 point,	 BCG∷SecDFG	 demonstrated	greater	 replication	 rate	 than	 the	 parental	 strain,	 indicated	 by	 the	 significantly	increased	bacterial	numbers	in	the	iLNs	and	spleen	at	day	7	post	vaccination	(Figure	4.4.B).	In	the	lungs	and	spleen,	the	numbers	of	BCG∷SecDFG	declined	to	undetectable	levels	by	day	84,	but	remained	elevated	in	the	iLNs,	indicating	enhanced	persistence	at	this	site.	
The	next	experiment	determined	the	associated	immune	responses	after	vaccination	with	BCG∷SecDFG.	Several	different	mycobacterial	proteins	found	both	intracellularly	(GroES)	 and	 secreted	 into	 the	 extracellular	 culture	 supernatants	 (Ag85A,	 Ag85B,	Ag85C,	MPT32,	TB10.4),	were	used	to	stimulate	lymphocytes	collected	from	BCGpMOD12	or	BCG∷SecDFG	vaccinated	mice	to	assess	 the	antigen-specific	 IFNγ-producing	cells	induced	by	vaccination.		
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Figure 4.3. In vitro survival of BCG∷SecDFG within murine macrophages. RAW 264.7 murine macrophage cells were seeded into 24-well plates at 2x105 cells/well and infected with BCGpMOD12/BCG∷SecDFG10 at a MOI of 1 (A) or 5 (B). Four hour later, cells were washed with PBS to remove extracellular bacteria and incubated for a further 20, 68 or 164 hours after which they were lysed and CFU determined by growth at 37 °C on supplemented 7H11 medium. Data are the means r SEM (n = 6) and represent a combination of two independent experiments. Statistically significant 
differences among the groups are shown as determined by ANOVA with Sidak’s multiple comparisons test (* p<0.1: ** p<0.01; **** p<0.0001).   
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Figure 4.4. Persistence of BCG∷SecDFG in murine organs following vaccination. C57BL/6 mice were vaccinated s.c. with 5x105 CFU BCGpMOD12/BCG∷SecDFG10 and lymph node, spleen, and lung collected at day 1, 7, 28 and 84 (A) to assess the bacterial load in each the inguinal lymph nodes (iLN), spleen or lungs (B). The data are the means r SEM and representative of two independent experiments. Detection limit of the assay shown by the dotted line (20 CFU/organ). Statistical significance was 
determined by ANOVA with Tukey’s multiple comparisons test (* p<0.1; ** p<0.01).  
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In	the	iLNs,	both	BCG	strains	revealed	heightened	IFNγ	responses	to	the	majority	of	secreted	antigens	at	day	28	post-vaccination,	compared	to	unvaccinated	mice	(Figure	4.5).	 In	 the	 lymph	nodes	of	BCG∷SecDFG	vaccinated	mice,	 there	was	a	 trend	 in	 the	number	 of	 lymphocytes	 secreting	 IFNγ	 specific	 to	 Ag85	 protein	 family	 members	(Ag85A,	Ag85B	and	Ag85C)	after	BCG∷SecDFG	vaccination,	however	 this	difference	was	not	statistically	different	(Figure	4.5).	BCG∷SecDFG	did	show	increased	responses	to	antigens	such	as	TB10.4	at	day	28,	but	 this	difference	did	not	reach	significance.	However,	responses	to	M.	tuberculosis	culture	filtrate	protein	(CFP)	were	significantly	increased	in	cells	from	BCG∷SecDFG	vaccinated	animals	at	day	28	and	84,	indicating	an	overall	response	heightened	response	to	a	multitude	of	secreted	antigens.	
In	 the	 spleen,	 the	 increased	 immunogenicity	 invoked	by	BCG∷SecDFG	compared	 to	parental	BCG	was	more	apparent.	This	was	particularly	 the	case	 for	 the	three	Ag85	antigens,	 especially	at	day	28	 (Figure	4.6).	 IFNγ	 responses	 to	both	TB10.4	and	CFP	were	higher	in	BCG∷SecDFG	vaccinated	mice	at	both	28	and	84	days,	demonstrating	persistent	immune	responses	to	these	antigens	after	vaccination	of	mice.	
4.2.4. Antigen-specific	 T	 cell	 proliferation	 and	 cytokine	 responses	
following	BCG∷SecDFG	delivery	The	 increased	persistence	and	 increased	IFNγ	 responses	to	BCG∷SecDFG	suggested	the	vaccine	may	result	in	increased	early	priming	of	T	cells.	To	test	this,	an	adoptive	transfer	model	of	P25-specific	CD4+	T	cells	was	utilised.	P25	transgenic	CD4+	T	cells	specific	 for	 the	 dominant	 P25	 epitope	 of	 Ag85B	 have	 been	 used	 extensively	 to	characterise	T	cell	responses	to	mycobacteria	(Nambiar	et	al.,	2012,	Yang	et	al.,	2018,	Cerqueira-Rodrigues	 et	 al.,	 2018,	 Athman	 et	 al.,	 2017).	 Approximately	 5x105	 CFSE-labelled	transgenic	P25	splenocytes	(CD45.1+)	were	transferred	to	recipient	C57BL/6	mice	(CD45.2+)	via	intravenous	(i.v.)	injection	1	day	prior	to	vaccination.	Mice	were	then	vaccinated	s.c.	with	BCG	or	BCG∷SecDFG	on	the	following	day	and	the	immune	response	generated	was	examined	in	the	draining	lymph	nodes	and	spleen	at	day	6	post-vaccination	(Figure	4.7.A).	
Mice	that	received	BCG∷SecDFG	had	a	higher	proportion	of	P25	CD4+	T	cells	compared	to	 mice	 that	 received	 BCGpMOD12,	 indicated	 by	 higher	 proportions	 and	 numbers	 of	CD45.1+	T	cells	in	the	draining	lymph	nodes	and	spleen.		
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Figure 4.5. Induction of antigen specific IFNγ-secreting cells in mouse lymph 
nodes following BCG∷SecDFG vaccination. C57BL/6 mice were vaccinated s.c. with 5x105 CFU BCGpMOD12 (blue bars), BCG∷SecDFG10 (red bars) or left unvaccinated (black bars) and the lymph nodes were collected at day 7, 28 and 84 post vaccination. Lymphocytes were stimulated ex-vivo with 10 Pg/mL of respective antigens or culture filtrate protein (CFP) for approximately 20 hours then incubated in 37 OC, 5% CO2. The number of antigen-specific IFNJ-secreting cells were enumerated by ELISPOT. Data are the means r SEM and are representative of two independent experiments. Statistical 
significance was calculated by ANOVA with Tukey’s multiple comparisons test (* p<0.1; ** p<0.01, *** p<0.001).  
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Figure 4.6. Induction of antigen specific IFNγ-secreting cells in mouse spleen 
following BCG∷SecDFG vaccination. C57BL/6 mice were vaccinated s.c. with 5x105 CFU BCGpMOD12 (blue bars), BCG∷SecDFG10 (red bars) or left unvaccinated (black bars) and the spleen was collected at day 7, 28 and 84 post vaccination. Lymphocytes were stimulated ex-vivo with 10 Pg/mL of respective antigens or culture filtrate protein (CFP) for approximately 20 hours then incubated in 37 OC, 5% CO2. The number of antigen-specific IFNJ-secreting cells were enumerated by ELISPOT. Data are the means 
r SEM and are representative of two independent experiments. Statistical significance 
was calculated by ANOVA with Tukey’s multiple comparisons test (* p<0.1; ** p<0.01, *** p<0.001, **** p<0.0001). 
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In	the	lymph	nodes	of	BCG∷SecDFG-vaccinated	mice,	over	10%	of	the	total	CD4+	T	cells	observed	were	found	to	be	CD45.1+	cells	with	less	than	5%	in	mice	that	received	BCG	(Figure	4.7.C),	which	translated	to	significantly	higher	CD45.1+	T	cells	in	BCG∷SecDFG-vaccinated	 mice	 compared	 to	 BCGpMOD12	 vaccinated	 or	 unvaccinated	 mice	 (Figure	4.7.D).	The	same	results	were	observed	in	the	spleen	where	BCG∷SecDFG	immunised	mice	 had	 a	 higher	percentage	 (Figure	 4.7.C)	 and	 number	 (Figure	 4.7.D)	 of	 CD45.1+	CD4+	T	cells	compared	to	BCGpMOD12	vaccinated	or	unvaccinated	animals.	Analysis	of	CFSE	profiles	also	showed	that	the	P25-specific	CD4+	T	cells	proliferated	more	in	both	lymph	 nodes	 and	 spleen	 of	 BCG∷SecDFG	 vaccinated	 mice,	 indicated	 by	 a	 high	proportion	of	proliferating	CD45.1+	T	cells	with	CFSElo	profile	(Figure	4.8).	Although	the	differences	of	CFSElo	CD45.1+	T	cells	shown	between	BCG	and	BCG∷SecDFG	groups	were	 not	 statistically	 significant,	 mice	 that	 received	 BCG∷SecDFG	 had	 nearly	 20%	more	of	CFSElo	CD45.1+	T	cells	in	the	lymph	nodes,	indicating	that	nearly	all	of	the	P25	CD4+	T	cells	in	these	mice	proliferated	following	vaccination	(Figure	4.8.C).	
Additionally,	 the	proportion	of	CD45.1+	T	 cells	with	 intermediate	 level	of	CFSE	was	higher	in	the	BCGpMOD12	group	demonstrating	less	proliferation	compared	to	cells	from	BCG∷SecDFG-vaccinated	 mice	 (Figure	 4.8.D).	 Additional	 analysis	 examining	 the	expression	 of	 various	 surface	 activation	 and	 homing	 markers	 such	 as	 CD62L	 and	CXCR3,	 as	 well	 as	 proliferation	 markers	 Ki67	 and	 KLRG-1,	 showed	 no	 significant	difference	on	 for	P25	T	 cells	 from	either	BCG	and	BCG∷SecDFG-vaccinated	animals	(Figure	4.9).	An	increase,	although	non-significant,	for	the	memory	marker	CD62L	was	observed	in	the	lymph	nodes	and	spleen	of	BCG∷SecDFG	immunised	mice	compared	to	those	that	received	parental	BCG	vaccination	(Figure	4.9.B).	
To	 investigate	 the	 functionality	of	 transferred	P25-specific	 CD4+	T	 cells,	 ex	 vivo	 re-stimulation	 with	 peptide	 P25	 (Ag85B240-254	 FQDAYNAAGGHNAVF,	 specific	 for	 P25	TCR)	 was	 utilised	 and	 cytokine	 release	 assessed.	 A	 similar	 pattern	 of	 cytokine-producing	 cells	 in	 BCGpMOD12	and	BCG∷SecDFG	 vaccinated	mice	was	 observed,	with	BCG	strains	generating	a	high	proportion	of	triple	positive	IFNγ+IL2+TNF+	CD45.1+	T	cells	in	both	lymph	nodes	and	spleen	as	well	as	double	positive	IL2+TNF+	and	single	TNF	producing	CD45.1+	CD4+	T	cells,	at	day	6	post	vaccination	(Figure	4.10).		
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Figure 4.7. Expansion of transferred P25-specific CD4+ T cells following 
BCG∷SecDFG vaccination. (A) Experimental summary explaining the adoptive transfer model of P25-specific CD4+ T cells utilised in this study. Approximately 5x105 CFSE-labelled P25 splenocytes (CD45.1+) were transferred via i.v. injection to C57BL/6 (CD45.2+) recipient mice (n=4) prior to vaccination. The following day mice were s.c. vaccination with 5x105 CFU of BCGpMOD12, BCG∷SecDFG or left unvaccinated. Six days after the vaccination mice were sacrificed and the number of lymphocytes were enumerated in the lymph nodes and spleen. Representative flow plots are shown (B), together with CD45.1+ P25-specific CD4+ T frequency (C) and numbers (D) in the lymph nodes and spleen as measured by flow cytometry. Data are the means r SEM (n = 6) and represent one of the 2 independent experiments. Statistically significant 
differences among the groups are shown as determined by ANOVA with Tukey’s multiple comparisons test (*** p<0.001; **** p<0.0001; Appendix 5 for gating strategy).   
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Figure 4.8. Proliferation of transferred P25-specific CD4+ T cells following 
BCG∷SecDFG vaccination. Representative flow plots (A) and histogram (B) of CFSE intensity for P25-specific CD4+ T cells. The frequency of CD45.1+ P25-specific CD4+ T cells in lymph nodes and spleen with low (C) and intermediate (D) level of CFSE intensity was measured by flow cytometry. Data are the means r SEM (n = 6) and represent one of the 2 independent experiments. Statistically significant differences 
among the groups are shown as determined by ANOVA with Tukey’s multiple comparisons test (* p<0.1; *** p<0.001; **** p<0.0001; Appendix 5 for gating strategy).  
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A	slightly	higher	but	non-significant	percentage	of	IL2+TNF+	CD45.1+	T	cells	was	also	observed	in	the	lymph	nodes	of	BCG∷SecDFG	vaccinated	mice	after	approximately	P25	peptide	 re-stimulation	 (Figure	 4.10.B).	 Single	 TNF	 producing	 CD45.1+	 T	 cells	were	showed	a	comparative	slight	increase	in	the	lymph	nodes	of	BCG∷SecDFG	immunised	mice	 but	 comparable	 in	 the	 spleen	 to	 those	 observed	 in	 the	 BCGpMOD12-vaccinated	group.	
4.2.5. The	 immunogenicity	 generated	 by	 subcutaneous	 BCG∷SecDFG	
vaccination	pre-	and	post-M.	tuberculosis	exposure	Live	 recombinant	 BCG∷SecDFG	 was	 delivered	 s.c.	 into	 mice	 to	 assess	 the	 vaccine-generated	immune	response	before	and	after	challenge	with	M.	tuberculosis	H37Rv.	To	assess	the	immunogenicity	prior	to	M.	tuberculosis	infection,	PBMCs	of	the	vaccinated	mice	were	collected	from	the	lateral	tail	vein	eight	weeks	after	vaccine	delivery.	Figure	4.11	shows,	although	in	very	low	magnitude,	there	was	a	significant	increase	displayed	in	the	frequency	of	double	positive	CD4+	T	cells	secreting	IFNγ	and	TNF	in	the	PBMCs	of	mice	vaccinated	with	BCG∷SecDFG	strain	following	in	vitro	antigen	restimulation.	The	rBCG	vaccinated	mice	were	also	observed	to	have	an	increase	in	the	frequency	of	IL2+TNF+	 CD4+	 T	 cells	 in	 the	 blood,	 although	 this	 difference	 was	 not	 statistically	significant.	 All	 groups	 observed	 in	 this	 study	 generated	 high	 percentages	 of	 single	producing	cytokine	CD4+	T	cells,	in	particular	IL-2	and	TNF	secreting	cells	(Figure	4.11).	
The	 next	 set	 of	 experiments	 determined	 the	 BCG∷SecDFG	 generated	 immune	responses	 post	 aerosol	M.	 tuberculosis	 H37Rv	 infection.	 Four	 and	 20	 weeks	 after	aerosol	M.	 tuberculosis	 challenge,	 immunogenicity	 generated	 by	 BCG∷SecDFG	 was	assessed	 locally	 in	 the	 lungs	 as	 well	 as	 systemically	 in	 the	 spleen.	 	 BCG∷SecDFG	vaccinated	mice	generated	an	increased	percentage	of	triple	positive	IFNγ+IL2+TNF+	CD4+	T	cells	in	the	lungs	at	4	weeks	following	M.	tuberculosis	aerosol	challenge	than	in	mice	 which	 received	 the	 parental	 BCG	 strain	 (Figure	 4.12.B).	 However,	 when	 this	subset	 was	 observed	 at	 the	 extended	 time	 point	 (approximately	 20	 weeks	 post	challenge),	 both	 BCGpMOD12	 and	 BCG∷SecDFG	 displayed	 similar	 proportions	 of	pulmonary	IFNγ+IL2+TNF+	CD4+	T	cells.	Other	important	subsets	with	high	frequencies	observed	across	the	groups	were	single	positive	CD4+	T	cells	producing	either	IFNγ	or	TNF	as	well	as	CD4+	T	cells	producing	both	IFNγ	and	TNF,	particularly	at	20	weeks	following	M.	tuberculosis	aerosol	challenge.	
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Figure 4.9. Phenotype of transferred P25-specific CD4+ T cell population 
following BCG∷SecDFG vaccination. Lymphocytes from mouse lymph nodes and spleen were processed and stained for surface and activation markers. The proportion of CXCR3+ (A), CD62Lhi (B), Ki67+ (C) and KLRGhi (D) CD45.1+ P25-specific CD4+ T cells were measured by flow cytometry. Data are shown as box-and-whisker plots of cell proportions with medians, interquartile ranges (IQR) and minimum to maximum values and represent one of the 2 independent experiments. Black bars: PBS-vaccinated mice; blue bars, BCGpMOD12-vaccinated mice; red bars, BCG∷SecDFG-vaccinated mice. Statistically significant differences among the groups are shown as determined by one-way ANOVA with Tukey’s multiple comparisons test (* p<0.1; ** p<0.01; *** p<0.001; **** p<0.0001).    
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Figure 4.10. Functionality of transferred P25-specific CD4+ T cells following 
BCG∷SecDFG vaccination. Antigen-specific cells were detected by intracellular immunostaining and flow cytometry after ex vivo stimulation with P25 peptide (10 
Pg/mL). (A) Representative flow pots of CD45.1+ T cells producing IFNγ, IL-2 or TNF. The frequency of cytokine-producing CD45.1+ T cells in the (B) lymph nodes or (C) spleen was assessed at 6 days after vaccination. Data are the means r SEM (n = 4) and represent one of the 2 independent experiments. Statistically significant differences among the groups are shown as determined by ANOVA with Tukey’s multiple comparisons test (* p<0.1; *** p<0.001; **** p<0.0001). 
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4.2.6. Protection	 afforded	 by	 BCG∷SecDFG	 against	 M.	 tuberculosis	
infection	The	final	set	of	experiments	for	this	chapter	was	aimed	at	determining	whether	live	recombinant	BCG	overexpressing	M.	tuberculosis	SecDFG	protein	could	provide	better	protection	than	the	parental	BCG	strain	against	aerosol	challenge	of	M.	tuberculosis	in	mice.	 Ten	weeks	 following	 s.c.	 immunisation	with	BCGpMOD12	 or	 BCG∷SecDFG,	mice	were	challenged	with	a	low	dose	of	M.	tuberculosis	H37Rv	(100	CFU	per	mouse).	Four	and	20	weeks	after	 the	 infection,	bacterial	numbers	 in	both	 spleen	and	 lungs	were	enumerated	to	determine	the	bacterial	burden	in	both	organs	(Figure	4.13.A).	
In	the	lungs,	both	BCGpMOD12	and	BCG∷SecDFG	s.c.	vaccination	provided	a	significant	protective	 effect	 when	 compared	 to	 unvaccinated	 controls	 at	 4	 weeks	 post	 M.	
tuberculosis	 challenge	 (Figure	 4.13.B).	 There	was	 no	 significant	 difference	 between	BCG∷SecDFG	 and	 the	 parental	 strain	 in	 the	 capacity	 to	 reduce	 bacterial	 burden,	indicated	by	similar	level	of	bacterial	reduction	in	the	lungs	of	infected	mice	(1.45	and	1.31	 log10	 respectively).	 When	 the	 bacterial	 number	 were	 enumerated	 at	 4	 weeks	following	 the	M.	 tuberculosis	 challenge	 in	 the	 spleen,	 BCG∷SecDFG	 provided	 better	protection	by	reducing	bacterial	counts	by	approximately	0.20	log10	CFU,	although	this	difference	was	not	statistically	significant	(Figure	4.13.C).	At	20	weeks	post	challenge	the	protective	effect	of	both	BCG	strains	had	waned	 in	the	 lung	(4.13.D)	and	spleen	(4.13.E),	with	neither	of	the	strains	providing	protection	against	infection	compared	to	unvaccinated	mice.	Overall,	these	results	indicate	that	BCG∷SecDFG	was	protective	against	M.	tuberculosis	infection	but	did	not	significantly	improve	upon	the	protective	afforded	by	parental	BCG.	
4.3. Discussion	
4.3.1. M.	tuberculosis	SecDFG	overexpression,	protein	transport	and	host-
cell	persistence	The	 currently	 licensed	 TB	 vaccine	 BCG	 provides	 insufficient	 protection	 against	pulmonary	 TB,	 the	 major	 disease	 manifestation	 and	 source	 of	 dissemination,	particularly	 in	 adolescent	 and	 adults	 (Kaufmann	 et	 al.,	 2015).	 Several	 studies	 have	shown	that	 the	efficacy	of	BCG	decline	with	time	after	vaccination	(Rodrigues	et	al.,	2011).	Hence	the	urgent	need	for	better	and	more	effective	vaccines	to	control	and	prevent	TB	infection.		
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Figure 4.11. Generation of multiple-cytokine producing CD4+ T cells in murine 
PBMCs following BCG∷SecDFG vaccination. C57BL/6 mice were vaccinated s.c. with 5x105 CFU of BCGpMOD12 or BCG∷SecDFG. Eight weeks after vaccination, PBMCs were isolated from the murine blood. Intracellular cytokine staining was performed after 4 hours re-stimulation with BCG sonicate antigen (10 Pg/mL) and 16 hours stimulation with Brefeldin A (A) Representative flow plots demonstrating changes in the frequency of IFNγ, IL2, and/or TNF positive CD4+ T cells in murine PBMCs after s.c. BCG∷SecDFG vaccination. (B) Frequency of multiple-cytokine producing CD4+ T cells. Data are the means r SEM (n = 6) and represent one of the 2 independent experiments. The statistical significance was determined by two-way ANOVA with Tukey’s multiple comparisons test (* p<0.1; *** p<0.001).  
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Figure	 4.12.	 Generation	 of	 polyfunctional	 pulmonary	 CD4+	 T	 cells	 by	
BCG∷SecDFG	 vaccination	 after	 M.	 tuberculosis	 challenge.	 C57BL/6	 mice	 were	vaccinated	 s.c.	 with	 5x105	 CFU	 of	 BCGpMOD12	 or	 BCG∷SecDFG.	 Ten	 weeks	 after	vaccination,	mice	were	 challenged	with	aerosol	M.	 tuberculosis	H37Rv.	 Intracellular	cytokine	staining	was	performed	after	4	hours	re-stimulation	with	CFP	(10	µg/mL)	and	16	hours	stimulation	with	Brefeldin.	(A)	Representative	flow	plots	demonstrating	changes	in	the	frequency	of	IFNγ,	IL2,	and/or	TNF	positive	CD4+	T	cells	in	murine	lungs	induced	 by	 s.c.	 BCG∷SecDFG	 vaccination.	 (B)	 Frequency	 of	 pulmonary	 multiple-cytokine	producing	CD4+	T	cells	assessed	at	4	(B)	and	20	(C)	weeks	post-M.	tuberculosis	challenge.	Data	are	the	means	±	SEM	(n	=	6)	and	represent	one	of	the	2	independent	experiments.	 The	 statistical	 significance	 was	 determined	 by	 two-way	 ANOVA	 with	Tukey’s	multiple	comparisons	test	(*	p<0.1;	****	p<0.0001).		 	
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Figure 4.13. Protection afforded by BCG∷SecDFG vaccination against aerosol M. 
tuberculosis infection in C57BL/6 mice. (A) C57BL/6 mice (n = 6) were immunized s.c. with 5x105 CFU of BCGpMOD12/ or BCG∷SecDFG10. Ten weeks post immunisation, mice were challenged with ~100CFU of M. tuberculosis H37Rv via aerosol route. Mice were euthanized 4 (B, C) and 20 weeks (D, E) after challenge to harvest the lungs (B, 
D) and spleen (C, E). The bacterial loads were enumerated following culture on Middlebrook 7H11 agar. The data are the means r SEM and representative of two independent experiments. Statistical significance was determined by ANOVA with 
Tukey’s multiple comparisons test (* p<0.1; ** p<0.01).  
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The	approach	to	develop	a	novel	TB	vaccine	addressed	in	this	chapter	was	to	improve	the	current	BCG	by	altering	protein	secretion,	thus	potentially	increasing	the	quality	and	magnitude	of	the	immune	responses	against	M.	tuberculosis	(Gröschel	et	al.,	2017).	The	 recombinant	 strain	 was	 generated	 by	 overexpressing	 SecDFG	 recombinant	protein	in	BCG	to	increase	transport	of	immunogenic	proteins	such	as	the	Ag85	family.		While	Western	blot	analysis	showed	that	both	SecD	and	SecF	were	overexpressed	in	the	 recombinant	 strain	 of	 BCG,	 expression	 of	 expression	 of	 SecG	was	 not	 detected	(Figure	 4.1).	M.	 tuberculosis	 SecG	 protein	 has	 a	molecular	weight	 of	 8.16	 kDa	may	detach	 from	 the	 blotted	membrane	 during	 incubation	 resulting	 in	 signal	 reduction	during	membrane	development	(Sasaki	et	al.,	2015).	Additional	analysis,	such	as	mass	spectrometry,	 could	 be	 used	 to	 identify	 the	 secreted	 SecG.	 Expression	 of	 the	recombinant	 proteins	 did	 appear	 to	 impact	 rBCG	 growth	 in	 culture	 (Figure	 4.2).	Studies	have	revealed	that	the	introduction	and	addition	of	constitutively-expressed	genes	can	cause	metabolic	changes	and	affect	the	growth	of	bacteria	(Geisel,	2011),	and	this	may	be	the	effect	observed	in	the	current	study.	
SDS-PAGE	and	Western	blotting	against	anti-ag85	complex	antibody	revealed	bands	with	a	molecular	weight	of	~34	kDa	in	the	culture	supernatants	of	all	strains,	although	both	clones	of	BCG∷SecDFG	showed	more	prominent	bands	indicating	the	difference	in	 the	 level	 of	 Ag85	 protein	 complex	 secreted	 into	 the	 media.	 This	 suggests	overexpression	 of	 SecDFG	 was	 indeed	 impacting	 protein	 transport.	 However,	Western/immunoblotting	 only	 provides	 a	 semi-quantitative	 assessment	 of	 global	protein	secreted	(Bass	et	al.,	2017).	Therefore,	a	more	comprehensive	study	using	a	more	accurate	quantification	analysis	such	as	mass	spectrometry	is	needed	in	order	to	thoroughly	 characterize	 all	 proteins	 secreted	 in	 the	 culture	 supernatant	 of	BCG∷SecDFG.	 A	 preliminary	 screen	 using	 isobaric	 tags	 for	 relative	 and	 absolute	quantitation	 (iTRAQ)	 for	 tandem	 mass	 spectrometry	 was	 performed	 in	 order	 to	identify	and	determine	the	amount	of	secreted	proteins	in	the	culture	supernatants	of	all	strains	studied.	Nearly	1500	proteins	were	identified	 in	BCG∷SecDFG10	and	over	200	were	upregulated	in	this	rBCG	compared	to	the	parental	strain	(data	not	shown).	This	indicates	that	the	overexpression	of	M.	tuberculosis	SecDFG	protein	in	BCG	affects	the	transport	of	several	proteins	to	the	extracellular	culture	fluids.	
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In	vitro	infection	studies	using	RAW	murine	macrophages	revealed	a	greater	survival	for	 BCG∷SecDFG	 over	 time	 (Figure	 4.3.A).	 The	 observed	 increase	 in	 the	 bacterial	numbers	 observed	 at	 72	 hours	 post	 infection	 might	 be	 caused	 by	 increased	proliferation	of	the	bacterial	inside	the	host	cells.	Protein	secretion	plays	a	crucial	role	in	modulating	 the	 interactions	 between	 bacteria,	 by	modulating	 host	 cell	 functions	including	vesicular	trafficking	and	host	immune	responses	(Mitchell	et	al.,	2016).	It	is	known	that	during	the	intracellular	life	cycle,	M.	tuberculosis	successfully	survive	and	replicate	inside	the	highly	degradative	environment	of	macrophages	due	to	its	ability	to	 secrete	 virulence	 factors	 that	 actively	 modify	 the	 host	 physiology	 to	 create	 a	conditions	permissive	to	bacterial	proliferation	(Forrellad	et	al.,	2013).	The	majority	of	proteins	exported	by	 the	Sec	 system	perform	vital	 functions	 including	of	several	important	virulence	factors	in	M.	tuberculosis	(Ligon	et	al.,	2012),	it	was	possible	that	by	 overexpressing	 SecDFG	 increases	 protein	 export	 efficiency	 that	 leads	 to	 better	secretion	of	beneficial	proteins	into	the	host	cells	resulting	in	enhanced	survival	of	the	bacterial	vaccine	inside	macrophages.	
4.3.2. In-vivo	 persistence	 of	 BCG∷SecDFG	 and	 generation	 of	 T	 cell	
immunity	Examination	of	BCG∷SecDFG	persistence	in	mice	revealed	greater	numbers	in	the	iLN	than	 other	 sites	 (Figure	 4.4).	 iLNs	 are	 located	 in	 fold	 of	 flank	 cranial	 to	 thigh	musculature	near	the	deep	circumflex	iliac	artery	(Van	den	Broeck	et	al.,	2006),	and	are	 the	 nearest	 draining	 lymph	 nodes	 located	 from	 the	 site	 of	 vaccine	 injection.	However,	when	observed	at	later	time	point	(day	7	post	vaccination),	it	was	clear	that	BCG∷SecDFG	replicates	more	than	the	parental	strain,	an	effect	that	was	also	seen	in	the	spleen,	correlating	with	enhanced	BCG∷SecDFG	persistence	seen	using	in	vitro	cell	culture.	In	the	lungs,	however,	BCG	was	essentially	undetectable	at	all	timepoints.	It	is	known	that	following	s.c.	vaccination,	initial	BCG	multiplication	occurs	in	the	draining	iLN	and	results	in	higher	bacterial	dissemination	in	the	spleen	than	in	the	lungs	(Olsen	et	al.,	2004).	It	has	been	proposed	that	BCG	chronically	persist	in	the	draining	lymph	nodes	of	mice	after	s.c.	vaccination	(Kaveh	et	al.,	2011)	and	may	function	as	a	reservoir	for	dissemination	 to	 the	 spleen	and	 lungs	 (Nandakumar	et	 al.,	 2014).	 Some	studies	have	 reported	 that	BCG	disseminates	 to	 the	 lung	 in	 low	numbers	around	20	weeks	following	 s.c.	 vaccination	 (Olsen	 et	 al.,	 2004).	 Overall,	 these	 data	 suggest	 that	 the	
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overexpression	 of	 M.	 tuberculosis	 SecDFG	 protein	 in	 BCG	 improved	 the	 bacterial	persistence	 in	murine	 organs	 particularly	 in	 the	 draining	 lymph	nodes	 and	 the	 s.c.	vaccination	of	this	rBCG	strain	caused	greater	dissemination	in	the	spleen.	Observation	with	longer	time-point	and	different	routes	of	vaccine	delivery	are	of	interest	to	further	define	the	capacity	of	SecDFG	overexpression	in	BCG	altering	the	vaccine	persistence.	
Measurement	 of	 the	 immune	 responses	 associated	with	BCG∷SecDFG	 and	 parental	BCG	vaccination	revealed	the	clearest	difference	upon	recall	to	member	of	the	Ag85	complex	 (Figure	 4.5,	 4.6).	 A	 similar	 result	 was	 observed	 upon	 recall	 with	 M.	
tuberculosis	 culture	 filtrate	 protein	 (CFP).	 CFP	 contains	 many	 different	 proteins	resulting	in	various	antigen	exposures	to	immune	cells,	the	most	predominant	of	these	being	 members	 of	 the	 Ag85	 complex	 (Giri	 et	 al.,	 2010).	 This	 also	 correlates	 with	previous	 work	 demonstrating	 enhanced	 immunogenicity	 of	 BCG	 overexpressing	Ag85B	 (Kong	 et	 al.,	 2011)	 and	 the	 role	 played	 by	 Ag85B	 in	 facilitating	 host	 cell	interaction	 (Prendergast	 et	 al.,	 2016).	 Enhanced	 Ag85B	 secretion	 was	 further	validated	when	examining	priming	of	Ag85B-specific	(P25)	transgenic	T	cells,	which	demonstrated	 increased	 proliferation	 of	 antigens	 specific	 T	 cells	 (Figure	 4.7,	 4.8).	Further,	a	higher	proportion	of	CD62L	positive	P25	CD4+	T	cells	were	observed	in	both	LNs	and	spleen	of	BCG∷SecDFG	vaccinated	mice	(Figure	4.9).	Studies	have	shown	that	central	 memory	 T	 cells	 play	 crucial	 roles	 in	 controlling	 M.	 tuberculosis	 infection	(Tonaco	 et	 al.,	 2017)	 and	BCG	 is	 known	 to	 induce	 small	 proportions	 of	 this	 subset	(Henao-Tamayo	 et	 al.,	 2010).	 Other	 surface	 markers	 observed	 in	 this	 study	 were	CXCR3,	KLRG-1	and	Ki67.	CXCR3,	similar	to	CD62L,	is	used	as	a	marker	for	T	memory	responses	whereas	KLRG-1	and	Ki67	are	used	as	T	cell	proliferation	markers	(Chu	et	al.,	 2016).	The	 findings	 from	 this	 study	 showed	 there	was	 no	 significant	 difference	observed	between	BCG∷SecDFG	and	the	parental	strain	for	these	markers,	indicating	that	 alteration	 of	 protein	 export	 did	 not	 have	 a	 broad	 effect	 on	 the	 expression	 of	memory/activation	markers	on	antigen-reactive	T	cells.	Analysis	of	cytokine	release	by	P25	T	 cells	did	however	 reveal	 that	BCG	overexpressing	M.	 tuberculosis	 SecDFG	protein	generated	high	 induction	of	polyfunctional	CD4+	T	 cells	producing	multiple	cytokines	including	IFNγ,	IL2	and	TNF.	IL2+TNF+	CD4+	T	cell	population	is	described	to	have	an	effector	memory	phenotype	with	high	proliferative	capacity	(Seder	et	al.,	2008,	Lindenstrøm	et	al.,	2013).	Therefore,	the	increased	proportion	observed	in	the	rBCG	
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vaccinated	mice	may	 contribute	 towards	 improved	 protective	 immunity	 against	M.	
tuberculosis	infection.	
4.3.3. BCG∷SecDFG	and	generation	of	protective	immunity	Analysis	 of	 immune	 responses	 in	 PBMCs	 after	 rBCG	 delivery	 generated	 low	proportions	 of	 responding	 T	 cells,	 with	 the	 most	 apparent	 difference	 in	 T	 cells	secreting	IFNγ	and	TNF,	representing	an	effector	phenotype	(Figure	4.12).	The	small	T	cell	responses	observed	could	be	due	to	the	decline	of	BCG	growth	as	it	is	subjected	to	clearance	within	the	host	cells	(Cruz	et	al.,	2010,	Lerm	and	Netea,	2016).	After	aerosol	challenge,	 BCG∷SecDFG	 induced	 greater	 Th1-type	 response	 indicated	 by	 increased	frequency	of	triple-cytokine	producing	CD4+	T	cells	(IFNγ,	IL2	and	TNF).	The	Th1-type	responses	have	been	well	described	as	an	essential	mechanism	of	protection	against	mycobacterial	diseases	including	TB	(O'Garra	et	al.,	2013)	and	polyfunctional	CD4+	T	cells	 secreting	 IFNγ,	 IL2	 and	 TNF	 has	 been	 proposed	 as	 a	marker	 of	 BCG-induced	immunity	(Nandakumar	et	al.,	2014).	At	extended	time	point	(approximately	20	weeks	after	M.	tuberculosis	challenge),	the	percentages	of	polyfunctional	pulmonary	CD4+	T	cells	lessened	in	both	vaccinated	groups	(Figure	4.12).	This	concurrent	decrease	in	the	magnitude	and	functionality	of	Th1-type	cytokine	producing	CD4+	T	cells	generated	by	BCG∷SecDFG	may	be	caused	by	the	fact	that	BCG	immunity	gradually	wanes	over	time	(Moliva	 et	 al.,	 2017).	 Other	 immune	 subsets	with	 dominant	 proportions	 generated	following	M.	tuberculosis	infection	were	double	positive	IFNγ+TNF+	or	single	IFNγ/TNF	producing	CD4+	T	cells.	Multiple	studies	have	shown	that	IFNγ	and	TNF	are	required	for	TB	immunity	although	in	contrast,	several	other	studies	have	also	show	that	the	magnitude	of	IFNγ-producing	T	cells	does	not	correlate	with	the	degree	of	protection	in	TB	(Mittrücker	et	al.,	2007).	
In	 accordance	 with	 the	 observed	 immunogenicity	 induced	 by	 BCG∷SecDFG,	 this	recombinant	 live	 vaccine	 overexpressing	 SecDFG	 protein	 was	 able	 to	 reduce	 the	bacterial	burden	in	both	lungs	and	spleen	of	M.	tuberculosis	infected	mice	by	1.45	and	1.02	log10	respectively	at	4	weeks	post	challenge.	Although	the	parental	strain	of	BCG	containing	the	empty	plasmid	also	showed	a	decreased	bacterial	burden,	BCG∷SecDFG	displayed	a	better	efficacy	with	greater	reduction	 in	both	organs	(Figure	4.14).	The	ability	of	BCG∷SecDFG	to	reduce	the	bacterial	loads	in	both	lungs	and	the	spleen	of	M.	
tuberculosis	infected	mice	at	early	time	point	following	challenge	correlates	with	the	
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increased	immunogenicity	observed	in	which	the	proportion	of	polyfunctional	CD4+	T	cells	was	significantly	 increased	 in	BCG∷SecDFG	vaccinated	mice.	As	SecD	and	SecF	mediate	 efficient	 secretion	 of	 virulence	 factors	 (Vörös	 et	 al.,	 2014)	 and	 SecG	accelerates	 the	 kinetic	 of	 protein	 export	 of	 Sec	 machinery	 (Bost	 and	 Belin,	 1997),	overexpressing	 these	 protein	 components	 in	 live	 BCG	 will	 therefore	 increase	 the	efficiency	 of	 the	 protein	 translocation	 in	 this	 bacterial	 vaccine	 resulting	 in	 greater	secretion	of	numerous	beneficial	proteins	into	the	extracellular	environment.	Several	mycobacterial	protein	factors	in	BCG	promote	persistency	and	persistent	BCG	bacilli	maintain	 the	 effector	 memory	 CD4+	 T	 cell	 in	 murine	 model	 (Kaveh	 et	 al.,	 2014).	Therefore,	overexpressing	SecDFG	protein	in	BCG	may	promote	more	efficient	protein	transport	particularly	persistence-related	proteins	that	can	generate	greater	memory	T	cell	responses	leading	to	better	efficacy	against	M.	tuberculosis	infection.	
4.4. Conclusions	and	future	directions	Overexpression	of	M.	tuberculosis	SecDFG	in	BCG	affected	the	protein	transport	system	causing	 major	 changes	 in	 the	 level	 of	 several	 proteins	 secretion	 including	 Ag85	complex	members	into	the	extracellular	milieu.	This	led	to	better	survival	inside	the	macrophages	 in-vitro	and	greater	persistence	of	vaccine	bacilli	 in	murine	organs	 in-
vivo.	In	addition,	BCG∷SecDFG	generated	greater	proportion	of	memory	T	cells	with	CD44+CD62Lhi	phenotype,	polyfunctional	CD4+	T	cells	producing	Th1-type	cytokines	as	well	as	provided	a	trend	of	greater	protective	efficacy	against	aerosol	M.	tuberculosis	infection	 at	 early	 time-point	 post	 challenge.	 These	 encouraging	 findings	 provide	 a	foundation	 for	 further	investigation	to	more	comprehensively	assess	 the	changes	 in	Sec	transport	machinery	within	BCG	resulting	in	improved	protein	secretion,	that	may	lead	 to	 improved	 immunogenicity	 and	 protective	 efficacy	 generated	 against	 M.	
tuberculosis	infection.	
However,	due	to	time	constraints,	various	aspects	are	yet	to	be	explored	in	order	to	further	characterize	the	BCG∷SecDFG	strain.	As	previously	mentioned,	it	is	crucial	to	further	 identify	 and	 asses	 the	 level	 of	 the	 proteins	 released	 into	 the	 extracellular	environment	 by	 the	 recombinant	 strain	 in	 comparison	 to	 the	 parental	 BCG.	 Two-dimensional	 (2-D)	 electrophoresis	 as	 well	 as	 mass	 spectrometry	 (MS)	 analysis	 of	culture	 supernatants	 to	 characterise	 changes	 and	 differences	 in	 secreted	 proteins	
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between	BCG∷SecDFG	and	its	parental	strain.	This	will	allow	better	understanding	of	the	physiological	changes	in	the	rBCG	bacilli	caused	by	SecDFG	overexpression.	
Following	the	assessment	of	BCG∷SecDFG	persistence	in	mice,	s.c.	vaccination	of	this	live	rBCG	strain	showed	higher	persistence	in	the	draining	iLNs	and	spleen	but	not	in	the	lungs,	due	to	the	nature	of	s.c.	vaccination	of	BCG	where	replication	occurs	in	the	draining	iLNs	(Nandakumar	et	al.,	2014).	However,	the	lungs	are	the	primary	site	of	M.	
tuberculosis	 infection,	 and	 peripherally	 delivered	 BCG	 does	 not	 adequately	 protect	against	pulmonary	TB	in	humans	(Horvath	et	al.,	2012).	Thus,	pulmonary	vaccination	to	induce	direct	local	immune	responses	in	the	lungs	is	critical	against	M.	tuberculosis	infection.	It	will	be	of	interest	to	assess	the	in	vivo	persistence,	immunogenicity	and	protective	responses	of	BCG∷SecDFG	when	delivered	as	a	pulmonary	vaccine.	
Finally,	it	would	be	of	interest	to	have	a	better	understanding	of	the	kinetics	of	immune	response	in	terms	of	expansion,	peak	and	contraction	of	the	T	cell	responses	generated	by	 BCG∷SecDFG.	 The	 study	 findings	 have	 shown	 that	 BCG∷SecDFG	 generated	 high	frequency	 of	 central	 memory	 CD4	 T	 cells,	 however	 it	 also	 appeared	 that	 this	 live	recombinant	vaccine	induced	the	generation	of	T	cells	with	high	expression	of	T	cell	senescence	marker	KLRG-1.	Therefore,	further	study	assessing	the	T	cell	kinetics	will	provide	better	insight	into	how	BCG	persistence	and	the	immune	senescence	affect	T	cell	 functionality,	which	may	 instruct	new	vaccination	strategies	 that	prevent	T	cell	attrition	and	exhaustion.	Finally,	TB	vaccines	 for	human	use	are	required	to	 impart	protection	 against	 infection	 in	 populations	 with	 different	 genetic	 backgrounds	(Counoupas	et	al.,	2016),	and	future	work	shall	assess	the	capacity	of	BCG∷SecDFG	in	inducing	 protective	 immunity	 against	M.	 tuberculosis	 infection	 in	 different	 murine	strains	and	diverse	animal	models.	
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5.1. Introduction and aims Tuberculosis (TB) is one of the most prevalent infectious disease-associated causes of death in the world. Over 90% of TB cases occur in developing countries with inadequate healthcare infrastructures and resources (WHO, 2018). The efficacy of M. 
bovis BCG vaccine, an attenuated M. bovis strain, against pulmonary TB varies enormously in different populations. Several hypotheses regarding the variation and inconsistency in BCG effectiveness have been proposed, including the progressive loss 
of BCG’s capacity to stimulate a durable immune response as well as the high prevalence of nontuberculous environmental mycobacteria which blocks or masks BCG-induced protection (Castillo-Rodal et al., 2006). Although BCG shows variable efficacy and limited protection against TB in adults, neonatal BCG provides effective protection against disseminated and pulmonary TB in infants and young children (Mangtani et al., 2013) hence the worldwide distribution and use of the vaccine in countries with high TB burden. For this reason the development of improved versions of BCG is an intense area of research (Singh et al., 2016). 
BCG offers a number of unique and beneficial features which make this vaccine suitable as a vaccine vehicle. it is affordable and easy to produce, is very stable and safe, is unaffected by maternal antibodies and therefore can be delivered at any time after birth. BCG also possesses inherent adjuvant properties, is highly immunogenic and can be administered orally as a single dose to elicit long-lasting immunity (Triccas, 2010, Bastos et al., 2009, Oliveira et al., 2017). For these reasons, BCG therefore is considered as an attractive vector for recombinant vaccine development. Studies have reported that several recombinant (r)BCG strains under development have the ability to induce both humoral and cellular immune responses in animal models (Oliveira et al., 2017). Development of rBCG strains has focused on the overexpression of immunodominant antigens of BCG and/or the introduction of antigens that may have been lost during the BCG attenuation process (da Costa et al., 2014). A second approach is to add immunostimulatory components to BCG in order to manipulate the immune responses following the vaccination resulting an extension in the quality and longevity of memory T cell responses against TB (Triccas, 2010). 
The use of pulmonary vaccination in TB vaccine development is an increasingly appealing strategy due to the fact that inhalational vaccination follows the natural 
 
138 Chapter 5. BCG∷DEC205 
primary route of M. tuberculosis infection in humans. This delivery method has been proposed to best mimic the induction of local immune response in the pulmonary mucosa followed by systemic immunity (Todoroff et al., 2013). In addition, specific memory T cells are known to be generated at sites of mucosal priming with the cells retained at the sites following antigen exposures (Lu and Hickey, 2007). This may be particularly beneficial in the case of M. tuberculosis infection where priming and recruitment of effector T cells to the lungs only occurs 1-2 weeks post vaccination (Reiley et al., 2008). 
M. tuberculosis uniquely targets lung dendritic cells (DCs) and alveolar macrophages (AMs) to disrupt and delay antigen presentation to T cells in the draining/mediastinal lymph nodes (mLNs). DCs, together with AMs, constitute the majority of professional APCs in the lungs, required for priming naïve T cells (Mihret, 2012), and defend against pulmonary infection by phagocytosing foreign particles and presenting their antigens to immune cells (Silva-Sánchez et al., 2015). M. tuberculosis infection disrupts the function of lung APCs by causing phagosome maturation arrest (Vergne et al., 2004), phagosome-lysosome fusion inhibition (Pieters, 2001), cytotoxicity delay (Quintero-Macías et al., 2012) and destabilisation of MHCII trafficking (Sendide et al., 2004). Furthermore, M. tuberculosis also inhibits the maturation and migration of lung DCs (Garcia-Romo et al., 2013) that ultimately leads to delayed M. tuberculosis-specific T cell responses (Quintero-Macías et al., 2012).  
In the case of pulmonary TB, lung DCs expressing DEC205 are a potential candidate to deliver mycobacterial antigens due to the in-situ interaction between DEC205+ DCs with M. tuberculosis bacilli in both lungs and mediastinal lymph nodes during airways infection (García‐Romo et al., 2004). Additionally, DEC205 is an endocytic receptor associated with antigen processing and presentation (Dudziak et al., 2007, Silva-Sánchez et al., 2015), mycobacterial recognition (von Garnier and Nicod, 2009), as well as the induction of Th1-type CD8+ responses (Idoyaga et al., 2008). 
The use of single-chain fragment variable (scFv) for vaccine development offers several advantages compared to whole antibody molecules. scFv molecules are single polypeptide chains incorporating both heavy and light chain variable regions with a polypeptide linker (Beckman et al., 2007). The heavy and light chains regions from the 
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same chain form a single Ab-binding site (Kim et al., 2005). Owing to their smaller size, scFv molecules have the capacity to penetrate tissue better than whole antibodies (Beckman et al., 2007) and the lack of Fc domain results in repeated administration without inducing unfavourable antibody-host response (Demangel et al., 2005). In addition, scFvs can be manufactured more economically than whole antibodies (Weisser and Hall, 2009). Furthermore, scFvs do not bind to Fc receptors expressed on DC and various other cell types that cause in the reduction of unspecific uptake and improved DEC205-specific antigen delivery (Birkholz et al., 2010). 
In this study, BCG was modified by expressing a scFv protein specific for the DC DEC205 receptor, conferring on the vaccine ability to interact with DCs either in a secreted (BCG∷DEC20585B) or a membrane bound form (BCG∷DEC20519kDa). It is hypothesised that directly targeting specific DC receptors could improve the early interaction between the vaccines and DCs leading to increased uptake of the bacteria and cell stimulation. The improved early interaction following the vaccination was proposed to induce a coordinated Th1 cell mediated immune response resulting in better protective efficacy against M. tuberculosis infection. Previous results from my laboratory (Baker et al, unpublished data) has shown that subcutaneous vaccination of DC-targeted BCG strains was able to increase the uptake of the bacterial vaccines and DC activation which translated into improved protective immunity in a murine model. As pulmonary delivery may generate protective resident memory T cells at the site of exposure to M. tuberculosis infection, this study determined if BCG∷DEC205 could be delivered directly to the site of infection in order to generate greater protective immunity against TB. Therefore, the following aims will be addressed in this chapter: 
(i) To assess the distribution of the DEC205 expression in different immune cells in murine organs. (ii) To determine the type of CD4+ and CD8+ T cell immunity elicited after pulmonary delivery of DC-targeted BCG strains in mice. (iii) To determine whether pulmonary vaccination of DC-targeted BCG strains improves protective capacity against M. tuberculosis infection. 
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5.2. Results 
5.2.1. Construction of recombinant BCG strains expressing DEC205 scFv 
protein and the mCherry reporter molecule The construction of recombinant BCG strains expressing single-chain fragment variable (scFv) protein specific for the DC receptor DEC205 was previously performed by Dr. Rachel Pinto and Lucy Baker (2015). A DNA fragment encoding mouse DEC205 scFv (34 kDa, containing only VH and VL domains separated by a G4S4 linker sequence) preceded by a HA-tag for immune detection was cloned into the pMV261 plasmid (Figure 5.1.A). Addition of the signal sequence of either M. tuberculosis Ag85B or 19kDa proteins created a scFv-secreted (BCG∷DEC20585B) or scFv-membrane bound form (BCG∷DEC20519kDa) of recombinant BCG. In order to develop reporter rBCG strains, a mCherry expressing plasmid (pNIP40) was electroporated into both candidate strains. The transformants were then plated onto solid 7H11 media with appropriate antibiotics. Approximately three weeks post inoculation, pink colonies were grown, indicating the expression of mCherry protein in the bacteria. The transformants were then screened for mCherry expression using flow cytometry and all strains tested were positive for the mCherry fluorescent protein (Figure 5.1.B). 
In order to detect the expression of DEC205 scFv protein in the recombinant BCG strains, both cell lysates and concentrated culture supernatants of both candidate strains were collected. The expression of the scFv DEC205 recombinant protein was confirmed by SDS-PAGE and Western blot by the HA tag detection using a rabbit recombinant monoclonal anti-HA antibody as described in Chapter 2 Section 2.3.6. A band of the expected size for DEC205 scFv (34 kDa) was detected in the cell lysates of BCG∷DEC19kDa indicating that DEC205 scFv was indeed successfully expressed in this recombinant BCG strain (Figure 5.1.C). However, it was not possible to detect the scFv expression in the culture supernatant of BCG∷DEC20585B, even with the use of BSA-free media and concentration of culture supernatant. This may be due to the large number of proteins secreted by mycobacteria (Gomez et al., 2000) resulting the difficulties to detect a certain protein in the crude supernatant solutions. 
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Figure 5.1. Construction, expression and analysis of recombinant BCG strains 
expressing DEC205 scFv protein and the mCherry reporter molecule. (A) Map of the recombinant prokaryotic expression plasmid pMV261-DEC205scFv. (B) Confirmation of mCherry expression in fluorescent clones of BCG∷DEC205. BCG strains were fixed with formalin and mCherry expression was measured by flow cytometry. (C) Immunoblot confirming the expression of DEC205 scFv protein in rBCG strains. Cell lysates and concentrated culture supernatants of rBCG candidate strains were prepared and run (10-20 μg) on a 12% SDS-PAGE gel. HA-tagged DEC205 scFv (~34 kDa) was detected using rabbit recombinant monoclonal anti-HA antibody, a secondary donkey anti-rabbit antibody IgG HRP (shown by the arrow; Lane 1: HA-tagged protein control, 2: BCGpMV261, 3: BCG∷DEC20585B, 4: BCGmCherry∷DEC20585B, 5: BCGmCherry, 6: BCG∷DEC20519kDa, 7: BCGmCherry∷DEC20519kDa). (D) Growth rate of rBCG strains expressing DEC205 scFv. Broth cultures of BCG Pasteur BCGmCherry, BCG∷DEC205 and BCGmCherry∷DEC205 strains were inoculated into supplemented Middlebrook 7H9 broth media and the cultures were incubated at 37°C with 5% CO2 as static cultures. The growth curves of the strains were generated by measurement of the OD at 600 nm. The values represent mean of the two independent cultures with standard deviation (SD).  
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The growth rates of the rBCG strains in supplemented 7H9 broth media (with appropriate antibiotics, refer to Table. 2.3.) were also assessed by measuring the optical density (OD) at 600 nm for 14 days. Figure 5.1.D shows that there were variations in the growth rates of BCG∷DEC205 when compared to BCG Pasteur containing the empty vector. The rBCG strains appeared to reach stationary phase slightly quicker than the parental BCG and started to multiply more slowly at day 8. The mCherry strains grew at slower rate when compared to non-mCherry expressing strains, particularly BCGmCherry∷DEC19kDa. 
5.2.2. BCG∷DEC205 interaction with DEC205 transfected CHO cells in-
vitro It was hypothesised that the expression of scFv DEC205-specific in BCG would improve the early interactions between DCs and bacterial vaccines. In order to examine this, Chinese hamster ovary (CHO) cells were transfected with mouse DEC205 and infected with BCG∷DEC205 strains. CHO and DEC205-transfected CHO cells were incubated with fluorescent mCherry rBCG strains and the frequency of mCherry+ cells determined by flow cytometry. Four hours after inoculation with BCGmCherry∷DEC205, there was an increased percentage of mCherry+ mDEC205-CHO cells compared to cells incubated with parental mCherry BCG strain at 4°C. This was observed in all MOIs used (Figure 5.2.B top row). mDEC205-CHO cells infected with BCGmCherry∷DEC205 had greater proportion of mCherry+ cells (5.3% of the total cells acquired) compared to normal CHO cells (0.9%) at a MOI of 5. Interestingly, when infection was performed at 37 °C (Figure 5.2.B bottom row), there was no significant difference observed between normal CHO and mDEC205-CHO cell lines when infected with mCherry fluorescent BCG/rBCG strains, suggesting the increased association was only apparent at low temperature. 
5.2.3. The expression of DEC205 on different types of immune cells in 
murine organs The next experiment examined the distribution of the DEC205 expression on immune cells in several murine organs, including the lungs, spleen, ear auricles, auricular lymph nodes (aLNs), inguinal lymph nodes (iLNs) and mediastinal lymph nodes (mLNs). 
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Figure 5.2. BCG∷DEC205 interaction with DEC205 transfected CHO cells in-vitro. Two x 105 CHO and mouse DEC205 transfected CHO (mDEC205-CHO) cells (A) were incubated with BCGmCherry or BCGmCherry∷DEC20585B at a MOI 1, 5 or 10 (B) and incubated at 4 (top panel) or 37°C (bottom panel). Four hours post infection cells were washed with complete RPMI media to remove extracellular bacteria and processed for surface and intracellular cytokine staining as described in Chapter 2 Section 2.5.3 prior to flow cytometry acquisition (Appendix 6). Data are representative of 2 independent 
experiments. Statistical significance was determined by ANOVA with Sidak’s multiple comparison test (* p<0.1; ** p<0.01; **** p<0.0001).   
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Figure 5.3. Expression of DEC205 on different immune cells in murine organs. 
(A) Female C57BL/6 mice (n=4) were sacrificed and the lungs, spleen, ear auricles, auricular lymph nodes (aLNs), inguinal lymph nodes (iLNs) and mediastinal lymph nodes (mLNs) were collected, processed and then stained prior to flow cytometry acquisition. (B) The mean fluorescence intensity (MFI) of DEC205 expression on immune cells in murine organs as determined by flow cytometry analysis. The negative control was fluorescence minus one (FMO) where samples contained all the fluorochromes used except DEC205-APC. Data represent the average MFI from 4 mice for each immune cell analysed.  
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Representative histogram plot in Figure 5.3.A shows that macrophages in all organs expressed higher levels of DEC205 compared to other types of immune cells, particularly alveolar macrophages (AMs) with MFI ten times greater than the control. In the three different lymph nodes, all observed immune cells expressed DEC205 with the greatest frequency of expression. Interestingly, in the auricle dermis of the ears, DEC205 seemed to be expressed only by macrophages whereas both macrophages and DCs, as well as neutrophils, expressed high frequencies of DEC205+ cells in the spleen. 
5.2.4. BCG∷DEC205-induced immunity post-intranasal vaccination Eight weeks following s.c. or i.n. vaccination with BCG∷DEC205 strains antigen specific T cell responses in the blood were assayed for cytokine production by intracellular staining of PBMCs and flow cytometry. Intranasal vaccination of BCG∷DEC205 induced the generation of polyfunctional CD4+ and CD8+ T cells in murine PBMCs (Figure 5.4). Upon recalling to BCG sonicate antigen, the greatest frequencies of triple positive IFNγ+IL2+TNF+ CD4+ and CD8+ T cells were observed in subcutaneously BCG∷DEC20585B vaccinated mice, whereas double positive IFNγ+IL2+ producing CD4+ and CD8+ T cells were more apparent in the blood of intranasally vaccinated BCG∷DEC20585B immunized mice (Figure 5.4). A large frequency of CD4+ T cells producing IFNγ (>10%) and TNF was shown in all groups of immunized mice (Figure 5.4.A). Single cytokine producing T cells were also observed in the CD8+ subset of all groups in this study (Figure 5.4.B). 
5.2.5. Phenotype and functionality of pulmonary T cells following 
intranasal delivery of BCG∷DEC205 after M. tuberculosis challenge The aim of the following experiments was to investigate the immune response generated by DC-targeted BCG strains when post M. tuberculosis challenge. To do this, C57BL/6 mice were immunised (i.n. or s.c.) with DC-targeted rBCG strains and 10 weeks after vaccine delivery, mice were challenged with aerosol M. tuberculosis H37Rv. Four weeks following the infection the CD4+ and CD8+ T cells activation profiles and cytokine secretion in the lung were determined. 
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Figure 5.4. BCG∷DEC205 induced immunity post intranasal vaccination in 
murine PBMCs. C57BL/6 mice (n = 6) were intranasally or subcutaneously vaccinated once with 5x105 CFU of BCG Pasteur/rBCG strains. Eight weeks following vaccine delivery, PBMCs were isolated from the blood. Intracellular cytokine staining was performed after 4 hours stimulation with BCG sonicate antigen and 16 hours stimulation with Brefeldin A to examine the frequency of IFNγ, IL2, and/or TNF producing CD4+ (A) or CD8+ (B) T cells (r SEM). Data are a representative of 2 independent experiments. Significance of differences between the groups was 
determined by ANOVA Tukey’s HSD post hoc test (* p<0.1; ** p<0.01; **** p<0.0001).    
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Figure 5.5. Proportion of activated pulmonary CD4+ and CD8+ T cells following M. 
tuberculosis challenge in BCG∷DEC205 immunized mice. C57BL/6 mice (n = 6) were vaccinated i.n. or s.c. with 5x105 CFU of BCG/BCG∷DEC205 and then challenged with aerosol M. tuberculosis H37Rv at week 10 following vaccination. Four weeks post challenge, mice were sacrificed, lung cells stained for surface markers and the activation profile of pulmonary T cells measured by flow cytometry (see Appendix 4 for gating strategy). CD44 and CD62L as well as KLRG1 and PD-1 profiles of T cells are shown as a representative flow pots (A). Frequency of CD44hiCD62Lhi/lo and KLRG1hi/loPD-1hi/lo CD4+ (B) and CD8+ (C) T cells were detected by surface staining and flow cytometry. Data are shown as box-and-whisker plots of cell proportions with medians, interquartile ranges (IQR) and minimum to maximum values. Statistically significant differences among the groups were determined by one-way ANOVA with 
Tukey’s multiple comparisons test (* p<0.1; ** p<0.01; *** p<0.001; **** p<0.0001).  
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In the lungs, there was a higher percentage of CD4+ T cells with an activated effector phenotype (CD44hiCD62Llo) in all BCG/rBCG vaccinated groups when compared unimmunised mice. Furthermore, an increased frequency of cells displaying a central memory phenotype (CD44hiCD62Lhi) was observed in both CD4+ (Figure 5.5.A) and CD8+ (Figure 5.5.B) T cells of intranasally BCG∷DEC205 vaccinated mice. Interestingly, mice that were vaccinated subcutaneously with BCG∷DEC20585B generated greater frequencies of KLRG1hiPD-1lo cells, with lower proportions of KLRG1hi cells observed in both CD4+ and CD8+ pulmonary T cells of mice intranasally immunized with BCG∷DEC205. Similar proportions of KLRG1loPD-1hi were observed in all groups including the unvaccinated mice for both CD4+ and CD8+ pulmonary T cells, with slightly increased frequencies of KLRG1loPD-1hi CD4+ T cells in the lungs of immunized mice following M. tuberculosis infection (Figure 5.5.B). 
Leukocytes from the lungs were recalled to whole M. tuberculosis culture filtrate proteins (CFP) and the cytokine production by CD4+ and CD8+ T cells was assessed by intracellular staining and flow cytometry. Overall, greatest responses were observed for i.n. delivered BCG∷DEC20585B compared to other groups. This was particularly evident for the IFNγ+IL2+TNF+ and IFNγ+IL2+IL17+ CD4+ T cell subsets, which were markedly elevated compared to other groups. Significantly enhanced frequency of IFNγ+TNF+ and TNF+ only secreting cells were also apparent after i.n. BCG∷DEC20585B vaccination compared to unvaccinated animals, which was not the case for other groups. Mice that received i.n. BCG∷DEC20585B vaccination also displayed increased frequency of polyfunctional CD4+ T cells producing IFNγ, IL-2, IL-17 and TNF compared to other groups, but this difference was not significant (Figure 5.6.B). 
Although the percentage of multiple cytokines producing CD8+ T cells in this study was not as great as that observed in CD4+ cell subset, it was of interest to see the differences in the capacity of these immune cells producing important cytokines following vaccination and subsequent M. tuberculosis challenge. Elevated proportions of multiple-cytokine (IFNγ+IL2+IL17+TNF+, IL2+IL17+TNF+ and IFNγ+TNF+) producing CD8+ T cells were observed in the lungs of i.n BCG∷DEC20585B vaccinated mice compared to other groups, but these differences did not reach significance (Figure 5.7.B).  
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Figure 5.6. Generation of antigen specific polyfunctional cytokine secreting CD4+ 
T cells in the lungs following BCG∷DEC205 vaccination and M. tuberculosis 
challenge. Antigen-specific cells were detected at 4 weeks after M. tuberculosis infection by intracellular immunostaining and flow cytometry after ex-vivo stimulation with CFP protein (10 Pg/mL) (A) Representative flow plots of CFP-specific CD4+ T cells producing multiple cytokines. (B) Frequency of cytokine-producing CD4+ T cells in the lungs. Data are the means r SEM (n = 6) and represent one of the 2 independent experiments. Statistically significant differences among the groups are shown as 
determined by ANOVA with Tukey’s HSD post hoc test (** p<0.01; **** p<0.0001).   
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Figure 5.7. Generation of antigen specific polyfunctional cytokine secreting CD8+ 
T cells in the lungs following BCG∷DEC205 vaccination and M. tuberculosis 
challenge. Antigen-specific cells were detected at 4 weeks after M. tuberculosis infection by intracellular immunostaining and flow cytometry after ex-vivo stimulation with CFP protein (10 Pg/mL) (A) Representative flow plots of CFP-specific CD8+ T cells producing multiple cytokines. (B) Frequency of cytokine-producing CD8+ T cells in the lungs. Data are the means r SEM (n = 6) and represent one of the 2 independent experiments. Statistically significant differences among the groups are shown as determined by ANOVA with Tukey’s HSD post hoc test.  
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Figure 5.8. Protection afforded by BCG∷DEC205 strains against aerosol M. 
tuberculosis infection in C57BL/6 mice. (A) C57BL/6 mice (n = 6) were immunised i.n. or s.c. with 5x105 CFU of BCG/BCG∷DEC205 strains. Ten weeks post immunisation, mice were challenged by ~100CFU of M. tuberculosis H37Rv via aerosol route. Mice were euthanised after 4 weeks post challenge and bacterial loads were enumerated in the lungs (B) and spleen (C). The data are the means r SEM and a combination of 2 independent experiments. Statistical significance was determined by ANOVA with 
Tukey’s multiple comparisons test (*** p<0.001; **** p<0.0001).      
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No difference in the proportion of polyfunctional CD8+ T cells with Th1-type response producing triple cytokines (IFNγ, IL2 and TNF) was seen in the lungs of immunised 
mice (Figure 5.7.B). Additionally, similar proportion of IFNγ producing CD8+ T cells was observed in all groups, following the same trend observed in CD4+ cells. 
5.2.6. Protective immunity afforded by BCG∷DEC205 intranasal 
vaccination To determine if differences in the generation of T cell immunity after rBCG delivery correlated with protection against infection, mice were vaccinated with rBCG strains and challenged 10 weeks later. Four weeks following M. tuberculosis infection, there was a significant increase in the protection afforded by BCG, BCG∷DEC20585B and BCG∷DEC20519kDa immunised mice compared to unvaccinated mice in both lungs and spleen. Specifically, there was an approximate 1.41 log10 reduction in bacterial number observed in the lungs of i.n. BCG∷DEC20585B vaccinated mice (Figure 5.8.B). This bacterial load was 0.56 and 0.18 log10 lower than s.c. BCG∷DEC20585B and wild type BCG respectively, although these differences were not statistically significance. A similar trend was observed in the spleen where i.n. BCG∷DEC20585B vaccinated mice had high reduction of bacterial burden in this organ (1.18 log10) comparable to that observed in unvaccinated mice, and this protection was greater than that observed after s.c. BCG∷DEC20585B delivery (Figure 5.8.C). Thus, overall there was a trend towards improved protection afforded by DC-targeted rBCG strains when delivered intranasally. 
5.3. Discussion 
5.3.1. BCG∷DEC205 as a novel live recombinant BCG vaccine strategy to 
directly target DCs TB remains a major global public health issue, despite the widespread use of the BCG Evidence suggests the protective efficacy afforded by BCG vaccination wanes with time (Rodrigues et al., 2011), therefore improved and more effective vaccines are urgently needed to better control and prevent TB infection. However, the development of novel TB vaccines is often hampered by insufficient knowledge of the protective immune mechanism against the disease. One approach to develop a novel TB vaccine is to improve the current BCG vaccine by expressing immune modulators to directly target immune pathways, which are essential in TB protective immunity (Kaufmann, 2011). 
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It is now clear that DCs are the major professional APCs with capacity to internalize, process and present antigens through MHC class I and II pathways (Guermonprez et al., 2002). DCs are known to induce strong immune response by activating naïve T cells and have the capability to respond to foreign pathogens (Guermonprez et al., 2002, Banchereau et al., 2000). In this study, novel live recombinant BCG strains expressing single-chain fragments variable (scFv) specific for DC receptor DEC205 (BCG∷DEC205) have been assessed. These recombinant strains were generated by expressing a secreted or membrane-bound form of scFv on the surface of BCG. Incorporation with mCherry fluorescent gene allowed the engineered bacteria to be visualised by flow cytometry and microscopy, as fluorescent proteins such as mCherry are very beneficial in studying interaction between host cells and microbes (Grimm et al., 2014). Western blot analysis confirmed expression of the scFv (34 kDa) in the lysate of BCG∷DEC19kDa (Figure 5.1.C) but the extracellular scFv in the culture supernatant of BCG∷DEC20585B could not be detected. A thorough analysis using mass spectrometry for culture supernatants as well as cell wall fractions of the rBCG strains could possibly be used to further confirm the expression of scFv in BCG. 
When cultured in 7H9 broth media, both strains of BCG∷DEC205 appeared to have a reduction in doubling time in their exponential phase prior to reaching stationary phase, compared to wild type BCG (Figure 5.1.D). In addition, all mCherry strains appeared to grow more slowly than non-mCherry strains. The introduction of recombinant plasmids has previously been shown to alter bacterial growth (Slater et al., 2008). 
Previous studies in my laboratory by Baker et al. have shown that the expression of scFv DEC05-specific protein in BCG improved the early interaction between mouse bone marrow dendritic cells (BMDCs) and the bacterial vaccine, that led to improved DC activation and promotion of chemokine and cytokine production (unpublished data). In the current study it was shown that BCG∷DEC20585B displayed greater association with DEC205 transfected CHO cells, particularly at higher MOIs and 4 °C (Figure 5.8). Intriguingly at lower MOIs control BCG showed some limited interaction with mDEC205-CHO cells, suggesting that BCG may naturally express molecules that bind DEC205.  Interestingly, when cells were incubated with the bacterial vaccine at 37 °C, there was no significant difference observed in both cell lines following 4 hours 
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incubation with BCG∷DEC205 or parental BCG. Although scFv is a stable protein at room temperature (Johnson et al., 2008), it appears that the degree of stability of DEC205 transfected CHO cells might be greatly influenced by temperature affecting the interaction between the cells and bacterial vaccine strains. 
5.3.2. DEC205 distribution on immune cells and vaccine targeting DEC205 was chosen as a target for the rBCG vaccines used in this study as it is an endocytic C-type lectin receptor expressed on the surface of DCs, which has the ability to constitutively express and recycle itself (Howard and Isacke, 2002), enhance antigen presentation via MHCII lysosomal compartments (Mahnke et al., 2000) and is abundantly expressed in the T cell areas of major lymphoid organs (Witmer-Pack et al., 1995, Pack et al., 2008). This current study found that DEC205 was mostly expressed on macrophages and DCs in the lungs, spleen and mediastinal lymph nodes of mice (Figure 5.2). This confirms previous findings that DEC205 is present on the majority of APCs including DCs in lungs and lymphoid organs (Pack et al., 2008). Furthermore, alveolar macrophages (AMs), along with lung DCs and neutrophils, appeared to show high expression of DEC205 indicating that lungs are rich with immune cells with a very specific receptor present on their surface resulting in effective targeting of vaccines. 
With regards to vaccine delivery, a high density of APCs including AMs and DCs observed in the murine lungs represents an ideal target to induce a strong immune response in both mucosal and systemic immunity (Blank et al., 2011, Kunda et al., 2013). It is also known that the lung consists of an intricate network of DCs which spreads throughout the conducting airways, lung interstitium, lung vasculature and pleura (GeurtsvanKessel and Lambrecht, 2008). There are at least five different subsets of DCs that have been identified in the murine lung including resident DCs, plasmacytoid DCs, alveolar DCs, inflammatory DCs and interferon-producing killer DCs (GeurtsvanKessel and Lambrecht, 2008, Lambrecht and Hammad, 2009). The study findings showing a high expression of DEC205 in the murine lungs combined with the fact that murine lungs are armed with abundant numbers and types of DCs, creates a solid foundation for further investigation towards pulmonary vaccine delivery targeting DCs. 
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5.3.3. Intranasal vaccination of BCG∷DEC205 and the enhanced 
development of immunity pre- and post-M. tuberculosis challenge Following M. tuberculosis challenge, increased proportions of both effector (CD44hiCD62Llo) and central memory (CD44hiCD62Lhi) CD4+ T cells shown for all BCG∷DEC205 vaccinated groups (Figure 5.4). Studies have shown that the superior protection afforded by BCG ΔureC∷hly (VPM1002, a recombinant BCG strain secreting pore-forming listeriolysin of Listeria monocytogenes) correlates with higher proportions and numbers of central memory T cells (Vogelzang et al., 2014). Effector T cells, on the other hand, can repress the replication of M. tuberculosis following mucosal vaccination (Jeyanathan et al., 2010). Furthermore, despite the short-lived characteristic, effector T cells drive high levels of proliferation following M. 
tuberculosis antigen exposures (Urdahl et al., 2011). Therefore, an increased proportion of both effector and memory T cells in the lungs of BCG∷DEC205 mice might contribute to providing strong protective immunity against M. tuberculosis. 
This study also showed that both unvaccinated and subcutaneously BCG∷DEC205 vaccinated mice had a higher proportion of KLRG1hiPD-1lo CD4+ and CD8+ T cells compared to that observed in mice that received pulmonary vaccination with rBCG strains (Figure 5.4.B and 5.4.C). KLRG1hiPD-1lo is a phenotype for terminally differentiated effector T cells producing cytokines with low proliferative capacity and a short lifespan (Urdahl et al., 2011). Thus, it appears intranasal vaccination of DC-targeted rBCG strains decreased the proportion, which may favour the generation of persistent memory T cells. Contrarily, there was no significant difference across the observed groups in the proportion of KLRG1loPD-1hi CD4+ and CD8+ T cell subset. KLRG1loPD-1hi is the profile of functionally exhausted T cells (Urdahl et al., 2011). The blockade of PD-1 programmed cell death ligand 1 has shown to improve T cell function and enhanced viral clearance in chronic lymphocytic choriomeningitis virus infection model (Barber et al., 2006). However, PD-1 expressing T cells in the TB model undergo robust proliferation and maintain a productive effector T cell response yet they are not functionally anergic (Reiley et al., 2010, Urdahl et al., 2011). Although in this study, there was no significant difference in the proportion of KLRG1loPD-1hi T cell subset, it was speculated that CD4+ T cells with KLRG1loPD-1hi profile function to supress CD4+ 
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T from fully differentiating and maintain long-term antigen-specific T cell populations that ultimately leads to the control of M. tuberculosis infection (Urdahl et al., 2011). 
Intranasal vaccination of mice with BCG∷DEC20585B induced greater Th1-type response indicated by increased frequency of triple cytokine producing CD4+ T cells (IFNγ, IL2 and TNF) in the lungs of immunised mice. Th1-type responses have been well acknowledged as an essential mechanism of protection against mycobacterial diseases including TB (O'Garra et al., 2013, Szpakowski et al., 2015, Kim et al., 2016). BCG vaccine can also induce long-lasting Th1 immunity as well as trigger CD8+ T cell responses (Matsuo and Yasutomi, 2011, Gu et al., 2016), correlating with what was observed in the current study (Figure 5.5 and 5.6). However, these multiple-cytokine producing cells subsets were less apparent after delivery of the membrane-bound scFv strain, BCG∷DEC20519kDa. This suggest that the location of scFv protein may play a role in determining the interaction between the bacterial vaccine and DCs, that ultimately affects the pathway of T cell activation to generate anti-TB immunity. 
Intranasal vaccination of BCG∷DEC20585B induced the generation of IL-17 producing CD4+ T cells (Figure 5.5.). It is known that Th17 CD4+ T cells play a significant role during M. tuberculosis infection (Torrado and Cooper, 2010, Zhang, 2018). IL-17 has also been reported to involve in the protection against highly virulent strains of M. 
tuberculosis (Gopal et al., 2014) possibly due to its role in recruiting Th1 cells to the site of infection (Torrado and Cooper, 2010). It is likely that a balanced Th1/Th17 response is necessary in providing optimal protection against M. tuberculosis infection, similar to that observed in BCG∷DEC20585B vaccinated mice. 
5.3.4. Protection afforded by Intranasal BCG∷DEC205 against M. 
tuberculosis infection Despite the increased immunogenicity observed in BCG∷DEC205 vaccinated mice, the protection afforded by these recombinant strains only showed a small trend of increased efficacy four weeks following M. tuberculosis infection (Figure 5.8.C). The ability of intranasal BCG∷DEC20585B vaccination to reduce bacterial numbers in the lung of immunised mice did however correlate with the heightened generation of Th1 and increased proportion of Th17 generated by the vaccine following M. tuberculosis challenge, compared to unvaccinated animals. Generally, T cells are primed and 
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programmed in draining lymph nodes by DCs before migrating towards infected tissues. Thus, DCs play essential roles in establishing T cell memory responses by translating innate immunity into immunological memory (Steinman and Hemmi, 2006). Therefore, by specifically targeting DEC205, a phagocytosis receptor mediating antigen uptake (Birkholz et al., 2010), intranasal vaccination of BCG∷DEC205 might have induced the maturation of lung DCs that consequently led to improved cellular immune responses and better protective efficacy against M. tuberculosis infection. As described above, enhanced Th17-type CD4+ T cell responses were also observed after BCG∷DEC20585B vaccination, and considering the previously defined role of these cells in vaccine-induced protection against TB infection (Gopal et al., 2013, Aguilo et al., 2015, Monin et al., 2015), this cell subset may have contributed to the protection afforded by the BCG∷DEC205 candidates. 
5.4. Conclusions and future directions Overall this study corroborates the potential of prospective of DC-targeted rBCG vaccination to improve immunity and protection against M. tuberculosis infection. It draws focus to the importance of DCs in initiating anti-mycobacterial immune responses. By targeting DEC205 on DCs with a secreted and membrane bound scFv engineered in BCG specifically at the site of infection, there was an improved association of DCs that translated into T cell activation, increased immunogenicity and a trend towards improved protection. Therefore, these encouraging findings provide a platform for further investigation to more conclusively determine the mechanism of interaction between BCG∷DEC205 with DCs, that will lead to protective influence generated against M. tuberculosis infection.  
Due to time constraints, numerous aspects in this study are yet to be explored. As previously mentioned above, the expression of recombinant DEC205 scFv needs to be further examined in both strains of BCG∷DEC205, particularly in the secreted form strain (BCG∷DEC20585B), as protein identification using immunoblot can be complex and difficult (Padula et al., 2017). It is also of interest to assess the exact location of 19kDa-fused scFv in BCG cell membrane, as well as determine how much of the scFv protein is secreted into the extracellular environment and the amount that remains inside the cell. 
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This study has also confirmed that DEC205 molecules are highly expressed on the majority of APCs including DCs and macrophages. While the recombinant BCG strains constructed in this study were aimed to target DCs, it will be important in future work to examine whether BCG∷DEC205 vaccination affect other APCs such as alveolar macrophages and lung interstitial macrophages. It would also be of interest in future experiments to investigate in-vivo uptake of BCG∷DEC205 vaccines by various cell types. 
Intranasal vaccination of BCG∷DEC205 revealed an increased in the frequency of both CD4+ and CD8+ T cells secreting multiple cytokines and a trend of improved protection against M. tuberculosis infection. However, in the case of pulmonary vaccines, it is important to distinguish between intranasal and inhalational delivery routes. Although it is possible that both routes may stimulate similar immune responses in the lungs, there is a particular concern regarding safety of the intranasal vaccination in humans. A critical issue for intranasal delivery is the potential direct access to the central nervous system through the olfactory region in the roof of the nasal cavity (Källenius et al., 2007). It has been reported that correctly formulated aerosolised inhalable dry powder vaccines may take advantage of the phagocytic activity of alveolar APCs (Garcia-Contreras et al., 2008, Wong et al., 2007). Therefore, a future investigation of stable dry powdered BCG∷DEC205 as an inhalational vaccine would be an important consideration in order to further enhance immune response against TB infection. 
Finally, considering that humans are the ultimate population where such vaccines will be used, BCG expressing human DEC205 scFv molecules could be developed, and interaction with human cells examined. In addition, the encouraging trend observed in protection studies should be investigated further. Ongoing experiments are currently investigating the protective efficacy of BCG∷DEC205 intranasal vaccination 24 weeks following aerosol challenge with M. tuberculosis H37Rv. Due to the long-term nature of these studies they could not be included in this thesis. It has previously been shown that the protection BCG offered by BCG in a murine model wanes over time (Andersen and Urdahl, 2015) yet subcutaneous vaccination of BCG∷DEC205 strains has shown to maintain its efficacy by reducing the bacterial number in the lungs of TB infected mice 24 weeks after challenge (Counoupas et al., 2017; unpublished data). Therefore, 
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examination of protection at these extended time points may further reveal differences between the DC-targeted and non-targeted BCG strains. 
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Tuberculosis (TB) remains a major global health problem and ranks as the top infectious killer worldwide, accounting 10.4 new incident cases and 1.7 million deaths estimated to have occurred in 2016 (WHO, 2017). In order to reach the reduction targets detailed in the WHO End TB Strategy, acceleration and more focused efforts in developing novel and effective vaccines are urgently needed. Despite good progress in TB vaccine research BCG remains the only available vaccine (Luca and Mihaescu, 2013). While the vaccine can to some extent protect infants from disseminated forms of TB, BCG provides variable efficacy and inconsistent protection against pulmonary TB in adults (Boer et al., 2015). Multiple vaccination strategies have been implemented to develop improved TB vaccine candidates in order to prevent relapse and global transmission of M. tuberculosis. In this study, novel fusion protein and live recombinant BCG strains were assessed for their immunogenicity and protective efficacy against M. 
tuberculosis infection in murine models. 
6.1. Latency antigen incorporation for effective TB subunit vaccine Subunit vaccines have been developed with the hope of boosting BCG-derived immunity to provide strong and long-lived immune responses against M. tuberculosis infection (Niu et al., 2015). TB subunit vaccines are mostly based on recombinant proteins formulated in adjuvants, or the use of attenuated viral vectors (Ottenhoff and Kaufmann, 2012). Comparison of adjuvanted recombinant protein and viral vectors expressing the same antigen revealed improved  memory and polyfunctional T cell generation by the protein vaccine in animal models (Billeskov et al., 2013). Thus, the development of novel recombinant protein-based subunit vaccines for TB is a highly feasible strategy to potentially provide long-term protection against this disease. There are currently three adjuvanted recombinant protein TB vaccine candidates in human clinical trials (Aeras, 2018). However, some of these subunit vaccines are based on antigens produced solely by replicating bacilli (detailed in Chapter 1). Studies have revealed that M. tuberculosis alters its metabolic state from active replicating to slow growing or non-replicating dormant-like state (Bacon et al., 2014). This accompanied by significant changes in M. tuberculosis gene expression profile affecting the available antigens to the immune system when the bacteria enter an anaerobic dormancy or starvation state (Ryndak et al., 2015). Therefore, ideal TB vaccines should not only 
 
164 Chapter 6. General Discussion and Conclusions 
provide protection against actively replicating bacteria, but also target those in dormancy state. 
The vaccine described in this study, CysVac5 containing antigens expressed at various stages of M. tuberculosis lifecycle and may provide an effective multistage TB vaccine. The vaccine incorporates two immunogenic secreted mycobacterial antigens Ag85B and MPT83 together with CysD,  which is highly expressed during chronic infection in mice and in vitro conditions that mimic the human granuloma during latency (Counoupas et al., 2016, Pinto et al., 2012). Importantly, as a multistage subunit vaccine, CysVac5/MPLA-DDA demonstrates promising efficacy results with the capacity to protect mice at early and extended time point following aerosol M. 
tuberculosis infection (Chapter 3). The stronger overall protection conferred by CysVac5 observed in this study might be the results of more comprehensive immunity elicited by each protein antigen of the vaccine against different stages of M. tuberculosis 
infection. However, definitive determination of the ‘multistage’ effect of the vaccine would require testing in models that assess vaccine effectiveness against disease reactivation in mice (Aagaard et al., 2011) or models that more closely mimic the human situation, such non-human primates (Lin et al., 2012). 
Despite the consistent level of protection observed in the lung, CysVac5 showed a variable protection in the spleen of M. tuberculosis infected mice. Although there was a trend towards improved protection, particularly at 20 weeks post infection when the BCG protection started to gradually wane, CysVac5 did not provide a significant reduction of bacterial burden in this organ (Chapter 3).  While many TB vaccines display efficacy against M. tuberculosis infection in the spleen (Triccas, 2010), splenic TB is a rare variant of abdominal extrapulmonary TB in humans (Fooladi et al., 2009). Therefore, variable protection observed in the spleen of infected mice in this model may not necessarily limit the capacity of CysVac5 to protect against M. tuberculosis infection when translated into human applications. Collectively, these results suggest that CysVac5 is a promising novel TB vaccine candidate that warrants further investigation to control pulmonary TB in humans. 
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6.2. Improving the current vaccine BCG BCG is considered as an attractive vector for recombinant vaccine development (Chapter 1). In this study, the BCG∷SecDFG strain was constructed by overexpressing 
M. tuberculosis SecDFG protein in order to improve the efficiency of Sec-dependent export increase secretion of immunogenic proteins (Chapter 4). Overexpression of M. 
tuberculosis SecDFG did impact vaccine persistence, immunity to secreted antigens and the production of polyfunctional CD4+ T cells producing Th1-type cytokines. However, the vaccine did not have a significant impact on protective efficacy, which does correlate with previous studies indicating that improving antigen secretion does not always translate to improved efficacy (Kong et al., 2011). One consideration is that the protective immunity imparted by BCG, as a live vaccine, may be difficult to alter by antigen expression, and modifications to the vaccine may need to have a more profound impact on the immune response. Indeed, the most advanced live TB vaccine in human trials, VPM1002, has been modified to improve host cell apoptosis and activation of CD8+ T cells by expression of a pore forming molecule from Listeria (Nieuwenhuizen et al., 2017).  
In this thesis a different immunostimulatory approach was used, which was to improve the early interaction between the bacterial vaccine and DCs, leading to increased uptake of the bacteria and immune stimulation (Chapter 5). Targeting DEC205 was selected as DEC205 has the ability to constitutively express and recycle itself (Howard and Isacke, 2002), enhance antigen presentation via MHCII lysosomal compartments (Mahnke et al., 2000) and is abundantly expressed in the T cell areas of major lymphoid organs (Pack et al., 2008). BCG∷DEC205 constructed for this study demonstrated an improved immunity compared to parental but did not significantly alter the protective efficacy of the vaccine (Chapter 5). It is possible that targeting other important DC receptors, such as Clec9A (Park et al., 2017), may be required for optimal protective immunity. Nonetheless, these encouraging findings provide a platform for further investigation to more conclusively determine the mechanism of interaction between BCG∷DEC205 with DCs, that will lead to protective influence generated against M. 
tuberculosis infection. Collectively, modifying BCG shows promising results, and coupled with the favourable safety profile and its efficacy in protecting children from 
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early TB infection support the development of rBCG for inclusion into current vaccination programs. 
6.3. Can polyfunctional CD4+ T cells be used as biosignature to predict TB 
vaccine protective efficacy? The correlation between vaccine-conferred protection and polyfunctional CD4+ T cells producing pro-inflammatory cytokines (IFN-γ, IL-2 and TNF) has been extensively investigated (Lewinsohn et al., 2017). This T cell subset has been used in animal and human TB vaccine studies as a measurable immune parameter, reflecting activity and potentially predicting the protective efficacy of a vaccine (Bhatt et al., 2015). Although several studies utilising the mouse TB model support the correlation between polyfunctional CD4+ T cells and vaccine-induced protection, a number of studies in mouse and human infants display no correlation between these T cell responses and protection (Lewinsohn et al., 2017). 
In this study, CysVac5 subunit vaccine formulated in either MPLA-DDA or AdvaxCpG induced significantly increased proportion of IFN-γ, IL-2 and TNF producing CD4+ T cells at pre- and post-M. tuberculosis exposure and did correlate to some extent with improved protection in the lungs of M. tuberculosis infected mice, particularly at extended time point post challenge (Chapter 3). However, in rBCG studies, both BCG∷SecDFG and BCG∷DEC205 showed significant increased frequencies in the antigen-specific polyfunctional CD4+ T cells but did not significantly modify the protective effect of the vaccine (Chapters 4 and 5). Thus, alternative immune responses may be important. CysVac5 vaccination appeared to also favour the induction of Th17 CD4+ T cells responses indicated by the generation of IL17 producing CD4+ T cells population pre- and post-M. tuberculosis challenge (Chapter 3). Although the role of IL17 in vaccine-induced protection against M. tuberculosis infection is not fully characterized (Cooper, 2010, Uranga et al., 2016), intranasal BCG vaccination is reported to be dependent on the anti-M. tuberculosis Th17 responses to control M. 
tuberculosis infection (Aguilo et al., 2015) and CysVac2 vaccination generates a strong Th17 response that leads to reduction of mycobacterial number in the lungs and spleen of M. tuberculosis-infected mice (Counoupas et al., 2016). This suggests that the correct balance between Th1 and Th17 responses may be essential for optimal protection 
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against M. tuberculosis infection, and vaccines generating such responses may be the ideal candidates for use in humans. 
6.4. Route of vaccine administration and the use of adjuvants contribute to TB 
vaccine protective efficacy Heterogeneity in the protective efficacy of TB vaccines has been attributed to several factors including route of vaccine administration (Barreto et al., 2006) and in subunit protein vaccine case, the use of appropriate adjuvants. Thus, exploring alternative routes for vaccine delivery and adjuvant formulations may be beneficial in developing novel TB vaccines. Peripherally delivered BCG does not provide adequate protection against pulmonary TB in humans and it has been associated with the generation of weak T cell responses in the lungs leading to the lack of airway luminal vaccine-specific T cells, delayed T cell priming and recruitment following M. tuberculosis challenge (Horvath et al., 2012, Shaler et al., 2012). Therefore, local immune responses generated by pulmonary vaccines may be critical in controlling M. tuberculosis infection. In this study, BCG∷DEC205 was assessed as both peripheral and pulmonary vaccine (Chapter 5). It appeared that BCG∷DEC205 delivered stronger immune responses when delivered intranasally than subcutaneously indicated by significantly higher proportion of Th1 and Th17 CD4+ T cells producing multiple cytokines observed in mice that received pulmonary BCG∷DEC205 (Chapter 5). In addition, intranasal BCG∷DEC205 decreased the proportion of T cell subset with KLRG1hiPD-1lo characteristic phenotype which may be beneficial considering this cell subset lacks capacity in proliferation and has a short life span (Urdahl et al., 2011) These findings therefore suggest that pulmonary vaccination of BCG∷DEC205 elicited stronger anti-TB immunity as it might best mimic the induction of local immune responses in the pulmonary mucosa of the lungs, the primary site of M. tuberculosis infection. 
Another challenge faced in TB vaccine development, particularly subunit vaccines, is the considerable safety concerns with adjuvants that could stimulate strong inflammatory responses; for example the MPLA-DDA combination used in this study is a potent adjuvant that induce can induce severe ulceration at the site of vaccination (Counoupas et al., unpublished data), thus generating inflammation, tissue destruction, and the potential for resulting pain and distress in the host animal (Stils Jr, 2005). This 
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study assessed the use of plant-based polysaccharide derived compound, Advax with the addition of oligonucleotide CpG7909 as an adjuvant formulation to deliver CysVac5 protein vaccine. Advax adjuvant has proved successful in human trials against various diseases with the capacity to enhance T cell responses with great safety and very well tolerated (Petrovsky and Cooper, 2015). When given subcutaneously into mice, CysVa5/AdvaxCpG induced high proportions of polyfunctional CD4+ T cells producing 
IFNγ, IL2, TNF and IL17 cytokines upon re-stimulation with vaccine antigens, although these responses and the resultant protection were not as strong as those seen with MPLA-DDA (Chapter 5). Thus, it appears the ideal vaccine will be one that induces sufficient release of inflammatory cytokines required for protective immunity but limits the induction of deleterious immune responses that induce immunopathology. 
6.5. Concluding remarks The generation of protective immunity against M. tuberculosis is a very well-orchestrated and complex process involving many components and pathways of the immune system. Progress towards the development of an effective vaccine is hampered by the lack of correlative readouts of immune protection coupled with limited understanding of the immune mechanism that determine disease progression versus containment. In summary, this study has assessed the immunogenicity and protective efficacy of novel multistage subunit protein-based vaccine and live recombinant BCG strains as peripheral and pulmonary TB vaccines against M. 
tuberculosis infection in murine models. In general, the novel vaccine candidates observed in this study induced greater immune responses that translated, in some instances, to improved protection against M. tuberculosis. Future work is to explore alternative routes for vaccine administration, adjuvant formulation and vaccination in secondary animal models for further preclinical evaluation and progression to clinical trials. 
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Appendix 1. Additional buffers and solutions 
Buffer/solution Components TAE buffer 40 mM Tris acetate, 1 mM EDTA (pH 8.0) Lysis-solubilisation buffer 8 M urea, 10 mM NaPO4 (pH 7.6), 300 mM NaCl Protein purification buffer 8 M urea, 50mM Tris (pH 7), 300 mM NaCl Lysis buffer 50 mM KPO4, 4 mM KCl, 5 mM b-ME, lysozyme 0.1 mg/mL, pH 8 Refolding buffer 25 mM HEPES, 0.1 M KCl, 1.5 mM DTT, 5% glycerol, pH 7.5 SDS-PAGE sample buffer 60 mM Tris (pH 6.8), 1% w/v SDS, 1% v/v β- mercaptoethanol, 10% v/v glycerol, 0.01% w/v bromophenol blue SDS-PAGE running buffer 25 mM Tris (pH 8.3), 192 mM glycine, 0.1% w/v SDS Coomassie blue stain 0.1% v/v Coomassie blue, 50% v/v methanol, 10% v/v acetic acid Transfer buffer 25 mM Tris (pH 8.3), 192 mM glycine, 0.1% w/v SDS, 20% v/v methanol 1x TBS-T buffer 150 mM NaCl, 2.5 mM KCl, 25 mM Tris (pH 7.4), 0.05% v/v Tween-20 Complete RPMI media RPMI medium containing L-glutamine and 25 mM HEPES (Invitrogen), supplemented with FCS (10% v/v), 2-mercaptoethanol (50 μM) and PenStrep (100 U/mL; Invitrogen) ACK lysis buffer 0.15 M NH4Cl, 1 mM KHCO3, 100 mM EDTA (pH 7.3) NPP buffer 15 mM Na2CO3, 35 mM NaHCO3, 1 mM MgCl2, 3 mM NaN3 Secondary antibody buffer 1 % v/v bovine serum albumin (BSA), 0.05% v/v Tween 20 in PBS FACS wash 2% v/v FCS in PBS PERM wash 10 mL of 10x Cytoperm was (BD Biosciences) in 90 mL of TDW 
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Transformation Storage Solution (TSS) buffer 10% (w/v) PEG-8000, 30 mM MgCl2, 5% (v/v) dimethyl sulfoxide, 10% (v/v) glycerol, in autoclaved LB broth Western blot transfer buffer 12% methanol, 12 mM Tris HCl (pH 8.3), and 85mM glycine Dialysis buffer 1 M HEPES (pH 7.5), glycerol, dithiothreitol (DTT), KCl. Dialysis buffer F 0.5 M Tris (pH 8), DTT, KCl, glycerol MES regeneration buffer 20 mM MES (2-N morpholine ethanesulfonic acid), 0.3 M NaCl, adjust pH to 5.0 Protein lysis buffer TBS (pH 7.5), 0.5 M EDTA, 10% Triton X-100 in TDW Folding buffer 50 mM Tris (pH 8.5), 9.6 mM NaCl, 0.4 mM KCl, 0.4 M sucrose, 0.05% PEG3550, 0.5% Triton X-100, 2 mM MgCl2, 2mM CaCl2, 1 mM glutathione (GSH), 0.1 mM glutathione disulphide (GSSG) in TDW. Plain urea buffer 8 M urea in TDW, adjust pH to 8.0 Urea buffer with salts 6 M urea, 1 M NaH2PO4, 1 M Na2HPO4, 1 M NaCl in TDW, adjust pH to 8.0 Urea buffer with Tris-HCl 6 M urea, 1 M NaCl, 1.5 M Tris-HCl (pH 8.8) in TDW, adjust pH to 7.5-8.0 Lysis buffer 50 mM K2PO4, 0.4 M KCl, 5 mM β-mercaptoethanol (ME), PMSF-Pepstatin A (1 tablet per 10 mL solution), lysozyme Cell freezing media 50% RPMI, 40% FCS, 10% DMSO, stored at 4 °C 
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Appendix 2. Antibodies used in this study 
Marker Clone Species Isotype Fluorochrome Source CCR6 29-2L17 Mouse IgG1 PE Cy7 BD BioSciences CD11b  MI/70 Rat IgG2b, k FITC BD BioSciences CD11c N418 Hamster igG AF700 Biolegend CD127 A7R34 Rat IgG2a, k BUV737 BD BioSciences CD205 NLDC-145 Rat IgG2a, k APC Biolegend CD205 NLDC-145 Rat IgG2a, k PE Biolegend CD25 BC96 Mouse IgG1, k PE Biolegend CD4 RM4-5 Rat IgG2a AF700 Biolegend CD44 IM7.8.1 Rat IgG2b PE-CF594 Biolegend CD44 IM7.8.1 Rat IgG2b FITC Biolegend CD44 IM7.8.1 Rat IgG2b BV605 Biolegend CD45 30-F11 Rat IgG2b, k APC Cy7 Biolegend CD45.1 A20.1 Mouse IgG2a, k APC Cy Biolegend CD45.1 A20.1 Mouse IgG2a, k PB Biolegend CD45.2 104 Mouse IgG2a, k BV510 Biolegend CD62L DREG-56 Mouse IgG1, k eFluor 450 ThermoFisher CD64 x-54-5/7.1 Mouse IgG1, k PE Cy7 Biolegend CD69 FN50 Mouse IgG1, k PE Biolegend CD69  FN50 Mouse IgG1, k FITC Biolegend CD8 53-6.7 Rat IgG2a, k APC Cy7 BD BioSciences CFSE - - - - ThermoFisher CXCR3 CXCR3-173 Hamster IgG BV605 BD BioSciences CXCR3 CXCR3-173 Hamster IgG APC Biolegend ESAT-6 Tet - - - APC NIH FC Block 2.4G2 Rat IgG2b, k - BD BioSciences 
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IFNγ XMG1.2 Rat IgG1, k PE Cy7 Biolegend IL17A TC11 Rat IgG1, k PB Biolegend IL17A TC11 Rat IgG1, k BV650 Biolegend IL2 C15.6 Rat IgG1, k PE Biolegend Ki67 Ki-67 Mouse IgG1, k PerCP Cy5.5 Biolegend KI67 16A8 Rat IgG2a, k FITC Biolegend KLRG-1 2F1 Hamster IgG FITC ThermoFisher KLRG-1 2F1 Hamster IgG AF488 ThermoFisher KLRG-1 2F1 Hamster IgG PE Cy7 Biolegend Live/dead - - - Blue dye cell stain Invitrogen Ly6C HK1.4 Rat IgG2c, k PerCP Cy5.5 Biolegend Ly6G 1A8 RUO Rat IgG1, k BUV395 BD BioSciences MHC-II M5/114.15.2 Rat IgG2b, k BV421 BD BioSciences P25 Tet - - - PE NIH PD1 EH12.1 Mouse IgG1, k BV785 BD BioSciences RorγT Q31-378 Mouse IgG2a, k PE-CF594 BD BioSciences SiglecF E50-2440 Rat IgG2a, k PE BD BioSciences Tbet 4B10 Mouse IgG1, k APC Biolegend Tbet 4B10 Mouse IgG1, k PerCP Cy5.5 Biolegend TNF MP6-XT22 Rat IgG1, k PerCP Cy5.5 Biolegend VPD - - - VPD450 BD BioSciences Streptavidin - - - PBMF/114.15.2 Invitrogen    
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Appendix 3. Gating strategy used for assessing intracellular cytokine release by T-lymphocytes. A time gate was applied to verify consistent fluorescence signal during sample acquisition. After excluding debris by FSC and SSC, dead cells were excluded by live/dead UV stain. The CD4+ and CD8+ T cell populations were gated, and the expression of IFNγ, IL2, IL17, and TNF was gated for CD4+ T cells. To quantitate cells producing multiple cytokines, a Boolean analysis was applied.   
Time 
SS
C-
A 
FSC-A 
FS
C-
H
 
SSC-A 
SS
C-
H
 
Singlets Lymphocytes Live cells 
SS
C-
H
 
FSC-H 
SS
C-
H
 
Live/Dead CD4+ 
CD
8+
 
CD
4+
 
CD
4+
 
CD
4+
 
CD
4+
 
IFNγ IL2 IL17 TNF 
CD4+ 
 
210 Appendix 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4. Gating strategy used for assessing activated pulmonary T cell following vaccination and M. tuberculosis challenge. A time gate was applied to verify consistent fluorescence signal during sample acquisition. After excluding debris by FSC and SSC, dead cells were excluded by live/dead UV stain. The CD4+ and CD8+ T cell populations were gated, and the expression of CD44, CD62L, KLRG and PD1 was gated for both CD4+ and CD8+ T cells.      
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Appendix 5. Gating strategy used for assessing P25-specific CD4+ T cells proliferation following vaccination. A time gate was applied to verify consistent fluorescence signal during sample acquisition. After excluding debris by FSC and SSC, dead cells were excluded by live/dead UV stain. The CD45.2+ and CD45.1+ T cell populations were gated from live CD4+ T cell population. The frequencies of activated proliferating P25-specific CD45.1+ T cells were then assessed by looking at the expression of CD44 and CFSElo/int/hi.  
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Appendix 6. Gating strategy used for assessing mCherry+ DEC205-transfected CHO cells following BCG∷DEC205 infection. A time gate was applied to verify consistent fluorescence signal during sample acquisition. After excluding debris by FSC and SSC, mCherry+ cells were selected and enumerated for further quantification.    
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Appendix 7. Gating strategy used for analysis the expression of DEC205 on different immune cells in murine organs. After excluding debris by FSC and SSC, dead cells were excluded by live/dead UV stain. CD45.2+ cells were isolated, then neutrophils gated based on Ly6Ghi CD11bhi expression. Ly6Glo were separated using SiglecF and CD11b markers into AMs (SiglecF+ CD11blo) and Eosinophils (SiglecF+ CD11bhi). DCs were gated using CD11c and MHCII markers with the criteria of CD11chi MHCII+. Furthermore, CD11c- were gated based on Ly6Chi CD11bhi to separate monocytes. Each of the immune cell subsets were then gated in DEC205+ population.   
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Appendix 8. Summary of achievements during candidature 
1. Conferences, presentations and courses attended 
2018 7th Annual Tuberculosis Control Symposium (TB-CRE) 
  Centenary Institute of Cancer Medicine and Cell Biology 
  May 31st – June 1st 2018, Sydney Australia (Oral presentation) 
2017 Immunology and Infectious Diseases Department Retreat Program 
  December 18-19th 2017, Hunter Valley 
  Quorrobolong, Australia (Oral presentation)   5th Annual Marie Bashir Institute (MBI) Colloquium   November 17th 2017, The University of Sydney   Sydney, Australia (Poster presentation)   Tuberculosis Control Symposium (TB-CRE)   Centenary Institute of Cancer Medicine and Cell Biology   August 11th 2017, Sydney Australia (Oral presentation)   New Developments in Our Basic Understanding of Tuberculosis   Keystone Symposia on Molecular and Cellular Biology   January 14-18th 2017, Vancouver, BC Canada (Poster presentation) 
2016 Australasian Society for Immunology (ASI) 8th Annual NSW-ACT Joint Branch Meeting (Immunology Retreat), November 24-25th 2016 
  Northbeach, Wollongong Australia (Oral presentation) 
  4th Annual Marie Bashir Institute (MBI) Colloquium 
  November 3rd 2016, The University of Sydney 
  Sydney, Australia (Poster presentation) Tuberculosis Control Symposium (TB-CRE) and  2nd Australia-China Symposium on Immunity in Tuberculosis Centenary Institute of Cancer Medicine and Cell Biology May 18th 2016, Sydney Australia (Oral presentation) 
2015 Tuberculosis Control Symposium (TB-CRE) 
  Woolcock Institute of Medical Research,   September 4th 2015, Sydney Australia (Oral presentation)   
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2. Awards 
2017 University of Sydney Postgraduate Research Support Scheme (PRSS)   Daphne Goulston Scholarship   Australia Awards – Supplementary Academic Support (Travel Awards)   University of Sydney Postgraduate Research Scholarship   The Centre of Research Excellence in Tuberculosis Control Scholarship   Department of Foreign Affairs and Trade (DFAT) Scholarship 
2016 Marie Bashir Institute (MBI) Colloquium Poster Prize Winner 
2015 Australia Awards Indonesia 
